Network meta-analysis

Nausea

Type 2 diabetes (adults)

longest follow-upRecorded harmsDoses of a drug pooledHazard ratio (from event counts)

194

Randomized trials

Treatments

103,420

Participants

14,280

Events

In plain language

Across 194 trials with 103,420 participants, 13 of 58 treatments had a clearly better result than placebo on nausea, 26 a clearly worse one, and for 19 the evidence could not tell them apart from placebo. The most favorable estimate was for Sulfonylurea: hazard ratio (from event counts) 0.02 (95% credible interval 0.00 to 0.15).

Lower values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.

Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Effects compared with Placebo

Hazard ratio (from event counts). Lower values favor the treatment.

Versus Placebo, log scale. Blue: Bayesian random effects posterior median with 95% credible interval (thick) and 95% prediction interval (dashed). Amber diamond: frequentist estimate with 95% confidence interval. Hover over or tab to a row for its values.

Effects of each treatment versus Placebo
Treatment	Bayesian HR (95% CrI)	95% prediction interval	Verdict
Sulfonylurea OTHER_ACTIVE_sulfonylurea	0.02 (0.00 to 0.15)	0.00 to 0.17	Better
Liraglutide after insulin degludec injection LIRAGL_SC	0.09 (0.00 to 0.92)	0.00 to 1.06	Better
Basal bolus insulin OTHER_ACTIVE_basal_bolus_insulin	0.14 (0.04 to 0.43)	0.03 to 0.54	Better
Insulin detemir INS_DETEMIR	0.17 (0.03 to 0.73)	0.02 to 0.91	Better
Premixed insulin INS_PREMIX	0.17 (0.08 to 0.36)	0.06 to 0.51	Better
Additional oad OTHER_ACTIVE_additional_OAD	0.18 (0.02 to 0.91)	0.02 to 1.06	Better
Insulin lispro (prandial) INS_LISPRO	0.19 (0.10 to 0.37)	0.07 to 0.50	Better
Insulin aspart (prandial) INS_ASPART	0.23 (0.08 to 0.65)	0.06 to 0.84	Better
Pioglitazone PIOGLITAZONE	0.25 (0.10 to 0.59)	0.08 to 0.77	Better
Rosiglitazone ROSIGLITAZONE	0.28 (0.05 to 1.14)	0.04 to 1.40	Unclear
Insulin glargine INS_GLARGINE	0.30 (0.22 to 0.40)	0.13 to 0.65	Better
Linagliptin LINAGLIPTIN	0.33 (0.01 to 9.96)	0.00 to 11.00	Unclear
Glimepiride GLIMEPIRIDE	0.37 (0.19 to 0.70)	0.14 to 0.99	Better
Insulin degludec INS_DEGLUDEC	0.40 (0.21 to 0.74)	0.15 to 1.05	Better
Standard care or no added treatment STANDARD_CARE	0.43 (0.10 to 1.45)	0.08 to 1.79	Unclear
Insulin icodec INS_ICODEC	0.50 (0.15 to 1.62)	0.13 to 2.02	Unclear
GLP-1 receptor agonist (liraglutide, exenatide, exenatide ER, albiglutide or dulaglutide) injection GLP1RE_SC	0.67 (0.19 to 2.14)	0.16 to 2.70	Unclear
Dapagliflozin DAPAGLIFLOZIN	0.69 (0.31 to 1.51)	0.23 to 2.03	Unclear
Investigator choice oral drug OTHER_ACTIVE_investigator_choice_oral_drug	0.72 (0.28 to 1.83)	0.22 to 2.37	Unclear
Sitagliptin SITAGLIPTIN	0.73 (0.52 to 1.00)	0.32 to 1.65	Better
Canagliflozin CANAGLIFLOZIN	0.75 (0.34 to 1.60)	0.26 to 2.12	Unclear
Glibenclamide GLIBENCLAMIDE	0.79 (0.12 to 3.52)	0.11 to 4.13	Unclear
Macupatide OTHER_ACTIVE_macupatide	0.85 (0.06 to 5.71)	0.06 to 6.85	Unclear
Exenatide extended release and dapagliflozin injection DAPAEXEN_SC	0.89 (0.32 to 2.38)	0.26 to 3.05	Unclear
Dulaglutide with macupatide injection DULAMACU_SC	1.00 (0.15 to 5.37)	0.13 to 6.37	Unclear
Bofanglutide (GZR18) injection BOFANG_SC	1.10 (0.14 to 14.16)	0.12 to 14.82	Unclear
Insulin degludec with liraglutide injection IDEGLIRA_SC	1.24 (0.75 to 2.05)	0.50 to 3.04	Unclear
Albiglutide injection ALBI_SC	1.53 (0.96 to 2.45)	0.64 to 3.70	Unclear
Exenatide extended release injection EXENER_SC	1.83 (1.32 to 2.58)	0.83 to 4.16	Worse
Efsubaglutide alfa injection EFSUBA_SC	1.87 (0.61 to 6.21)	0.49 to 7.62	Unclear
Vildagliptin VILDAGLIPTIN	2.08 (0.39 to 9.85)	0.34 to 11.87	Unclear
Semaglutide tablet SEMA_PO	2.54 (1.86 to 3.48)	1.14 to 5.60	Worse
Mazdutide injection MAZD_SC	2.60 (1.19 to 5.90)	0.89 to 7.93	Worse
Insulin glargine with lixisenatide injection IGLARLIXI_SC	2.61 (1.73 to 4.05)	1.13 to 6.24	Worse
Metformin METFORMIN	2.85 (1.33 to 6.31)	0.97 to 8.31	Worse
Dulaglutide injection DULA_SC	2.85 (2.24 to 3.67)	1.33 to 6.14	Worse
Liraglutide injection LIRA_SC	3.30 (2.68 to 4.12)	1.55 to 7.27	Worse
Liraglutide plus canagliflozin injection CANALIRA_SC	3.30 (1.01 to 10.24)	0.83 to 13.25	Worse
Tirzepatide injection TIRZ_SC	3.35 (2.36 to 4.77)	1.46 to 7.69	Worse
Retatrutide injection RETA_SC	3.41 (1.32 to 8.97)	1.03 to 11.73	Worse
Insulin icodec with semaglutide injection ICOSEMA_SC	3.58 (1.52 to 8.41)	1.16 to 11.24	Worse
Semaglutide injection SEMA_SC	3.64 (2.80 to 4.74)	1.65 to 7.99	Worse
Exenatide and rosiglitazone injection EXENROSI_SC	3.91 (1.48 to 10.28)	1.15 to 13.28	Worse
Exenatide injection EXEN_SC	4.00 (3.06 to 5.28)	1.83 to 9.03	Worse
Ecnoglutide injection ECNO_SC	4.03 (0.79 to 37.67)	0.66 to 41.85	Unclear
Lixisenatide injection LIXI_SC	4.22 (3.39 to 5.36)	1.96 to 9.19	Worse
Exenimp implant EXENIMP_IMPLANT	4.38 (1.73 to 11.45)	1.31 to 14.76	Worse
Orforglipron tablet ORFO_PO	4.84 (3.21 to 7.32)	2.06 to 11.30	Worse
Safiglipron (HRS-7535) tablet SAFIGL_PO	5.10 (2.35 to 11.44)	1.76 to 15.00	Worse
Ecc500 po ECC500_PO	5.12 (0.99 to 51.01)	0.85 to 60.09	Unclear
Polyethylene glycol loxenatide injection PEGLOX_SC	5.23 (1.76 to 17.42)	1.39 to 21.81	Worse
Taspoglutide injection TASP_SC	5.35 (3.38 to 8.53)	2.30 to 12.93	Worse
Cotadutide injection COTA_SC	6.09 (3.25 to 11.74)	2.34 to 16.16	Worse
Loti po LOTI_PO	6.61 (3.06 to 14.62)	2.26 to 19.54	Worse
HRS-7535 tablet HRS7535_PO	8.90 (2.69 to 37.84)	2.09 to 43.85	Worse
Visepegenatide injection VISEPE_SC	9.97 (2.99 to 45.99)	2.43 to 54.33	Worse
Danuglipron tablet DANU_PO	10.41 (3.05 to 48.38)	2.52 to 58.97	Worse
Efpe sc EFPE_SC	11.74 (4.09 to 41.74)	3.20 to 51.46	Worse

Ranking

How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.

League table

Every treatment against every other: hazard ratio (from event counts) of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.

Every treatment in a row compared with every treatment in a column
Row versus column	PLACEBO	OTHER_ACTIVE_sulfonylurea	LIRAGL_SC	OTHER_ACTIVE_basal_bolus_insulin	INS_DETEMIR	INS_PREMIX	OTHER_ACTIVE_additional_OAD	INS_LISPRO	INS_ASPART	PIOGLITAZONE	ROSIGLITAZONE	INS_GLARGINE	LINAGLIPTIN	GLIMEPIRIDE	INS_DEGLUDEC	STANDARD_CARE	INS_ICODEC	GLP1RE_SC	DAPAGLIFLOZIN	OTHER_ACTIVE_investigator_choice_oral_drug	SITAGLIPTIN	CANAGLIFLOZIN	GLIBENCLAMIDE	OTHER_ACTIVE_macupatide	DAPAEXEN_SC	DULAMACU_SC	BOFANG_SC	IDEGLIRA_SC	ALBI_SC	EXENER_SC	EFSUBA_SC	VILDAGLIPTIN	SEMA_PO	MAZD_SC	IGLARLIXI_SC	METFORMIN	DULA_SC	LIRA_SC	CANALIRA_SC	TIRZ_SC	RETA_SC	ICOSEMA_SC	SEMA_SC	EXENROSI_SC	EXEN_SC	ECNO_SC	LIXI_SC	EXENIMP_IMPLANT	ORFO_PO	SAFIGL_PO	ECC500_PO	PEGLOX_SC	TASP_SC	COTA_SC	LOTI_PO	HRS7535_PO	VISEPE_SC	DANU_PO	EFPE_SC
PLACEBO	PLACEBO	46.78 6.63 to 1022	11.64 1.09 to 458	7.30 2.33 to 27.56	5.79 1.36 to 34.17	5.74 2.75 to 13.10	5.53 1.10 to 53.84	5.25 2.71 to 10.51	4.26 1.54 to 12.23	3.93 1.70 to 9.68	3.62 0.88 to 21.14	3.36 2.50 to 4.55	3.04 0.10 to 199	2.68 1.42 to 5.15	2.49 1.34 to 4.74	2.30 0.69 to 10.12	1.99 0.62 to 6.48	1.50 0.47 to 5.19	1.46 0.66 to 3.25	1.38 0.55 to 3.51	1.37 1.00 to 1.92	1.34 0.62 to 2.98	1.26 0.28 to 8.34	1.18 0.17 to 15.94	1.13 0.42 to 3.09	1.00 0.19 to 6.84	0.91 0.07 to 7.40	0.81 0.49 to 1.33	0.66 0.41 to 1.04	0.55 0.39 to 0.76	0.53 0.16 to 1.64	0.48 0.10 to 2.58	0.39 0.29 to 0.54	0.38 0.17 to 0.84	0.38 0.25 to 0.58	0.35 0.16 to 0.75	0.35 0.27 to 0.45	0.30 0.24 to 0.37	0.30 0.10 to 0.99	0.30 0.21 to 0.42	0.29 0.11 to 0.76	0.28 0.12 to 0.66	0.27 0.21 to 0.36	0.26 0.10 to 0.68	0.25 0.19 to 0.33	0.25 0.03 to 1.26	0.24 0.19 to 0.30	0.23 0.09 to 0.58	0.21 0.14 to 0.31	0.20 0.09 to 0.42	0.20 0.02 to 1.01	0.19 0.06 to 0.57	0.19 0.12 to 0.30	0.16 0.09 to 0.31	0.15 0.07 to 0.33	0.11 0.03 to 0.37	0.10 0.02 to 0.33	0.10 0.02 to 0.33	0.09 0.02 to 0.24
OTHER_ACTIVE_sulfonylurea	0.02 0.00 to 0.15	OTHER_ACTIVE_sulfonylurea	0.25 0.01 to 17.76	0.16 0.01 to 1.78	0.12 0.00 to 1.75	0.12 0.01 to 1.05	0.12 0.00 to 2.28	0.11 0.01 to 0.91	0.09 0.00 to 0.85	0.08 0.00 to 0.69	0.08 0.00 to 1.04	0.07 0.00 to 0.51	0.06 0.00 to 6.25	0.06 0.00 to 0.44	0.05 0.00 to 0.41	0.05 0.00 to 0.60	0.04 0.00 to 0.43	0.03 0.00 to 0.32	0.03 0.00 to 0.26	0.03 0.00 to 0.26	0.03 0.00 to 0.21	0.03 0.00 to 0.23	0.03 0.00 to 0.41	0.02 0.00 to 0.61	0.02 0.00 to 0.21	0.02 0.00 to 0.33	0.02 0.00 to 0.36	0.02 0.00 to 0.13	0.01 0.00 to 0.10	0.01 0.00 to 0.08	0.01 0.00 to 0.11	0.01 0.00 to 0.13	0.01 0.00 to 0.06	0.01 0.00 to 0.07	0.01 0.00 to 0.06	0.01 0.00 to 0.06	0.01 0.00 to 0.05	0.01 0.00 to 0.04	0.01 0.00 to 0.06	0.01 0.00 to 0.05	0.01 0.00 to 0.06	0.01 0.00 to 0.05	0.01 0.00 to 0.04	0.01 0.00 to 0.05	0.01 0.00 to 0.04	0.00 0.00 to 0.07	0.01 0.00 to 0.04	0.00 0.00 to 0.04	0.00 0.00 to 0.03	0.00 0.00 to 0.03	0.00 0.00 to 0.06	0.00 0.00 to 0.04	0.00 0.00 to 0.03	0.00 0.00 to 0.03	0.00 0.00 to 0.03	0.00 0.00 to 0.02	0.00 0.00 to 0.02	0.00 0.00 to 0.02	0.00 0.00 to 0.02
LIRAGL_SC	0.09 0.00 to 0.92	4.05 0.06 to 193	LIRAGL_SC	0.63 0.01 to 9.44	0.49 0.01 to 9.98	0.48 0.01 to 6.04	0.46 0.01 to 13.43	0.44 0.01 to 5.73	0.36 0.01 to 5.09	0.33 0.01 to 4.47	0.30 0.01 to 6.31	0.29 0.01 to 3.15	0.25 0.00 to 30.67	0.23 0.01 to 2.65	0.21 0.01 to 2.52	0.20 0.00 to 3.26	0.16 0.00 to 2.56	0.12 0.00 to 1.99	0.12 0.00 to 1.54	0.12 0.00 to 1.45	0.12 0.00 to 1.31	0.11 0.00 to 1.47	0.11 0.00 to 2.17	0.10 0.00 to 3.73	0.09 0.00 to 1.30	0.08 0.00 to 1.91	0.07 0.00 to 1.88	0.07 0.00 to 0.77	0.06 0.00 to 0.63	0.05 0.00 to 0.51	0.04 0.00 to 0.67	0.04 0.00 to 0.80	0.03 0.00 to 0.37	0.03 0.00 to 0.39	0.03 0.00 to 0.38	0.03 0.00 to 0.37	0.03 0.00 to 0.32	0.03 0.00 to 0.27	0.03 0.00 to 0.39	0.03 0.00 to 0.29	0.02 0.00 to 0.33	0.02 0.00 to 0.30	0.02 0.00 to 0.25	0.02 0.00 to 0.30	0.02 0.00 to 0.23	0.02 0.00 to 0.43	0.02 0.00 to 0.22	0.02 0.00 to 0.26	0.02 0.00 to 0.20	0.02 0.00 to 0.21	0.01 0.00 to 0.32	0.02 0.00 to 0.23	0.02 0.00 to 0.18	0.01 0.00 to 0.16	0.01 0.00 to 0.16	0.01 0.00 to 0.14	0.01 0.00 to 0.13	0.01 0.00 to 0.12	0.01 0.00 to 0.10
OTHER_ACTIVE_basal_bolus_insulin	0.14 0.04 to 0.43	6.41 0.56 to 163	1.58 0.11 to 68.72	OTHER_ACTIVE_basal_bolus_insulin	0.78 0.11 to 6.55	0.78 0.17 to 3.16	0.75 0.09 to 9.22	0.71 0.17 to 2.68	0.57 0.11 to 2.74	0.53 0.11 to 2.26	0.49 0.07 to 4.22	0.46 0.12 to 1.45	0.41 0.01 to 28.70	0.36 0.08 to 1.32	0.33 0.08 to 1.16	0.31 0.05 to 1.97	0.27 0.04 to 1.38	0.20 0.03 to 1.05	0.20 0.04 to 0.81	0.18 0.04 to 0.83	0.19 0.05 to 0.62	0.18 0.04 to 0.72	0.17 0.02 to 1.52	0.16 0.02 to 2.73	0.15 0.03 to 0.66	0.13 0.02 to 1.29	0.12 0.01 to 1.33	0.11 0.03 to 0.32	0.09 0.02 to 0.30	0.07 0.02 to 0.24	0.07 0.01 to 0.36	0.06 0.01 to 0.49	0.05 0.01 to 0.17	0.05 0.01 to 0.21	0.05 0.01 to 0.17	0.05 0.01 to 0.18	0.05 0.01 to 0.15	0.04 0.01 to 0.13	0.04 0.01 to 0.21	0.04 0.01 to 0.13	0.04 0.01 to 0.17	0.04 0.01 to 0.16	0.04 0.01 to 0.12	0.03 0.01 to 0.15	0.03 0.01 to 0.11	0.03 0.00 to 0.26	0.03 0.01 to 0.10	0.03 0.01 to 0.13	0.03 0.01 to 0.09	0.03 0.01 to 0.11	0.03 0.00 to 0.21	0.03 0.00 to 0.12	0.03 0.01 to 0.08	0.02 0.01 to 0.08	0.02 0.00 to 0.08	0.01 0.00 to 0.08	0.01 0.00 to 0.07	0.01 0.00 to 0.07	0.01 0.00 to 0.06
INS_DETEMIR	0.17 0.03 to 0.73	8.24 0.57 to 213	2.02 0.10 to 103	1.29 0.15 to 8.82	INS_DETEMIR	1.00 0.15 to 5.03	0.96 0.08 to 13.64	0.90 0.14 to 4.50	0.73 0.10 to 4.22	0.67 0.10 to 3.53	0.62 0.07 to 6.33	0.58 0.10 to 2.45	0.52 0.01 to 42.06	0.46 0.07 to 2.20	0.42 0.07 to 2.03	0.39 0.04 to 3.20	0.34 0.04 to 2.18	0.26 0.03 to 1.75	0.25 0.04 to 1.24	0.24 0.03 to 1.32	0.24 0.04 to 1.00	0.23 0.03 to 1.18	0.22 0.02 to 2.29	0.20 0.02 to 4.02	0.19 0.03 to 1.05	0.17 0.02 to 1.80	0.15 0.01 to 2.09	0.14 0.02 to 0.63	0.11 0.02 to 0.51	0.09 0.02 to 0.38	0.09 0.01 to 0.60	0.08 0.01 to 0.73	0.07 0.01 to 0.30	0.07 0.01 to 0.34	0.07 0.01 to 0.29	0.06 0.01 to 0.31	0.06 0.01 to 0.26	0.05 0.01 to 0.22	0.05 0.01 to 0.34	0.05 0.01 to 0.23	0.05 0.01 to 0.28	0.05 0.01 to 0.26	0.05 0.01 to 0.20	0.04 0.01 to 0.26	0.04 0.01 to 0.19	0.04 0.00 to 0.40	0.04 0.01 to 0.17	0.04 0.01 to 0.22	0.04 0.01 to 0.16	0.03 0.00 to 0.18	0.03 0.00 to 0.31	0.03 0.00 to 0.19	0.03 0.01 to 0.15	0.03 0.00 to 0.13	0.03 0.00 to 0.13	0.02 0.00 to 0.13	0.02 0.00 to 0.11	0.02 0.00 to 0.12	0.01 0.00 to 0.09
INS_PREMIX	0.17 0.08 to 0.36	8.14 0.95 to 189	2.08 0.17 to 85.85	1.29 0.32 to 5.80	1.00 0.20 to 6.77	INS_PREMIX	0.98 0.15 to 9.81	0.90 0.34 to 2.37	0.73 0.20 to 2.65	0.68 0.22 to 2.09	0.62 0.13 to 4.12	0.58 0.25 to 1.25	0.54 0.02 to 35.44	0.46 0.17 to 1.20	0.43 0.16 to 1.12	0.40 0.09 to 2.05	0.34 0.09 to 1.41	0.26 0.06 to 1.08	0.25 0.08 to 0.74	0.24 0.07 to 0.78	0.24 0.10 to 0.53	0.23 0.08 to 0.69	0.22 0.04 to 1.72	0.20 0.02 to 3.11	0.19 0.05 to 0.65	0.17 0.03 to 1.36	0.16 0.01 to 1.39	0.14 0.06 to 0.34	0.11 0.04 to 0.26	0.09 0.04 to 0.21	0.09 0.02 to 0.35	0.08 0.01 to 0.53	0.07 0.03 to 0.15	0.07 0.02 to 0.19	0.07 0.03 to 0.15	0.06 0.02 to 0.18	0.06 0.03 to 0.13	0.05 0.02 to 0.11	0.05 0.01 to 0.21	0.05 0.02 to 0.12	0.05 0.01 to 0.16	0.05 0.02 to 0.15	0.05 0.02 to 0.10	0.04 0.01 to 0.14	0.04 0.02 to 0.09	0.04 0.00 to 0.27	0.04 0.02 to 0.09	0.04 0.01 to 0.12	0.04 0.01 to 0.08	0.03 0.01 to 0.10	0.03 0.00 to 0.21	0.03 0.01 to 0.12	0.03 0.01 to 0.07	0.03 0.01 to 0.08	0.03 0.01 to 0.08	0.02 0.00 to 0.08	0.02 0.00 to 0.07	0.02 0.00 to 0.07	0.01 0.00 to 0.06
OTHER_ACTIVE_additional_OAD	0.18 0.02 to 0.91	8.51 0.44 to 263	2.17 0.07 to 110	1.33 0.11 to 10.60	1.04 0.07 to 12.23	1.02 0.10 to 6.54	OTHER_ACTIVE_additional_OAD	0.96 0.09 to 5.59	0.77 0.07 to 5.25	0.70 0.07 to 4.53	0.65 0.05 to 7.17	0.61 0.06 to 3.11	0.54 0.01 to 49.82	0.48 0.05 to 2.77	0.44 0.04 to 2.58	0.41 0.03 to 3.71	0.36 0.03 to 2.66	0.27 0.02 to 2.08	0.26 0.02 to 1.64	0.25 0.02 to 1.63	0.25 0.03 to 1.29	0.24 0.02 to 1.43	0.23 0.02 to 2.84	0.21 0.01 to 4.49	0.20 0.02 to 1.36	0.18 0.01 to 2.27	0.15 0.01 to 2.44	0.15 0.01 to 0.80	0.12 0.01 to 0.64	0.10 0.01 to 0.51	0.09 0.01 to 0.72	0.09 0.01 to 0.91	0.07 0.01 to 0.37	0.07 0.01 to 0.42	0.07 0.01 to 0.37	0.06 0.01 to 0.39	0.06 0.01 to 0.32	0.05 0.01 to 0.28	0.05 0.00 to 0.42	0.05 0.01 to 0.28	0.05 0.00 to 0.34	0.05 0.00 to 0.31	0.05 0.01 to 0.24	0.05 0.00 to 0.32	0.05 0.00 to 0.24	0.04 0.00 to 0.47	0.04 0.00 to 0.22	0.04 0.00 to 0.27	0.04 0.00 to 0.20	0.04 0.00 to 0.22	0.03 0.00 to 0.38	0.03 0.00 to 0.24	0.03 0.00 to 0.18	0.03 0.00 to 0.17	0.03 0.00 to 0.16	0.02 0.00 to 0.16	0.02 0.00 to 0.14	0.02 0.00 to 0.14	0.01 0.00 to 0.11
INS_LISPRO	0.19 0.10 to 0.37	9.07 1.10 to 190	2.29 0.17 to 92.13	1.41 0.37 to 5.96	1.11 0.22 to 7.33	1.11 0.42 to 2.97	1.04 0.18 to 10.97	INS_LISPRO	0.80 0.25 to 2.83	0.74 0.26 to 2.20	0.70 0.15 to 4.50	0.64 0.31 to 1.29	0.59 0.02 to 42.17	0.51 0.21 to 1.25	0.47 0.19 to 1.14	0.44 0.11 to 2.15	0.38 0.10 to 1.44	0.28 0.07 to 1.16	0.28 0.10 to 0.79	0.26 0.08 to 0.82	0.26 0.13 to 0.54	0.25 0.09 to 0.72	0.24 0.05 to 1.73	0.22 0.03 to 3.24	0.21 0.06 to 0.70	0.19 0.03 to 1.40	0.17 0.01 to 1.56	0.15 0.07 to 0.34	0.12 0.06 to 0.26	0.10 0.05 to 0.21	0.10 0.03 to 0.38	0.09 0.02 to 0.56	0.07 0.04 to 0.15	0.07 0.03 to 0.20	0.07 0.03 to 0.15	0.07 0.02 to 0.18	0.07 0.03 to 0.13	0.06 0.03 to 0.11	0.06 0.01 to 0.22	0.06 0.03 to 0.11	0.06 0.02 to 0.18	0.05 0.02 to 0.16	0.05 0.03 to 0.11	0.05 0.02 to 0.15	0.05 0.02 to 0.09	0.05 0.00 to 0.28	0.05 0.02 to 0.09	0.04 0.01 to 0.13	0.04 0.02 to 0.09	0.04 0.01 to 0.10	0.04 0.00 to 0.23	0.04 0.01 to 0.13	0.04 0.02 to 0.08	0.03 0.01 to 0.08	0.03 0.01 to 0.08	0.02 0.00 to 0.09	0.02 0.00 to 0.07	0.02 0.00 to 0.07	0.02 0.00 to 0.06
INS_ASPART	0.23 0.08 to 0.65	11.19 1.17 to 277	2.81 0.20 to 124	1.75 0.37 to 9.35	1.37 0.24 to 10.52	1.36 0.38 to 5.03	1.31 0.19 to 14.69	1.24 0.35 to 4.06	INS_ASPART	0.93 0.24 to 3.61	0.88 0.15 to 6.63	0.80 0.27 to 2.29	0.73 0.02 to 57.55	0.63 0.18 to 2.18	0.58 0.17 to 1.93	0.55 0.11 to 3.25	0.47 0.10 to 2.20	0.35 0.07 to 1.70	0.34 0.09 to 1.24	0.33 0.08 to 1.32	0.32 0.11 to 0.94	0.31 0.09 to 1.10	0.30 0.05 to 2.43	0.28 0.03 to 4.53	0.26 0.06 to 1.10	0.24 0.03 to 2.09	0.21 0.01 to 2.35	0.19 0.06 to 0.59	0.16 0.05 to 0.47	0.13 0.04 to 0.37	0.13 0.03 to 0.58	0.11 0.02 to 0.80	0.09 0.03 to 0.26	0.09 0.02 to 0.33	0.09 0.03 to 0.27	0.08 0.02 to 0.29	0.08 0.03 to 0.23	0.07 0.02 to 0.20	0.07 0.02 to 0.33	0.07 0.02 to 0.20	0.07 0.02 to 0.28	0.07 0.02 to 0.25	0.06 0.02 to 0.17	0.06 0.01 to 0.25	0.06 0.02 to 0.17	0.06 0.00 to 0.41	0.06 0.02 to 0.16	0.05 0.01 to 0.22	0.05 0.02 to 0.15	0.05 0.01 to 0.17	0.04 0.00 to 0.33	0.04 0.01 to 0.20	0.04 0.01 to 0.13	0.04 0.01 to 0.13	0.04 0.01 to 0.13	0.03 0.00 to 0.13	0.02 0.00 to 0.11	0.02 0.00 to 0.11	0.02 0.00 to 0.09
PIOGLITAZONE	0.25 0.10 to 0.59	12.01 1.44 to 270	3.07 0.22 to 126	1.88 0.44 to 9.05	1.49 0.28 to 10.35	1.47 0.48 to 4.50	1.42 0.22 to 15.29	1.35 0.45 to 3.85	1.08 0.28 to 4.12	PIOGLITAZONE	0.92 0.18 to 6.58	0.86 0.34 to 2.04	0.79 0.02 to 54.03	0.68 0.23 to 1.94	0.63 0.21 to 1.79	0.59 0.13 to 3.13	0.51 0.12 to 2.11	0.38 0.09 to 1.70	0.37 0.11 to 1.18	0.35 0.10 to 1.22	0.35 0.14 to 0.81	0.34 0.10 to 1.09	0.33 0.06 to 2.36	0.30 0.04 to 4.44	0.29 0.08 to 0.99	0.26 0.04 to 2.03	0.23 0.02 to 2.20	0.20 0.07 to 0.53	0.17 0.06 to 0.43	0.14 0.06 to 0.32	0.14 0.03 to 0.55	0.12 0.02 to 0.76	0.10 0.04 to 0.24	0.10 0.03 to 0.31	0.10 0.04 to 0.25	0.09 0.03 to 0.28	0.09 0.04 to 0.21	0.08 0.03 to 0.18	0.08 0.02 to 0.33	0.08 0.03 to 0.19	0.07 0.02 to 0.26	0.07 0.02 to 0.23	0.07 0.03 to 0.16	0.07 0.02 to 0.23	0.06 0.03 to 0.15	0.06 0.01 to 0.40	0.06 0.02 to 0.14	0.06 0.02 to 0.20	0.05 0.02 to 0.13	0.05 0.02 to 0.15	0.05 0.00 to 0.33	0.05 0.01 to 0.20	0.05 0.02 to 0.12	0.04 0.01 to 0.12	0.04 0.01 to 0.12	0.03 0.01 to 0.13	0.03 0.00 to 0.11	0.02 0.00 to 0.11	0.02 0.00 to 0.09
ROSIGLITAZONE	0.28 0.05 to 1.14	13.01 0.96 to 370	3.33 0.16 to 165	2.06 0.24 to 13.99	1.62 0.16 to 14.97	1.60 0.24 to 7.66	1.55 0.14 to 21.13	1.43 0.22 to 6.82	1.14 0.15 to 6.64	1.09 0.15 to 5.50	ROSIGLITAZONE	0.92 0.16 to 3.88	0.83 0.02 to 72.48	0.73 0.11 to 3.47	0.69 0.10 to 3.10	0.64 0.07 to 4.95	0.54 0.07 to 3.55	0.40 0.05 to 2.74	0.40 0.06 to 2.06	0.38 0.05 to 2.11	0.38 0.06 to 1.65	0.36 0.05 to 1.88	0.35 0.03 to 3.72	0.32 0.02 to 5.99	0.31 0.04 to 1.77	0.28 0.02 to 3.00	0.24 0.01 to 3.51	0.22 0.04 to 0.95	0.18 0.03 to 0.79	0.15 0.03 to 0.63	0.14 0.02 to 0.94	0.13 0.01 to 1.19	0.11 0.02 to 0.46	0.10 0.02 to 0.53	0.10 0.02 to 0.46	0.10 0.01 to 0.49	0.10 0.02 to 0.40	0.08 0.01 to 0.34	0.08 0.01 to 0.53	0.08 0.01 to 0.35	0.08 0.01 to 0.44	0.08 0.01 to 0.41	0.08 0.01 to 0.32	0.07 0.01 to 0.29	0.07 0.01 to 0.28	0.06 0.00 to 0.64	0.07 0.01 to 0.27	0.06 0.01 to 0.33	0.06 0.01 to 0.25	0.05 0.01 to 0.27	0.05 0.00 to 0.46	0.05 0.01 to 0.33	0.05 0.01 to 0.23	0.04 0.01 to 0.21	0.04 0.01 to 0.21	0.03 0.00 to 0.20	0.03 0.00 to 0.19	0.03 0.00 to 0.18	0.02 0.00 to 0.14
INS_GLARGINE	0.30 0.22 to 0.40	14.01 1.95 to 315	3.49 0.32 to 138	2.19 0.69 to 8.15	1.73 0.41 to 10.44	1.71 0.80 to 3.98	1.63 0.32 to 16.21	1.56 0.77 to 3.19	1.26 0.44 to 3.74	1.17 0.49 to 2.97	1.08 0.26 to 6.39	INS_GLARGINE	0.91 0.03 to 60.33	0.80 0.40 to 1.59	0.73 0.40 to 1.39	0.68 0.20 to 3.00	0.60 0.18 to 1.98	0.45 0.14 to 1.55	0.43 0.19 to 1.01	0.41 0.16 to 1.07	0.41 0.28 to 0.62	0.40 0.18 to 0.92	0.37 0.08 to 2.54	0.35 0.05 to 4.74	0.33 0.12 to 0.94	0.30 0.05 to 2.06	0.27 0.02 to 2.25	0.24 0.15 to 0.39	0.20 0.12 to 0.32	0.16 0.11 to 0.24	0.16 0.05 to 0.51	0.14 0.03 to 0.79	0.12 0.08 to 0.18	0.11 0.05 to 0.26	0.11 0.07 to 0.17	0.10 0.05 to 0.23	0.10 0.08 to 0.14	0.09 0.06 to 0.12	0.09 0.03 to 0.30	0.09 0.06 to 0.13	0.09 0.03 to 0.23	0.08 0.03 to 0.20	0.08 0.06 to 0.12	0.08 0.03 to 0.21	0.07 0.05 to 0.11	0.07 0.01 to 0.39	0.07 0.05 to 0.10	0.07 0.03 to 0.17	0.06 0.04 to 0.10	0.06 0.02 to 0.13	0.06 0.01 to 0.31	0.06 0.02 to 0.17	0.06 0.03 to 0.09	0.05 0.02 to 0.10	0.05 0.02 to 0.10	0.03 0.01 to 0.12	0.03 0.01 to 0.10	0.03 0.01 to 0.10	0.03 0.01 to 0.08
LINAGLIPTIN	0.33 0.01 to 9.96	16.43 0.16 to 1287	3.97 0.03 to 560	2.46 0.03 to 91.04	1.91 0.02 to 90.51	1.85 0.03 to 62.62	1.86 0.02 to 106	1.69 0.02 to 53.92	1.37 0.02 to 50.20	1.27 0.02 to 43.13	1.20 0.01 to 57.99	1.10 0.02 to 33.41	LINAGLIPTIN	0.86 0.01 to 27.65	0.80 0.01 to 25.02	0.75 0.01 to 29.09	0.65 0.01 to 24.59	0.49 0.01 to 18.55	0.48 0.01 to 15.17	0.45 0.01 to 15.51	0.45 0.01 to 14.03	0.43 0.01 to 14.69	0.42 0.01 to 21.95	0.40 0.00 to 31.48	0.36 0.00 to 12.45	0.32 0.00 to 17.01	0.27 0.00 to 17.25	0.26 0.00 to 8.00	0.21 0.00 to 6.55	0.18 0.00 to 5.37	0.17 0.00 to 6.45	0.16 0.00 to 6.51	0.13 0.00 to 3.92	0.12 0.00 to 4.19	0.12 0.00 to 3.93	0.11 0.00 to 3.73	0.11 0.00 to 3.35	0.10 0.00 to 2.88	0.10 0.00 to 3.97	0.10 0.00 to 2.91	0.09 0.00 to 3.28	0.09 0.00 to 3.19	0.09 0.00 to 2.72	0.08 0.00 to 2.95	0.08 0.00 to 2.44	0.07 0.00 to 3.49	0.08 0.00 to 2.31	0.07 0.00 to 2.44	0.07 0.00 to 2.04	0.06 0.00 to 2.04	0.06 0.00 to 2.88	0.06 0.00 to 2.25	0.06 0.00 to 1.87	0.05 0.00 to 1.71	0.05 0.00 to 1.65	0.04 0.00 to 1.36	0.03 0.00 to 1.22	0.03 0.00 to 1.13	0.03 0.00 to 1.01
GLIMEPIRIDE	0.37 0.19 to 0.70	17.70 2.29 to 409	4.44 0.38 to 176	2.77 0.76 to 12.13	2.19 0.45 to 13.84	2.16 0.83 to 5.84	2.09 0.36 to 20.69	1.97 0.80 to 4.84	1.59 0.46 to 5.45	1.47 0.52 to 4.40	1.37 0.29 to 8.85	1.25 0.63 to 2.48	1.16 0.04 to 77.12	GLIMEPIRIDE	0.92 0.38 to 2.24	0.86 0.22 to 4.26	0.74 0.19 to 2.78	0.55 0.15 to 2.23	0.54 0.19 to 1.50	0.52 0.17 to 1.57	0.51 0.25 to 1.04	0.50 0.18 to 1.40	0.47 0.10 to 3.41	0.44 0.06 to 6.03	0.42 0.13 to 1.34	0.38 0.06 to 2.75	0.34 0.03 to 3.08	0.30 0.13 to 0.67	0.24 0.11 to 0.53	0.20 0.10 to 0.40	0.20 0.05 to 0.72	0.18 0.03 to 1.07	0.15 0.07 to 0.29	0.14 0.05 to 0.39	0.14 0.07 to 0.30	0.13 0.05 to 0.35	0.13 0.07 to 0.25	0.11 0.06 to 0.21	0.11 0.03 to 0.43	0.11 0.05 to 0.22	0.11 0.03 to 0.33	0.10 0.04 to 0.29	0.10 0.05 to 0.20	0.10 0.03 to 0.30	0.09 0.05 to 0.18	0.09 0.01 to 0.54	0.09 0.04 to 0.17	0.09 0.03 to 0.26	0.08 0.04 to 0.16	0.07 0.03 to 0.20	0.07 0.01 to 0.44	0.07 0.02 to 0.25	0.07 0.03 to 0.15	0.06 0.02 to 0.15	0.06 0.02 to 0.15	0.04 0.01 to 0.17	0.04 0.01 to 0.15	0.03 0.01 to 0.14	0.03 0.01 to 0.11
INS_DEGLUDEC	0.40 0.21 to 0.74	19.02 2.42 to 420	4.78 0.40 to 194	3.00 0.87 to 12.03	2.36 0.49 to 15.22	2.34 0.89 to 6.29	2.27 0.39 to 22.39	2.13 0.87 to 5.26	1.72 0.52 to 5.74	1.59 0.56 to 4.75	1.46 0.32 to 9.83	1.36 0.72 to 2.53	1.24 0.04 to 81.42	1.08 0.45 to 2.60	INS_DEGLUDEC	0.94 0.24 to 4.52	0.80 0.22 to 3.04	0.60 0.16 to 2.39	0.59 0.22 to 1.60	0.56 0.19 to 1.66	0.56 0.28 to 1.07	0.54 0.20 to 1.45	0.51 0.10 to 3.65	0.47 0.06 to 7.20	0.45 0.14 to 1.46	0.41 0.07 to 3.02	0.37 0.03 to 3.28	0.33 0.18 to 0.59	0.27 0.12 to 0.57	0.22 0.11 to 0.43	0.22 0.06 to 0.79	0.19 0.04 to 1.16	0.16 0.08 to 0.32	0.15 0.06 to 0.42	0.15 0.07 to 0.31	0.14 0.05 to 0.37	0.14 0.07 to 0.27	0.12 0.06 to 0.23	0.12 0.03 to 0.45	0.12 0.06 to 0.23	0.12 0.04 to 0.37	0.11 0.04 to 0.33	0.11 0.06 to 0.21	0.10 0.03 to 0.32	0.10 0.05 to 0.19	0.10 0.01 to 0.59	0.10 0.05 to 0.18	0.09 0.03 to 0.27	0.08 0.04 to 0.17	0.08 0.03 to 0.22	0.08 0.01 to 0.48	0.08 0.02 to 0.27	0.08 0.03 to 0.16	0.07 0.03 to 0.16	0.06 0.02 to 0.17	0.05 0.01 to 0.18	0.04 0.01 to 0.16	0.04 0.01 to 0.15	0.03 0.01 to 0.12
STANDARD_CARE	0.43 0.10 to 1.45	20.58 1.66 to 520	5.10 0.31 to 230	3.22 0.51 to 18.84	2.54 0.31 to 22.26	2.52 0.49 to 10.74	2.44 0.27 to 31.15	2.27 0.46 to 9.46	1.82 0.31 to 9.36	1.69 0.32 to 7.56	1.57 0.20 to 13.52	1.46 0.33 to 5.10	1.33 0.03 to 96.91	1.16 0.23 to 4.49	1.07 0.22 to 4.19	STANDARD_CARE	0.85 0.13 to 4.65	0.64 0.10 to 3.71	0.63 0.12 to 2.64	0.60 0.11 to 2.62	0.60 0.13 to 2.04	0.58 0.11 to 2.43	0.55 0.07 to 5.02	0.50 0.04 to 9.06	0.48 0.08 to 2.33	0.43 0.05 to 3.99	0.39 0.02 to 4.40	0.35 0.08 to 1.25	0.29 0.06 to 1.05	0.24 0.05 to 0.82	0.23 0.04 to 1.22	0.20 0.02 to 1.71	0.17 0.04 to 0.59	0.17 0.03 to 0.71	0.17 0.04 to 0.60	0.15 0.03 to 0.66	0.15 0.03 to 0.52	0.13 0.03 to 0.43	0.13 0.02 to 0.70	0.13 0.03 to 0.45	0.12 0.02 to 0.59	0.12 0.02 to 0.53	0.12 0.03 to 0.41	0.11 0.02 to 0.51	0.11 0.02 to 0.38	0.10 0.01 to 0.84	0.10 0.02 to 0.35	0.10 0.02 to 0.47	0.09 0.02 to 0.32	0.08 0.02 to 0.36	0.08 0.01 to 0.65	0.08 0.01 to 0.42	0.08 0.02 to 0.30	0.07 0.01 to 0.27	0.06 0.01 to 0.27	0.05 0.01 to 0.28	0.04 0.01 to 0.23	0.04 0.00 to 0.24	0.04 0.01 to 0.18
INS_ICODEC	0.50 0.15 to 1.62	24.13 2.34 to 592	6.09 0.39 to 265	3.77 0.73 to 22.26	2.92 0.46 to 24.63	2.93 0.71 to 11.51	2.78 0.38 to 32.34	2.63 0.69 to 10.01	2.11 0.45 to 10.05	1.97 0.47 to 8.14	1.85 0.28 to 14.65	1.68 0.50 to 5.57	1.54 0.04 to 123	1.35 0.36 to 5.13	1.25 0.33 to 4.63	1.18 0.21 to 7.65	INS_ICODEC	0.75 0.15 to 3.92	0.73 0.18 to 2.94	0.69 0.16 to 3.10	0.69 0.21 to 2.31	0.67 0.17 to 2.59	0.63 0.10 to 5.57	0.60 0.06 to 9.77	0.57 0.12 to 2.58	0.51 0.07 to 4.62	0.45 0.03 to 5.13	0.41 0.11 to 1.41	0.33 0.09 to 1.16	0.27 0.08 to 0.89	0.26 0.05 to 1.33	0.24 0.03 to 1.75	0.20 0.06 to 0.66	0.19 0.05 to 0.79	0.19 0.05 to 0.65	0.18 0.04 to 0.72	0.18 0.05 to 0.57	0.15 0.05 to 0.50	0.15 0.03 to 0.78	0.15 0.04 to 0.50	0.15 0.03 to 0.68	0.14 0.06 to 0.32	0.14 0.04 to 0.43	0.13 0.03 to 0.59	0.13 0.04 to 0.41	0.12 0.01 to 0.94	0.12 0.04 to 0.39	0.12 0.02 to 0.50	0.10 0.03 to 0.36	0.10 0.02 to 0.38	0.10 0.01 to 0.78	0.10 0.02 to 0.47	0.09 0.03 to 0.33	0.08 0.02 to 0.31	0.08 0.02 to 0.31	0.06 0.01 to 0.31	0.05 0.01 to 0.27	0.05 0.01 to 0.25	0.04 0.01 to 0.20
GLP1RE_SC	0.67 0.19 to 2.14	32.34 3.17 to 859	8.14 0.50 to 365	5.01 0.95 to 28.66	3.90 0.57 to 32.14	3.87 0.93 to 15.52	3.76 0.48 to 45.53	3.51 0.86 to 13.47	2.85 0.59 to 13.80	2.61 0.59 to 11.56	2.47 0.37 to 20.39	2.24 0.64 to 7.27	2.03 0.05 to 146	1.81 0.45 to 6.73	1.66 0.42 to 6.09	1.56 0.27 to 9.93	1.33 0.25 to 6.65	GLP1RE_SC	0.97 0.23 to 3.90	0.92 0.20 to 4.26	0.92 0.26 to 3.01	0.90 0.22 to 3.71	0.84 0.12 to 7.65	0.79 0.08 to 13.03	0.74 0.16 to 3.49	0.67 0.08 to 6.29	0.60 0.04 to 6.44	0.54 0.14 to 1.85	0.44 0.12 to 1.53	0.36 0.10 to 1.20	0.35 0.06 to 1.84	0.32 0.05 to 2.50	0.26 0.07 to 0.87	0.25 0.06 to 1.05	0.26 0.08 to 0.76	0.23 0.05 to 0.95	0.23 0.07 to 0.76	0.20 0.06 to 0.65	0.20 0.04 to 1.04	0.20 0.06 to 0.66	0.19 0.04 to 0.88	0.19 0.04 to 0.77	0.18 0.05 to 0.59	0.17 0.04 to 0.76	0.17 0.05 to 0.55	0.16 0.01 to 1.23	0.16 0.05 to 0.50	0.15 0.03 to 0.67	0.14 0.04 to 0.47	0.13 0.03 to 0.51	0.13 0.01 to 1.01	0.13 0.02 to 0.65	0.12 0.03 to 0.43	0.11 0.03 to 0.42	0.10 0.02 to 0.40	0.07 0.01 to 0.41	0.07 0.01 to 0.36	0.06 0.01 to 0.35	0.06 0.01 to 0.28
DAPAGLIFLOZIN	0.69 0.31 to 1.51	32.39 3.87 to 752	8.24 0.65 to 323	5.06 1.24 to 23.08	3.99 0.81 to 27.19	3.96 1.35 to 12.21	3.82 0.61 to 41.44	3.59 1.26 to 10.17	2.94 0.81 to 10.97	2.69 0.85 to 9.00	2.50 0.48 to 17.41	2.30 0.99 to 5.38	2.09 0.07 to 144	1.84 0.67 to 5.17	1.69 0.62 to 4.53	1.58 0.38 to 8.46	1.36 0.34 to 5.63	1.04 0.26 to 4.44	DAPAGLIFLOZIN	0.95 0.28 to 3.19	0.95 0.41 to 2.21	0.92 0.31 to 2.75	0.87 0.16 to 6.67	0.81 0.10 to 12.10	0.78 0.27 to 2.14	0.69 0.11 to 5.29	0.62 0.04 to 5.93	0.55 0.22 to 1.39	0.45 0.18 to 1.13	0.37 0.17 to 0.81	0.37 0.09 to 1.48	0.33 0.06 to 2.04	0.27 0.11 to 0.63	0.26 0.08 to 0.80	0.26 0.11 to 0.63	0.24 0.08 to 0.72	0.24 0.11 to 0.54	0.21 0.09 to 0.47	0.21 0.05 to 0.87	0.20 0.09 to 0.48	0.20 0.06 to 0.68	0.19 0.06 to 0.60	0.19 0.08 to 0.43	0.17 0.05 to 0.62	0.17 0.08 to 0.39	0.17 0.02 to 1.06	0.16 0.07 to 0.37	0.16 0.05 to 0.53	0.14 0.06 to 0.34	0.13 0.06 to 0.28	0.13 0.01 to 0.84	0.13 0.03 to 0.48	0.13 0.05 to 0.31	0.11 0.04 to 0.30	0.10 0.03 to 0.31	0.08 0.02 to 0.33	0.07 0.01 to 0.29	0.07 0.01 to 0.28	0.06 0.01 to 0.22
OTHER_ACTIVE_investigator_choice_oral_drug	0.72 0.28 to 1.83	34.34 3.83 to 858	8.67 0.69 to 354	5.43 1.20 to 25.36	4.24 0.76 to 32.40	4.21 1.28 to 14.00	4.06 0.62 to 45.43	3.80 1.21 to 12.00	3.07 0.76 to 12.22	2.84 0.82 to 10.35	2.62 0.47 to 18.63	2.42 0.94 to 6.33	2.23 0.06 to 154	1.94 0.64 to 5.90	1.78 0.60 to 5.28	1.68 0.38 to 9.03	1.45 0.32 to 6.42	1.08 0.23 to 5.07	1.05 0.31 to 3.53	OTHER_ACTIVE_investigator_choice_oral_drug	0.99 0.38 to 2.62	0.97 0.30 to 3.26	0.92 0.16 to 6.84	0.87 0.11 to 13.16	0.81 0.21 to 3.15	0.74 0.11 to 5.98	0.65 0.04 to 6.54	0.58 0.21 to 1.62	0.47 0.17 to 1.35	0.40 0.15 to 1.04	0.39 0.09 to 1.66	0.35 0.06 to 2.38	0.28 0.11 to 0.74	0.28 0.08 to 0.92	0.28 0.10 to 0.75	0.25 0.08 to 0.84	0.25 0.10 to 0.65	0.22 0.09 to 0.54	0.22 0.05 to 0.96	0.22 0.08 to 0.57	0.21 0.05 to 0.76	0.20 0.06 to 0.71	0.20 0.08 to 0.52	0.18 0.05 to 0.72	0.18 0.07 to 0.46	0.17 0.02 to 1.17	0.17 0.06 to 0.44	0.16 0.04 to 0.62	0.15 0.05 to 0.40	0.14 0.04 to 0.46	0.14 0.01 to 0.91	0.14 0.03 to 0.58	0.13 0.05 to 0.38	0.12 0.04 to 0.36	0.11 0.03 to 0.36	0.08 0.01 to 0.38	0.07 0.01 to 0.33	0.07 0.01 to 0.32	0.06 0.01 to 0.25
SITAGLIPTIN	0.73 0.52 to 1.00	34.21 4.74 to 727	8.62 0.76 to 342	5.38 1.62 to 20.61	4.18 1.00 to 26.08	4.18 1.89 to 9.97	4.02 0.77 to 39.21	3.82 1.85 to 7.97	3.09 1.06 to 9.06	2.84 1.23 to 7.19	2.64 0.61 to 16.05	2.44 1.62 to 3.63	2.21 0.07 to 141	1.95 0.96 to 3.98	1.80 0.94 to 3.61	1.67 0.49 to 7.42	1.44 0.43 to 4.85	1.08 0.33 to 3.87	1.06 0.45 to 2.46	1.01 0.38 to 2.63	SITAGLIPTIN	0.97 0.43 to 2.25	0.92 0.20 to 6.32	0.85 0.12 to 11.60	0.82 0.30 to 2.30	0.73 0.13 to 5.14	0.66 0.05 to 5.51	0.58 0.33 to 1.03	0.48 0.27 to 0.82	0.40 0.26 to 0.60	0.39 0.11 to 1.25	0.35 0.07 to 1.85	0.29 0.19 to 0.41	0.28 0.12 to 0.64	0.28 0.16 to 0.45	0.25 0.11 to 0.57	0.25 0.17 to 0.37	0.22 0.15 to 0.30	0.22 0.07 to 0.74	0.22 0.14 to 0.34	0.21 0.07 to 0.57	0.20 0.08 to 0.49	0.20 0.13 to 0.29	0.19 0.07 to 0.52	0.18 0.12 to 0.27	0.18 0.02 to 0.94	0.17 0.12 to 0.25	0.17 0.06 to 0.43	0.15 0.09 to 0.25	0.14 0.06 to 0.32	0.14 0.01 to 0.74	0.14 0.04 to 0.43	0.14 0.08 to 0.22	0.12 0.06 to 0.24	0.11 0.05 to 0.25	0.08 0.02 to 0.29	0.07 0.02 to 0.25	0.07 0.01 to 0.24	0.06 0.02 to 0.19
CANAGLIFLOZIN	0.75 0.34 to 1.60	35.20 4.44 to 774	8.75 0.68 to 375	5.54 1.39 to 24.95	4.29 0.85 to 29.02	4.35 1.45 to 13.17	4.14 0.70 to 45.33	3.92 1.39 to 10.81	3.18 0.91 to 11.29	2.94 0.92 to 9.75	2.75 0.53 to 18.80	2.50 1.09 to 5.66	2.31 0.07 to 155	1.99 0.71 to 5.49	1.84 0.69 to 4.91	1.73 0.41 to 8.90	1.48 0.39 to 5.93	1.12 0.27 to 4.64	1.09 0.36 to 3.22	1.03 0.31 to 3.37	1.03 0.44 to 2.32	CANAGLIFLOZIN	0.96 0.18 to 7.12	0.87 0.11 to 13.30	0.84 0.24 to 2.90	0.75 0.12 to 5.88	0.67 0.05 to 6.38	0.60 0.24 to 1.46	0.49 0.20 to 1.17	0.41 0.17 to 0.92	0.39 0.10 to 1.54	0.36 0.06 to 2.17	0.29 0.12 to 0.67	0.28 0.09 to 0.87	0.28 0.11 to 0.67	0.26 0.09 to 0.77	0.26 0.11 to 0.58	0.23 0.10 to 0.49	0.23 0.06 to 0.84	0.22 0.10 to 0.50	0.22 0.06 to 0.73	0.21 0.07 to 0.64	0.21 0.10 to 0.44	0.19 0.05 to 0.67	0.19 0.08 to 0.42	0.18 0.02 to 1.14	0.18 0.08 to 0.39	0.17 0.05 to 0.57	0.15 0.06 to 0.36	0.15 0.05 to 0.43	0.14 0.01 to 0.91	0.14 0.03 to 0.55	0.14 0.05 to 0.34	0.12 0.04 to 0.33	0.11 0.04 to 0.34	0.08 0.02 to 0.35	0.07 0.01 to 0.30	0.07 0.01 to 0.30	0.06 0.01 to 0.23
GLIBENCLAMIDE	0.79 0.12 to 3.52	37.40 2.46 to 1093	9.45 0.46 to 452	5.88 0.66 to 43.06	4.64 0.44 to 45.60	4.59 0.58 to 25.47	4.39 0.35 to 61.50	4.12 0.58 to 20.72	3.34 0.41 to 21.16	3.06 0.42 to 17.19	2.82 0.27 to 29.05	2.67 0.39 to 12.04	2.40 0.05 to 197	2.11 0.29 to 10.40	1.95 0.27 to 10.04	1.83 0.20 to 13.86	1.58 0.18 to 10.47	1.19 0.13 to 8.11	1.15 0.15 to 6.07	1.08 0.15 to 6.29	1.09 0.16 to 4.99	1.04 0.14 to 5.68	GLIBENCLAMIDE	0.92 0.07 to 17.62	0.88 0.11 to 5.47	0.78 0.07 to 8.58	0.69 0.03 to 9.83	0.63 0.09 to 3.00	0.52 0.08 to 2.44	0.43 0.07 to 1.99	0.41 0.05 to 2.68	0.38 0.04 to 3.54	0.31 0.05 to 1.38	0.30 0.04 to 1.64	0.30 0.04 to 1.38	0.28 0.04 to 1.50	0.28 0.04 to 1.25	0.24 0.04 to 1.04	0.24 0.03 to 1.58	0.24 0.03 to 1.06	0.22 0.03 to 1.35	0.22 0.03 to 1.19	0.22 0.03 to 0.97	0.20 0.02 to 1.19	0.20 0.03 to 0.89	0.18 0.01 to 1.81	0.19 0.03 to 0.84	0.18 0.02 to 1.01	0.16 0.02 to 0.75	0.15 0.02 to 0.80	0.14 0.01 to 1.48	0.15 0.02 to 0.97	0.15 0.02 to 0.69	0.13 0.02 to 0.65	0.12 0.01 to 0.62	0.09 0.01 to 0.61	0.08 0.01 to 0.52	0.07 0.01 to 0.52	0.07 0.01 to 0.43
OTHER_ACTIVE_macupatide	0.85 0.06 to 5.71	40.95 1.65 to 1403	10.21 0.27 to 630	6.33 0.37 to 64.14	4.92 0.25 to 64.97	4.90 0.32 to 40.29	4.76 0.22 to 93.64	4.47 0.31 to 34.50	3.52 0.22 to 33.26	3.32 0.23 to 28.00	3.12 0.17 to 41.05	2.85 0.21 to 19.59	2.52 0.03 to 275	2.26 0.17 to 16.37	2.13 0.14 to 15.67	1.98 0.11 to 22.93	1.65 0.10 to 16.29	1.26 0.08 to 12.37	1.23 0.08 to 10.20	1.15 0.08 to 9.52	1.18 0.09 to 8.03	1.15 0.08 to 9.24	1.09 0.06 to 14.35	OTHER_ACTIVE_macupatide	0.97 0.06 to 8.41	0.84 0.05 to 9.55	0.72 0.02 to 12.88	0.69 0.05 to 4.78	0.56 0.04 to 3.87	0.46 0.03 to 3.25	0.44 0.03 to 4.03	0.41 0.02 to 5.18	0.33 0.02 to 2.27	0.32 0.02 to 2.54	0.33 0.02 to 2.29	0.29 0.02 to 2.28	0.30 0.02 to 2.01	0.26 0.02 to 1.78	0.26 0.02 to 2.32	0.25 0.02 to 1.74	0.24 0.02 to 2.15	0.23 0.02 to 1.92	0.23 0.02 to 1.57	0.22 0.01 to 1.78	0.21 0.02 to 1.45	0.19 0.01 to 2.63	0.20 0.01 to 1.37	0.19 0.01 to 1.67	0.18 0.01 to 1.23	0.17 0.01 to 1.32	0.15 0.01 to 2.04	0.16 0.01 to 1.51	0.16 0.01 to 1.14	0.14 0.01 to 1.06	0.13 0.01 to 1.02	0.09 0.00 to 0.95	0.08 0.00 to 0.83	0.08 0.00 to 0.76	0.07 0.00 to 0.66
DAPAEXEN_SC	0.89 0.32 to 2.38	43.05 4.68 to 1078	10.60 0.77 to 457	6.63 1.51 to 34.52	5.17 0.95 to 37.90	5.16 1.53 to 18.65	4.99 0.73 to 56.33	4.66 1.42 to 15.64	3.82 0.91 to 15.43	3.47 1.01 to 12.92	3.24 0.56 to 24.52	3.01 1.07 to 8.35	2.82 0.08 to 203	2.38 0.75 to 7.69	2.23 0.68 to 7.09	2.08 0.43 to 11.93	1.77 0.39 to 8.19	1.35 0.29 to 6.26	1.29 0.47 to 3.69	1.23 0.32 to 4.79	1.23 0.43 to 3.35	1.20 0.34 to 4.23	1.13 0.18 to 9.27	1.03 0.12 to 16.81	DAPAEXEN_SC	0.90 0.13 to 7.50	0.80 0.05 to 8.77	0.72 0.24 to 2.16	0.58 0.19 to 1.68	0.48 0.18 to 1.24	0.47 0.10 to 2.18	0.43 0.07 to 2.82	0.35 0.12 to 0.97	0.34 0.10 to 1.20	0.34 0.12 to 0.97	0.31 0.09 to 1.08	0.31 0.11 to 0.85	0.27 0.10 to 0.73	0.27 0.06 to 1.23	0.27 0.09 to 0.74	0.26 0.07 to 1.00	0.25 0.07 to 0.91	0.24 0.09 to 0.67	0.23 0.06 to 0.91	0.22 0.08 to 0.61	0.22 0.02 to 1.55	0.21 0.07 to 0.58	0.20 0.05 to 0.76	0.18 0.06 to 0.53	0.17 0.06 to 0.55	0.17 0.01 to 1.20	0.17 0.04 to 0.70	0.17 0.06 to 0.49	0.15 0.05 to 0.46	0.13 0.04 to 0.48	0.10 0.02 to 0.48	0.09 0.01 to 0.43	0.08 0.01 to 0.41	0.07 0.02 to 0.32
DULAMACU_SC	1.00 0.15 to 5.37	47.27 3.03 to 1417	12.37 0.52 to 654	7.45 0.77 to 61.99	5.92 0.56 to 64.68	5.79 0.74 to 38.05	5.64 0.44 to 96.34	5.30 0.71 to 32.27	4.20 0.48 to 31.79	3.90 0.49 to 26.29	3.63 0.33 to 43.67	3.35 0.49 to 18.41	3.12 0.06 to 293	2.65 0.36 to 15.68	2.43 0.33 to 14.89	2.31 0.25 to 21.86	1.98 0.22 to 14.32	1.50 0.16 to 11.78	1.44 0.19 to 9.21	1.35 0.17 to 9.40	1.38 0.19 to 7.72	1.33 0.17 to 8.66	1.29 0.12 to 15.07	1.19 0.10 to 20.63	1.11 0.13 to 7.98	DULAMACU_SC	0.88 0.04 to 12.74	0.80 0.11 to 4.59	0.65 0.09 to 3.57	0.54 0.08 to 3.00	0.52 0.06 to 3.93	0.48 0.04 to 5.05	0.39 0.06 to 2.21	0.38 0.05 to 2.47	0.38 0.05 to 2.16	0.34 0.04 to 2.19	0.35 0.05 to 1.86	0.30 0.04 to 1.65	0.30 0.03 to 2.34	0.30 0.04 to 1.69	0.29 0.03 to 1.98	0.28 0.03 to 1.78	0.27 0.04 to 1.51	0.26 0.03 to 1.74	0.25 0.04 to 1.36	0.23 0.01 to 2.69	0.24 0.03 to 1.27	0.23 0.03 to 1.52	0.21 0.03 to 1.17	0.19 0.02 to 1.25	0.18 0.01 to 2.13	0.19 0.02 to 1.40	0.19 0.03 to 1.06	0.16 0.02 to 0.97	0.15 0.02 to 1.00	0.11 0.01 to 0.93	0.10 0.01 to 0.76	0.09 0.01 to 0.74	0.08 0.01 to 0.63
BOFANG_SC	1.10 0.14 to 14.16	56.28 2.81 to 2637	14.17 0.53 to 978	8.17 0.75 to 145	6.74 0.48 to 128	6.36 0.72 to 91.44	6.50 0.41 to 181	5.75 0.64 to 78.60	4.67 0.43 to 71.31	4.38 0.45 to 60.14	4.12 0.28 to 88.82	3.67 0.45 to 50.40	3.71 0.06 to 417	2.95 0.32 to 39.83	2.73 0.30 to 35.87	2.59 0.23 to 46.14	2.20 0.19 to 34.70	1.66 0.16 to 27.20	1.62 0.17 to 22.79	1.54 0.15 to 22.83	1.50 0.18 to 20.08	1.48 0.16 to 20.20	1.45 0.10 to 30.26	1.39 0.08 to 41.82	1.24 0.11 to 18.62	1.13 0.08 to 23.61	BOFANG_SC	0.88 0.10 to 11.85	0.71 0.08 to 9.74	0.59 0.07 to 7.99	0.59 0.05 to 8.72	0.54 0.04 to 10.85	0.43 0.05 to 5.63	0.42 0.04 to 5.91	0.42 0.05 to 5.49	0.38 0.04 to 5.42	0.39 0.05 to 5.12	0.33 0.04 to 4.39	0.34 0.03 to 5.08	0.32 0.04 to 4.45	0.32 0.03 to 4.61	0.31 0.03 to 4.27	0.30 0.04 to 3.97	0.28 0.03 to 4.11	0.27 0.03 to 3.56	0.26 0.01 to 5.50	0.26 0.03 to 3.35	0.25 0.02 to 3.71	0.23 0.03 to 2.94	0.21 0.02 to 3.04	0.21 0.01 to 4.29	0.21 0.02 to 3.19	0.20 0.02 to 2.80	0.18 0.02 to 2.45	0.17 0.02 to 2.33	0.12 0.01 to 1.95	0.11 0.01 to 1.85	0.10 0.01 to 1.70	0.09 0.01 to 1.46
IDEGLIRA_SC	1.24 0.75 to 2.05	58.72 7.76 to 1290	14.81 1.29 to 573	9.13 3.12 to 31.99	7.25 1.59 to 45.17	7.17 2.98 to 18.06	6.88 1.26 to 67.37	6.54 2.94 to 14.75	5.28 1.70 to 16.64	4.90 1.88 to 13.53	4.51 1.05 to 27.99	4.17 2.57 to 6.89	3.81 0.12 to 261	3.31 1.49 to 7.42	3.08 1.69 to 5.61	2.88 0.80 to 13.29	2.47 0.71 to 8.74	1.87 0.54 to 6.91	1.82 0.72 to 4.56	1.72 0.62 to 4.83	1.71 0.97 to 3.02	1.66 0.68 to 4.21	1.60 0.33 to 10.81	1.46 0.21 to 20.69	1.40 0.46 to 4.15	1.24 0.22 to 9.01	1.14 0.08 to 9.77	IDEGLIRA_SC	0.82 0.42 to 1.56	0.68 0.38 to 1.19	0.67 0.18 to 2.32	0.60 0.12 to 3.42	0.49 0.27 to 0.87	0.47 0.19 to 1.19	0.48 0.25 to 0.87	0.43 0.18 to 1.09	0.43 0.26 to 0.73	0.38 0.23 to 0.62	0.38 0.11 to 1.35	0.37 0.21 to 0.65	0.36 0.12 to 1.08	0.35 0.13 to 0.93	0.34 0.20 to 0.59	0.32 0.11 to 0.94	0.31 0.18 to 0.53	0.31 0.03 to 1.71	0.29 0.17 to 0.50	0.28 0.09 to 0.79	0.26 0.14 to 0.49	0.24 0.10 to 0.61	0.24 0.02 to 1.36	0.23 0.07 to 0.78	0.23 0.12 to 0.45	0.20 0.09 to 0.45	0.19 0.07 to 0.47	0.14 0.03 to 0.53	0.12 0.03 to 0.46	0.12 0.02 to 0.44	0.10 0.03 to 0.34
ALBI_SC	1.53 0.96 to 2.45	71.77 9.58 to 1573	18.00 1.59 to 720	11.33 3.29 to 45.67	8.86 1.97 to 55.27	8.75 3.80 to 22.27	8.51 1.56 to 84.41	8.02 3.89 to 16.70	6.43 2.14 to 20.64	5.94 2.34 to 16.21	5.54 1.27 to 34.36	5.11 3.11 to 8.56	4.74 0.15 to 313	4.08 1.90 to 9.06	3.77 1.77 to 8.30	3.51 0.95 to 16.86	3.03 0.86 to 10.70	2.28 0.65 to 8.50	2.23 0.88 to 5.54	2.12 0.74 to 5.90	2.09 1.22 to 3.69	2.05 0.85 to 5.11	1.93 0.41 to 13.31	1.79 0.26 to 23.45	1.71 0.60 to 5.13	1.53 0.28 to 10.83	1.41 0.10 to 11.92	1.23 0.64 to 2.38	ALBI_SC	0.83 0.49 to 1.44	0.82 0.23 to 2.79	0.73 0.15 to 4.15	0.60 0.34 to 1.06	0.59 0.23 to 1.46	0.59 0.31 to 1.06	0.53 0.22 to 1.29	0.53 0.32 to 0.89	0.46 0.28 to 0.76	0.46 0.14 to 1.60	0.46 0.26 to 0.79	0.44 0.15 to 1.28	0.43 0.16 to 1.12	0.42 0.25 to 0.71	0.39 0.14 to 1.09	0.38 0.23 to 0.63	0.37 0.04 to 2.14	0.36 0.22 to 0.60	0.35 0.12 to 0.96	0.32 0.17 to 0.58	0.30 0.12 to 0.74	0.30 0.03 to 1.67	0.29 0.08 to 0.98	0.29 0.15 to 0.54	0.25 0.11 to 0.55	0.23 0.09 to 0.57	0.17 0.04 to 0.63	0.15 0.03 to 0.57	0.15 0.03 to 0.54	0.13 0.03 to 0.41
EXENER_SC	1.83 1.32 to 2.58	85.95 11.87 to 1859	21.51 1.96 to 878	13.58 4.19 to 52.36	10.57 2.62 to 61.68	10.53 4.83 to 24.69	10.09 1.95 to 98.60	9.64 4.69 to 20.13	7.81 2.70 to 23.37	7.11 3.17 to 17.59	6.70 1.58 to 40.00	6.15 4.20 to 9.20	5.68 0.19 to 364	4.91 2.47 to 10.15	4.52 2.31 to 9.26	4.18 1.22 to 19.23	3.64 1.12 to 12.23	2.76 0.83 to 9.94	2.67 1.23 to 5.89	2.52 0.96 to 6.75	2.52 1.67 to 3.84	2.46 1.09 to 5.78	2.33 0.50 to 15.31	2.15 0.31 to 29.77	2.06 0.81 to 5.50	1.85 0.33 to 12.50	1.68 0.13 to 13.94	1.48 0.84 to 2.64	1.20 0.69 to 2.06	EXENER_SC	0.98 0.28 to 3.18	0.88 0.18 to 4.96	0.72 0.47 to 1.13	0.70 0.29 to 1.64	0.70 0.42 to 1.16	0.64 0.28 to 1.47	0.64 0.44 to 0.95	0.55 0.39 to 0.79	0.56 0.18 to 1.90	0.55 0.35 to 0.86	0.53 0.20 to 1.45	0.51 0.21 to 1.27	0.50 0.35 to 0.74	0.47 0.17 to 1.31	0.46 0.32 to 0.66	0.46 0.05 to 2.33	0.43 0.29 to 0.64	0.42 0.15 to 1.10	0.38 0.23 to 0.64	0.36 0.16 to 0.79	0.36 0.03 to 1.92	0.35 0.10 to 1.09	0.34 0.20 to 0.59	0.30 0.15 to 0.60	0.28 0.12 to 0.64	0.20 0.05 to 0.71	0.18 0.04 to 0.64	0.18 0.04 to 0.62	0.15 0.04 to 0.47
EFSUBA_SC	1.87 0.61 to 6.21	89.75 9.21 to 2368	22.70 1.49 to 1085	14.07 2.76 to 79.49	11.04 1.68 to 91.84	10.90 2.86 to 46.46	10.67 1.39 to 133	9.90 2.65 to 39.80	7.85 1.73 to 39.86	7.35 1.81 to 32.07	7.04 1.07 to 61.12	6.27 1.97 to 21.86	5.93 0.15 to 414	5.03 1.39 to 20.07	4.64 1.26 to 17.85	4.38 0.82 to 28.32	3.78 0.75 to 18.88	2.82 0.54 to 16.18	2.71 0.67 to 11.47	2.58 0.60 to 11.66	2.59 0.80 to 8.97	2.53 0.65 to 10.17	2.43 0.37 to 20.96	2.27 0.25 to 34.23	2.11 0.46 to 9.83	1.92 0.25 to 18.11	1.71 0.11 to 19.34	1.50 0.43 to 5.59	1.22 0.36 to 4.39	1.02 0.31 to 3.57	EFSUBA_SC	0.90 0.14 to 7.02	0.74 0.23 to 2.50	0.71 0.18 to 2.99	0.72 0.21 to 2.51	0.66 0.16 to 2.73	0.65 0.21 to 2.20	0.56 0.18 to 1.92	0.58 0.11 to 3.03	0.56 0.17 to 1.93	0.55 0.12 to 2.47	0.52 0.13 to 2.22	0.51 0.16 to 1.74	0.48 0.11 to 2.19	0.47 0.15 to 1.63	0.45 0.04 to 3.58	0.44 0.14 to 1.49	0.43 0.10 to 1.89	0.39 0.12 to 1.40	0.37 0.09 to 1.55	0.35 0.03 to 3.01	0.36 0.07 to 1.84	0.35 0.10 to 1.22	0.31 0.08 to 1.19	0.28 0.07 to 1.16	0.21 0.03 to 1.18	0.18 0.03 to 1.04	0.18 0.03 to 0.97	0.16 0.03 to 0.78
VILDAGLIPTIN	2.08 0.39 to 9.85	98.90 7.83 to 2875	25.06 1.24 to 1270	15.40 2.04 to 113	12.43 1.37 to 126	11.97 1.87 to 68.66	11.62 1.09 to 173	11.00 1.77 to 59.07	8.80 1.25 to 57.29	8.11 1.32 to 50.15	7.82 0.84 to 80.35	6.97 1.26 to 33.83	6.42 0.15 to 557	5.59 0.94 to 30.43	5.18 0.86 to 27.50	4.89 0.59 to 40.87	4.10 0.57 to 29.08	3.09 0.40 to 22.07	3.01 0.49 to 17.75	2.85 0.42 to 17.41	2.86 0.54 to 13.74	2.78 0.46 to 15.89	2.66 0.28 to 28.41	2.45 0.19 to 46.28	2.33 0.35 to 14.82	2.08 0.20 to 23.80	1.86 0.09 to 24.95	1.68 0.29 to 8.35	1.37 0.24 to 6.77	1.13 0.20 to 5.47	1.11 0.14 to 7.30	VILDAGLIPTIN	0.82 0.15 to 3.96	0.79 0.13 to 4.48	0.80 0.14 to 3.94	0.72 0.12 to 4.20	0.73 0.14 to 3.46	0.63 0.12 to 2.96	0.62 0.09 to 4.73	0.62 0.11 to 2.98	0.60 0.09 to 3.84	0.57 0.09 to 3.39	0.57 0.11 to 2.76	0.52 0.08 to 3.44	0.52 0.10 to 2.53	0.49 0.03 to 5.14	0.49 0.09 to 2.38	0.47 0.07 to 3.04	0.43 0.08 to 2.14	0.41 0.06 to 2.29	0.39 0.02 to 3.73	0.39 0.05 to 2.67	0.39 0.07 to 1.96	0.34 0.06 to 1.78	0.31 0.05 to 1.78	0.23 0.03 to 1.67	0.20 0.02 to 1.46	0.19 0.02 to 1.46	0.17 0.02 to 1.16
SEMA_PO	2.54 1.86 to 3.48	118 16.72 to 2583	29.84 2.73 to 1137	18.78 5.74 to 73.49	14.65 3.38 to 88.75	14.66 6.61 to 34.65	14.00 2.67 to 135	13.34 6.47 to 28.17	10.76 3.82 to 32.40	9.93 4.11 to 25.73	9.19 2.16 to 56.41	8.52 5.63 to 13.07	7.75 0.25 to 475	6.79 3.39 to 13.88	6.26 3.15 to 12.91	5.83 1.70 to 26.24	5.08 1.52 to 17.05	3.79 1.15 to 13.71	3.70 1.59 to 8.81	3.52 1.35 to 9.33	3.48 2.42 to 5.17	3.39 1.49 to 8.04	3.22 0.73 to 21.21	3.02 0.44 to 40.37	2.85 1.03 to 8.05	2.54 0.45 to 17.80	2.32 0.18 to 18.78	2.04 1.15 to 3.66	1.67 0.94 to 2.93	1.39 0.88 to 2.12	1.35 0.40 to 4.38	1.22 0.25 to 6.68	SEMA_PO	0.98 0.41 to 2.22	0.97 0.58 to 1.62	0.89 0.38 to 2.04	0.89 0.61 to 1.28	0.77 0.54 to 1.09	0.77 0.24 to 2.60	0.76 0.48 to 1.20	0.74 0.27 to 1.98	0.71 0.29 to 1.76	0.70 0.47 to 1.03	0.65 0.24 to 1.78	0.63 0.42 to 0.95	0.63 0.07 to 3.29	0.60 0.41 to 0.87	0.58 0.21 to 1.53	0.52 0.33 to 0.83	0.50 0.21 to 1.15	0.50 0.05 to 2.63	0.48 0.14 to 1.52	0.47 0.28 to 0.82	0.42 0.20 to 0.83	0.39 0.17 to 0.83	0.29 0.06 to 0.97	0.25 0.06 to 0.89	0.24 0.05 to 0.84	0.22 0.06 to 0.65
MAZD_SC	2.60 1.19 to 5.90	124 14.64 to 2783	30.97 2.56 to 1291	19.60 4.82 to 88.40	15.23 2.95 to 101	14.98 5.14 to 46.78	14.55 2.38 to 160	13.74 4.97 to 39.17	11.10 3.03 to 40.29	10.25 3.26 to 34.31	9.71 1.87 to 65.48	8.70 3.79 to 20.41	8.15 0.24 to 558	6.99 2.54 to 19.62	6.46 2.39 to 17.30	6.05 1.41 to 30.95	5.17 1.27 to 21.83	3.93 0.95 to 17.41	3.82 1.25 to 11.92	3.62 1.08 to 12.41	3.57 1.56 to 8.53	3.51 1.15 to 10.84	3.34 0.61 to 25.47	3.08 0.39 to 45.69	2.94 0.83 to 10.47	2.63 0.40 to 20.28	2.36 0.17 to 22.54	2.11 0.84 to 5.23	1.70 0.69 to 4.32	1.43 0.61 to 3.42	1.41 0.33 to 5.44	1.27 0.22 to 7.90	1.02 0.45 to 2.42	MAZD_SC	1.00 0.41 to 2.40	0.91 0.30 to 2.75	0.91 0.42 to 2.03	0.79 0.35 to 1.82	0.80 0.20 to 3.26	0.77 0.33 to 1.85	0.76 0.21 to 2.66	0.72 0.23 to 2.38	0.72 0.31 to 1.64	0.67 0.20 to 2.28	0.65 0.28 to 1.54	0.63 0.06 to 4.09	0.62 0.27 to 1.41	0.60 0.18 to 2.04	0.54 0.22 to 1.34	0.51 0.17 to 1.53	0.50 0.04 to 3.29	0.50 0.12 to 1.88	0.49 0.19 to 1.22	0.43 0.15 to 1.16	0.39 0.13 to 1.19	0.29 0.06 to 1.27	0.26 0.04 to 1.12	0.25 0.05 to 1.06	0.22 0.05 to 0.83
IGLARLIXI_SC	2.61 1.73 to 4.05	124 16.51 to 2669	30.86 2.67 to 1255	19.31 5.90 to 75.47	15.13 3.45 to 92.72	15.09 6.80 to 37.03	14.49 2.74 to 143	13.67 6.58 to 30.17	11.10 3.77 to 34.28	10.29 4.04 to 27.75	9.54 2.17 to 58.41	8.74 5.85 to 13.86	8.15 0.25 to 510	6.96 3.34 to 15.09	6.49 3.18 to 13.41	6.04 1.67 to 28.20	5.18 1.54 to 18.57	3.91 1.32 to 13.26	3.81 1.59 to 9.37	3.62 1.33 to 10.31	3.59 2.21 to 6.22	3.53 1.48 to 8.73	3.31 0.72 to 23.03	3.06 0.44 to 41.96	2.93 1.04 to 8.70	2.62 0.46 to 18.73	2.36 0.18 to 20.00	2.10 1.15 to 3.94	1.70 0.94 to 3.18	1.42 0.86 to 2.38	1.40 0.40 to 4.74	1.26 0.25 to 6.96	1.03 0.62 to 1.73	1.00 0.42 to 2.44	IGLARLIXI_SC	0.92 0.38 to 2.23	0.91 0.58 to 1.48	0.79 0.50 to 1.27	0.80 0.24 to 2.72	0.78 0.47 to 1.31	0.77 0.26 to 2.15	0.73 0.29 to 1.88	0.72 0.45 to 1.17	0.67 0.24 to 1.88	0.65 0.41 to 1.06	0.64 0.07 to 3.56	0.62 0.42 to 0.93	0.59 0.21 to 1.67	0.54 0.30 to 0.98	0.51 0.21 to 1.25	0.51 0.05 to 2.81	0.50 0.14 to 1.64	0.49 0.27 to 0.91	0.43 0.20 to 0.93	0.39 0.16 to 0.95	0.29 0.07 to 1.07	0.26 0.05 to 0.94	0.25 0.05 to 0.91	0.22 0.06 to 0.69
METFORMIN	2.85 1.33 to 6.31	139 16.35 to 3008	33.16 2.70 to 1458	21.60 5.43 to 94.78	16.67 3.21 to 114	16.54 5.68 to 51.37	16.12 2.56 to 174	14.94 5.47 to 41.23	12.01 3.46 to 46.09	11.30 3.55 to 36.85	10.40 2.03 to 74.14	9.60 4.40 to 21.66	8.99 0.27 to 601	7.66 2.88 to 21.60	7.13 2.73 to 18.77	6.66 1.52 to 33.92	5.70 1.39 to 23.59	4.32 1.05 to 18.37	4.17 1.38 to 12.73	3.97 1.19 to 13.29	3.93 1.76 to 9.21	3.87 1.30 to 11.31	3.63 0.67 to 27.85	3.42 0.44 to 51.18	3.25 0.93 to 11.06	2.91 0.46 to 22.60	2.64 0.18 to 23.45	2.31 0.92 to 5.68	1.88 0.77 to 4.62	1.57 0.68 to 3.59	1.51 0.37 to 6.12	1.38 0.24 to 8.51	1.13 0.49 to 2.61	1.09 0.36 to 3.30	1.09 0.45 to 2.61	METFORMIN	1.00 0.47 to 2.17	0.87 0.39 to 1.92	0.87 0.22 to 3.64	0.85 0.37 to 1.96	0.83 0.24 to 2.81	0.80 0.25 to 2.52	0.78 0.35 to 1.77	0.73 0.21 to 2.54	0.71 0.32 to 1.62	0.70 0.07 to 4.45	0.67 0.31 to 1.54	0.65 0.19 to 2.16	0.59 0.25 to 1.40	0.56 0.18 to 1.67	0.56 0.05 to 3.48	0.55 0.18 to 1.54	0.53 0.22 to 1.32	0.47 0.17 to 1.25	0.44 0.14 to 1.29	0.32 0.06 to 1.35	0.28 0.05 to 1.23	0.27 0.05 to 1.14	0.24 0.05 to 0.91
DULA_SC	2.85 2.24 to 3.67	134 19.07 to 3016	33.44 3.10 to 1334	21.18 6.68 to 78.88	16.64 3.78 to 98.92	16.49 7.75 to 37.84	15.72 3.08 to 157	15.07 7.57 to 30.71	12.07 4.27 to 35.64	11.17 4.76 to 28.37	10.40 2.51 to 62.86	9.61 6.99 to 13.32	8.80 0.30 to 552	7.66 3.96 to 14.92	7.07 3.73 to 13.57	6.58 1.94 to 28.99	5.69 1.75 to 18.85	4.27 1.32 to 15.17	4.17 1.84 to 9.51	3.96 1.54 to 10.23	3.94 2.69 to 5.84	3.84 1.73 to 8.81	3.60 0.80 to 24.35	3.36 0.50 to 44.60	3.21 1.17 to 8.90	2.86 0.54 to 18.52	2.59 0.20 to 21.96	2.30 1.37 to 3.89	1.88 1.13 to 3.09	1.56 1.05 to 2.29	1.53 0.46 to 4.85	1.38 0.29 to 7.34	1.13 0.78 to 1.63	1.10 0.49 to 2.38	1.09 0.68 to 1.74	1.00 0.46 to 2.12	DULA_SC	0.87 0.64 to 1.16	0.87 0.27 to 2.85	0.85 0.59 to 1.24	0.84 0.32 to 2.13	0.80 0.33 to 1.91	0.79 0.57 to 1.09	0.73 0.27 to 2.00	0.72 0.51 to 1.00	0.71 0.07 to 3.68	0.68 0.49 to 0.94	0.65 0.25 to 1.68	0.59 0.37 to 0.93	0.56 0.24 to 1.24	0.56 0.06 to 2.95	0.55 0.17 to 1.64	0.53 0.32 to 0.89	0.47 0.24 to 0.91	0.43 0.19 to 0.97	0.32 0.07 to 1.12	0.29 0.06 to 0.99	0.27 0.06 to 0.95	0.24 0.07 to 0.71
LIRA_SC	3.30 2.68 to 4.12	153 22.64 to 3298	38.27 3.65 to 1538	24.33 7.84 to 92.08	19.03 4.54 to 114	18.97 8.92 to 44.05	18.21 3.61 to 172	17.39 8.72 to 35.50	14.00 5.00 to 40.89	12.88 5.61 to 32.40	12.01 2.93 to 71.61	11.05 8.01 to 15.66	10.02 0.35 to 667	8.84 4.66 to 16.95	8.18 4.42 to 15.67	7.58 2.31 to 32.87	6.54 2.02 to 21.55	4.95 1.54 to 17.36	4.82 2.15 to 10.87	4.59 1.86 to 11.33	4.55 3.28 to 6.45	4.42 2.04 to 10.15	4.14 0.96 to 27.47	3.85 0.56 to 52.86	3.73 1.37 to 10.07	3.31 0.61 to 22.44	3.04 0.23 to 24.99	2.66 1.62 to 4.39	2.17 1.32 to 3.54	1.80 1.26 to 2.58	1.77 0.52 to 5.58	1.59 0.34 to 8.49	1.30 0.92 to 1.84	1.27 0.55 to 2.84	1.26 0.79 to 1.99	1.15 0.52 to 2.56	1.15 0.86 to 1.56	LIRA_SC	1.01 0.32 to 3.19	0.99 0.67 to 1.46	0.96 0.36 to 2.54	0.92 0.39 to 2.21	0.91 0.67 to 1.24	0.85 0.31 to 2.31	0.83 0.60 to 1.14	0.82 0.09 to 4.20	0.78 0.58 to 1.05	0.75 0.28 to 1.94	0.68 0.44 to 1.07	0.65 0.29 to 1.43	0.65 0.06 to 3.37	0.63 0.19 to 1.90	0.61 0.38 to 1.01	0.54 0.28 to 1.02	0.50 0.22 to 1.10	0.37 0.09 to 1.29	0.33 0.07 to 1.13	0.31 0.07 to 1.09	0.28 0.08 to 0.84
CANALIRA_SC	3.30 1.01 to 10.24	156 15.79 to 3731	38.61 2.58 to 1725	24.56 4.74 to 136	19.14 2.94 to 153	18.85 4.78 to 77.32	18.64 2.36 to 222	17.18 4.58 to 67.30	13.84 3.07 to 65.30	12.93 3.04 to 54.47	12.03 1.89 to 97.16	11.06 3.29 to 35.64	10.12 0.25 to 756	8.76 2.32 to 32.09	8.17 2.21 to 29.37	7.62 1.44 to 48.47	6.50 1.29 to 32.48	4.93 0.96 to 25.67	4.80 1.16 to 19.54	4.50 1.04 to 19.23	4.54 1.35 to 14.46	4.37 1.19 to 15.58	4.19 0.63 to 34.55	3.85 0.43 to 62.80	3.68 0.81 to 16.33	3.31 0.43 to 30.08	2.95 0.20 to 32.88	2.65 0.74 to 9.16	2.17 0.62 to 7.23	1.80 0.53 to 5.67	1.73 0.33 to 8.94	1.61 0.21 to 11.57	1.30 0.38 to 4.19	1.25 0.31 to 5.06	1.24 0.37 to 4.20	1.15 0.27 to 4.53	1.15 0.35 to 3.70	0.99 0.31 to 3.09	CANALIRA_SC	0.98 0.29 to 3.21	0.94 0.21 to 4.41	0.91 0.22 to 3.70	0.90 0.27 to 2.80	0.83 0.18 to 3.85	0.82 0.25 to 2.64	0.78 0.06 to 6.15	0.77 0.24 to 2.49	0.75 0.17 to 3.20	0.67 0.20 to 2.26	0.64 0.16 to 2.55	0.61 0.05 to 4.84	0.62 0.12 to 3.00	0.61 0.17 to 2.09	0.54 0.14 to 1.91	0.49 0.12 to 2.05	0.37 0.06 to 1.99	0.32 0.05 to 1.73	0.30 0.05 to 1.63	0.28 0.05 to 1.34
TIRZ_SC	3.35 2.36 to 4.77	158 21.48 to 3490	39.55 3.48 to 1587	24.72 7.58 to 96.66	19.50 4.43 to 121	19.27 8.64 to 46.72	18.43 3.51 to 182	17.53 9.02 to 34.75	14.16 4.93 to 43.21	13.12 5.39 to 34.59	12.24 2.86 to 73.82	11.22 7.68 to 16.73	10.33 0.34 to 669	8.94 4.46 to 18.44	8.25 4.41 to 15.87	7.74 2.23 to 34.13	6.62 1.99 to 22.55	5.04 1.51 to 17.77	4.90 2.07 to 11.60	4.61 1.77 to 12.43	4.62 2.92 to 7.32	4.50 1.99 to 10.52	4.23 0.94 to 28.79	3.93 0.57 to 51.47	3.76 1.34 to 10.79	3.36 0.59 to 23.22	3.09 0.22 to 25.54	2.70 1.53 to 4.71	2.19 1.26 to 3.81	1.83 1.17 to 2.85	1.79 0.52 to 5.85	1.61 0.34 to 8.71	1.32 0.84 to 2.07	1.29 0.54 to 3.00	1.28 0.77 to 2.13	1.17 0.51 to 2.68	1.17 0.80 to 1.71	1.01 0.69 to 1.50	1.02 0.31 to 3.46	TIRZ_SC	0.98 0.35 to 2.61	0.94 0.38 to 2.32	0.92 0.61 to 1.39	0.86 0.32 to 2.37	0.84 0.55 to 1.28	0.82 0.09 to 4.43	0.79 0.53 to 1.19	0.76 0.28 to 2.05	0.69 0.40 to 1.18	0.66 0.27 to 1.52	0.65 0.06 to 3.59	0.64 0.18 to 1.99	0.62 0.35 to 1.11	0.55 0.27 to 1.13	0.51 0.22 to 1.18	0.38 0.08 to 1.34	0.33 0.07 to 1.17	0.32 0.07 to 1.15	0.28 0.07 to 0.88
RETA_SC	3.41 1.32 to 8.97	163 18.10 to 3947	41.37 3.04 to 1874	25.62 5.79 to 132	20.23 3.62 to 147	19.79 6.08 to 70.18	19.30 2.96 to 219	18.08 5.70 to 58.08	14.75 3.57 to 59.93	13.45 3.79 to 51.31	12.52 2.29 to 99.35	11.50 4.35 to 31.52	10.87 0.30 to 744	9.13 3.04 to 29.18	8.51 2.69 to 26.83	8.04 1.68 to 45.13	6.87 1.46 to 33.05	5.19 1.13 to 25.53	5.03 1.46 to 17.37	4.76 1.31 to 18.54	4.72 1.74 to 13.35	4.65 1.36 to 16.17	4.45 0.74 to 36.13	4.09 0.46 to 65.54	3.86 1.00 to 15.25	3.46 0.51 to 29.29	3.16 0.22 to 31.83	2.77 0.93 to 8.17	2.26 0.78 to 6.52	1.88 0.69 to 5.12	1.83 0.40 to 8.03	1.66 0.26 to 11.55	1.35 0.50 to 3.66	1.32 0.38 to 4.72	1.31 0.46 to 3.85	1.20 0.36 to 4.10	1.20 0.47 to 3.13	1.04 0.39 to 2.79	1.06 0.23 to 4.86	1.02 0.38 to 2.83	RETA_SC	0.96 0.27 to 3.54	0.94 0.36 to 2.56	0.88 0.23 to 3.50	0.86 0.32 to 2.33	0.83 0.08 to 5.77	0.81 0.30 to 2.20	0.78 0.21 to 3.07	0.70 0.26 to 2.03	0.68 0.19 to 2.28	0.65 0.06 to 4.76	0.65 0.14 to 2.87	0.64 0.23 to 1.88	0.56 0.18 to 1.75	0.52 0.15 to 1.79	0.38 0.07 to 1.91	0.34 0.06 to 1.62	0.33 0.06 to 1.57	0.28 0.06 to 1.26
ICOSEMA_SC	3.58 1.52 to 8.41	173 19.95 to 3758	42.62 3.32 to 1919	26.49 6.40 to 125	20.78 3.92 to 151	21.01 6.60 to 66.00	19.94 3.20 to 219	18.92 6.41 to 54.59	15.11 4.07 to 57.70	14.19 4.28 to 48.26	13.10 2.42 to 92.29	12.01 4.93 to 29.28	10.93 0.31 to 788	9.55 3.41 to 27.94	8.84 3.07 to 25.11	8.31 1.88 to 45.26	7.14 3.09 to 16.37	5.40 1.30 to 23.62	5.22 1.68 to 16.41	4.94 1.41 to 17.78	4.92 2.03 to 12.27	4.81 1.57 to 14.78	4.53 0.84 to 34.94	4.30 0.52 to 63.76	4.00 1.09 to 14.83	3.60 0.56 to 29.40	3.26 0.23 to 31.66	2.89 1.07 to 7.68	2.35 0.89 to 6.19	1.96 0.79 to 4.75	1.91 0.45 to 7.98	1.74 0.29 to 11.18	1.41 0.57 to 3.47	1.38 0.42 to 4.41	1.38 0.53 to 3.47	1.25 0.40 to 4.03	1.25 0.52 to 3.00	1.09 0.45 to 2.57	1.10 0.27 to 4.58	1.07 0.43 to 2.66	1.04 0.28 to 3.72	ICOSEMA_SC	0.99 0.43 to 2.24	0.92 0.24 to 3.36	0.90 0.36 to 2.17	0.87 0.08 to 5.56	0.85 0.35 to 2.05	0.82 0.22 to 2.84	0.74 0.28 to 1.88	0.70 0.22 to 2.16	0.69 0.06 to 4.71	0.68 0.16 to 2.77	0.67 0.25 to 1.75	0.59 0.20 to 1.70	0.54 0.17 to 1.73	0.40 0.08 to 1.80	0.35 0.06 to 1.57	0.34 0.06 to 1.53	0.30 0.06 to 1.18
SEMA_SC	3.64 2.80 to 4.74	170 24.44 to 3769	42.36 3.94 to 1720	26.70 8.50 to 100	21.01 4.99 to 124	21.00 9.65 to 48.66	19.96 4.12 to 190	19.16 9.50 to 39.41	15.39 5.83 to 43.20	14.21 6.09 to 36.27	13.13 3.15 to 80.73	12.20 8.59 to 17.72	11.24 0.37 to 729	9.74 4.98 to 19.43	8.96 4.71 to 17.81	8.32 2.44 to 38.34	7.21 2.32 to 23.14	5.41 1.69 to 19.15	5.33 2.31 to 12.05	5.02 1.92 to 13.17	4.99 3.45 to 7.43	4.86 2.30 to 10.50	4.57 1.03 to 30.99	4.28 0.64 to 56.49	4.08 1.49 to 11.35	3.66 0.66 to 25.20	3.35 0.25 to 27.06	2.93 1.71 to 5.01	2.39 1.41 to 4.01	1.99 1.35 to 2.88	1.96 0.57 to 6.14	1.75 0.36 to 9.44	1.44 0.97 to 2.12	1.39 0.61 to 3.19	1.39 0.85 to 2.23	1.28 0.56 to 2.83	1.27 0.92 to 1.75	1.10 0.81 to 1.50	1.11 0.36 to 3.64	1.09 0.72 to 1.63	1.07 0.39 to 2.80	1.01 0.45 to 2.33	SEMA_SC	0.93 0.35 to 2.54	0.91 0.63 to 1.31	0.90 0.09 to 4.65	0.86 0.62 to 1.21	0.83 0.31 to 2.14	0.75 0.46 to 1.20	0.71 0.31 to 1.58	0.71 0.07 to 3.78	0.70 0.20 to 2.15	0.68 0.40 to 1.14	0.60 0.30 to 1.18	0.55 0.24 to 1.26	0.41 0.09 to 1.40	0.37 0.08 to 1.24	0.35 0.07 to 1.22	0.31 0.08 to 0.91
EXENROSI_SC	3.91 1.48 to 10.28	188 20.78 to 4415	46.47 3.28 to 2082	29.20 6.46 to 147	22.86 3.88 to 171	22.71 7.02 to 76.51	21.86 3.14 to 248	20.52 6.52 to 65.64	16.69 4.07 to 68.50	15.34 4.33 to 56.71	14.04 3.49 to 83.55	13.13 4.81 to 35.99	12.07 0.34 to 834	10.36 3.34 to 32.54	9.64 3.08 to 29.95	9.02 1.98 to 50.97	7.79 1.68 to 36.12	5.78 1.31 to 27.85	5.73 1.61 to 20.22	5.43 1.39 to 20.64	5.39 1.92 to 14.86	5.29 1.50 to 18.66	4.98 0.84 to 40.01	4.61 0.56 to 72.79	4.40 1.10 to 17.44	3.91 0.58 to 34.47	3.58 0.24 to 35.58	3.16 1.07 to 9.08	2.56 0.92 to 7.28	2.13 0.76 to 5.80	2.08 0.46 to 9.12	1.92 0.29 to 13.09	1.54 0.56 to 4.22	1.49 0.44 to 5.09	1.48 0.53 to 4.14	1.38 0.39 to 4.65	1.37 0.50 to 3.64	1.18 0.43 to 3.20	1.20 0.26 to 5.50	1.17 0.42 to 3.17	1.14 0.29 to 4.34	1.09 0.30 to 4.14	1.07 0.39 to 2.87	EXENROSI_SC	0.98 0.38 to 2.48	0.95 0.09 to 6.77	0.92 0.34 to 2.50	0.89 0.24 to 3.21	0.81 0.28 to 2.29	0.77 0.22 to 2.59	0.74 0.06 to 5.11	0.74 0.16 to 3.23	0.73 0.25 to 2.08	0.64 0.20 to 2.02	0.59 0.17 to 2.05	0.43 0.08 to 2.12	0.39 0.06 to 1.81	0.37 0.06 to 1.75	0.33 0.07 to 1.41
EXEN_SC	4.00 3.06 to 5.28	187 26.07 to 4060	46.90 4.28 to 1874	29.51 9.11 to 112	22.90 5.35 to 144	22.94 11.49 to 50.36	22.17 4.23 to 213	21.10 10.84 to 41.33	16.92 5.93 to 50.43	15.65 6.79 to 38.63	14.45 3.62 to 83.64	13.41 9.45 to 19.61	12.25 0.41 to 790	10.73 5.66 to 20.46	9.85 5.17 to 19.32	9.22 2.65 to 40.41	7.97 2.41 to 26.53	5.96 1.83 to 20.98	5.84 2.56 to 13.19	5.52 2.15 to 14.67	5.50 3.72 to 8.30	5.32 2.40 to 12.50	5.06 1.13 to 33.55	4.71 0.69 to 63.73	4.49 1.65 to 12.55	4.00 0.74 to 27.77	3.66 0.28 to 30.23	3.22 1.88 to 5.62	2.63 1.59 to 4.30	2.18 1.51 to 3.16	2.15 0.61 to 6.86	1.92 0.40 to 10.51	1.58 1.05 to 2.35	1.53 0.65 to 3.55	1.53 0.95 to 2.45	1.40 0.62 to 3.14	1.40 1.00 to 1.95	1.21 0.88 to 1.67	1.21 0.38 to 4.03	1.19 0.78 to 1.81	1.16 0.43 to 3.13	1.11 0.46 to 2.74	1.10 0.76 to 1.58	1.02 0.40 to 2.62	EXEN_SC	0.99 0.11 to 5.28	0.95 0.68 to 1.31	0.91 0.36 to 2.22	0.82 0.51 to 1.34	0.78 0.34 to 1.75	0.78 0.08 to 4.26	0.77 0.23 to 2.35	0.75 0.46 to 1.21	0.66 0.33 to 1.30	0.60 0.26 to 1.38	0.45 0.10 to 1.53	0.40 0.08 to 1.37	0.38 0.08 to 1.33	0.34 0.09 to 1.02
ECNO_SC	4.03 0.79 to 37.67	205 14.37 to 8099	53.69 2.35 to 3183	30.66 3.87 to 389	25.26 2.52 to 398	23.96 3.67 to 263	24.19 2.13 to 512	21.72 3.61 to 219	17.90 2.45 to 206	15.96 2.53 to 174	15.90 1.56 to 260	13.61 2.56 to 129	13.82 0.29 to 1320	10.85 1.86 to 109	10.13 1.69 to 105	9.79 1.19 to 137	8.20 1.07 to 101	6.19 0.81 to 79.01	6.00 0.94 to 62.31	5.73 0.86 to 62.41	5.54 1.06 to 52.47	5.48 0.88 to 56.13	5.45 0.55 to 93.27	5.26 0.38 to 142	4.59 0.64 to 51.46	4.30 0.37 to 77.12	3.78 0.18 to 80.08	3.26 0.59 to 32.83	2.70 0.47 to 25.17	2.19 0.43 to 20.69	2.22 0.28 to 25.95	2.03 0.19 to 32.46	1.58 0.30 to 15.16	1.59 0.24 to 15.95	1.56 0.28 to 15.23	1.43 0.22 to 14.46	1.41 0.27 to 13.48	1.22 0.24 to 11.74	1.28 0.16 to 15.86	1.21 0.23 to 11.51	1.20 0.17 to 12.51	1.16 0.18 to 12.37	1.11 0.22 to 10.78	1.05 0.15 to 11.39	1.01 0.19 to 9.48	ECNO_SC	0.95 0.18 to 9.18	0.94 0.14 to 10.54	0.83 0.15 to 8.11	0.79 0.13 to 8.68	0.78 0.05 to 12.63	0.79 0.10 to 8.92	0.76 0.14 to 7.09	0.67 0.12 to 6.76	0.62 0.10 to 6.24	0.46 0.05 to 5.87	0.40 0.04 to 5.13	0.38 0.04 to 4.98	0.34 0.04 to 3.83
LIXI_SC	4.22 3.39 to 5.36	199 28.06 to 4356	49.53 4.57 to 1950	31.23 9.86 to 118	24.40 5.80 to 148	24.31 11.61 to 56.23	23.26 4.51 to 222	22.21 11.23 to 46.38	17.97 6.39 to 53.06	16.57 7.03 to 41.74	15.27 3.65 to 88.35	14.18 10.24 to 20.18	12.89 0.43 to 846	11.34 5.84 to 22.27	10.45 5.47 to 20.31	9.75 2.87 to 43.12	8.41 2.58 to 27.99	6.33 1.99 to 21.89	6.18 2.69 to 14.17	5.82 2.28 to 15.46	5.80 4.04 to 8.52	5.66 2.57 to 12.81	5.32 1.19 to 35.43	4.97 0.73 to 68.54	4.74 1.73 to 13.38	4.20 0.79 to 28.64	3.89 0.30 to 31.34	3.41 2.01 to 5.78	2.77 1.66 to 4.63	2.30 1.56 to 3.40	2.26 0.67 to 7.15	2.02 0.42 to 11.11	1.67 1.15 to 2.43	1.61 0.71 to 3.64	1.62 1.07 to 2.40	1.48 0.65 to 3.24	1.48 1.07 to 2.03	1.28 0.95 to 1.71	1.29 0.40 to 4.21	1.26 0.84 to 1.89	1.23 0.45 to 3.29	1.18 0.49 to 2.90	1.16 0.83 to 1.62	1.08 0.40 to 2.93	1.06 0.76 to 1.47	1.05 0.11 to 5.44	LIXI_SC	0.97 0.36 to 2.52	0.87 0.55 to 1.40	0.83 0.36 to 1.85	0.83 0.08 to 4.39	0.80 0.24 to 2.47	0.79 0.47 to 1.31	0.69 0.35 to 1.35	0.64 0.28 to 1.43	0.47 0.11 to 1.64	0.42 0.09 to 1.44	0.41 0.09 to 1.39	0.36 0.10 to 1.07
EXENIMP_IMPLANT	4.38 1.73 to 11.45	212 23.36 to 5031	53.52 3.86 to 2321	32.83 7.63 to 162	25.52 4.60 to 199	25.26 8.18 to 84.20	24.55 3.76 to 269	23.25 7.47 to 72.50	18.83 4.59 to 79.24	17.31 5.12 to 63.88	16.09 3.03 to 115	14.71 5.80 to 40.00	13.66 0.41 to 945	11.73 3.91 to 36.62	10.87 3.67 to 33.31	10.24 2.15 to 57.15	8.68 1.98 to 40.21	6.61 1.48 to 30.79	6.45 1.90 to 21.35	6.09 1.61 to 23.32	6.04 2.32 to 16.55	5.88 1.76 to 20.82	5.56 0.99 to 44.93	5.34 0.60 to 79.52	4.94 1.31 to 19.30	4.43 0.66 to 36.73	4.01 0.27 to 40.07	3.53 1.27 to 10.60	2.87 1.04 to 8.16	2.38 0.91 to 6.49	2.34 0.53 to 10.24	2.13 0.33 to 14.29	1.73 0.66 to 4.73	1.68 0.49 to 5.71	1.68 0.60 to 4.70	1.54 0.46 to 5.23	1.54 0.60 to 4.03	1.33 0.52 to 3.53	1.33 0.31 to 5.92	1.31 0.49 to 3.61	1.28 0.33 to 4.87	1.22 0.35 to 4.49	1.21 0.47 to 3.21	1.12 0.31 to 4.24	1.09 0.45 to 2.76	1.07 0.09 to 7.24	1.03 0.40 to 2.80	EXENIMP_IMPLANT	0.90 0.33 to 2.56	0.86 0.26 to 2.96	0.85 0.07 to 5.86	0.83 0.18 to 3.46	0.82 0.30 to 2.32	0.72 0.23 to 2.31	0.66 0.20 to 2.30	0.49 0.09 to 2.25	0.44 0.07 to 2.04	0.41 0.07 to 1.95	0.37 0.08 to 1.55
ORFO_PO	4.84 3.21 to 7.32	225 30.90 to 5018	57.30 5.02 to 2278	35.82 10.57 to 144	28.21 6.44 to 173	27.78 12.03 to 70.26	26.81 5.05 to 263	25.41 11.66 to 56.07	20.59 6.87 to 62.79	18.95 7.60 to 51.76	17.64 3.98 to 109	16.21 10.00 to 27.15	14.95 0.49 to 939	12.91 6.11 to 27.84	11.98 5.78 to 25.57	11.20 3.14 to 52.15	9.58 2.81 to 33.65	7.24 2.14 to 26.56	7.10 2.94 to 17.16	6.68 2.50 to 18.88	6.66 4.04 to 11.10	6.50 2.75 to 16.37	6.12 1.33 to 41.91	5.69 0.81 to 78.46	5.41 1.90 to 15.92	4.86 0.86 to 35.47	4.40 0.34 to 35.90	3.90 2.06 to 7.36	3.17 1.72 to 5.85	2.63 1.56 to 4.42	2.59 0.71 to 8.55	2.35 0.47 to 12.91	1.91 1.20 to 3.04	1.85 0.75 to 4.48	1.85 1.02 to 3.30	1.69 0.72 to 4.05	1.69 1.07 to 2.68	1.47 0.93 to 2.29	1.48 0.44 to 5.09	1.44 0.85 to 2.48	1.42 0.49 to 3.91	1.36 0.53 to 3.51	1.33 0.83 to 2.16	1.23 0.44 to 3.59	1.21 0.75 to 1.95	1.20 0.12 to 6.53	1.15 0.71 to 1.82	1.11 0.39 to 3.02	ORFO_PO	0.94 0.40 to 2.25	0.94 0.09 to 5.21	0.93 0.26 to 2.98	0.90 0.49 to 1.68	0.79 0.37 to 1.71	0.73 0.30 to 1.74	0.55 0.12 to 1.96	0.48 0.10 to 1.72	0.46 0.09 to 1.64	0.41 0.11 to 1.28
SAFIGL_PO	5.10 2.35 to 11.44	242 29.59 to 5652	61.56 4.80 to 2577	37.90 9.42 to 178	29.74 5.69 to 206	29.43 10.20 to 92.32	28.43 4.65 to 319	26.86 9.75 to 75.57	21.77 6.05 to 81.94	19.92 6.49 to 65.17	18.66 3.67 to 126	17.19 7.55 to 40.07	15.49 0.49 to 1081	13.66 5.09 to 38.92	12.66 4.59 to 34.48	11.91 2.79 to 62.72	10.15 2.60 to 42.40	7.61 1.95 to 33.07	7.44 3.53 to 16.40	7.03 2.15 to 24.27	7.02 3.10 to 16.36	6.85 2.33 to 21.58	6.49 1.25 to 47.94	6.04 0.76 to 90.02	5.77 1.83 to 18.13	5.13 0.80 to 42.11	4.69 0.33 to 43.12	4.14 1.63 to 10.41	3.35 1.35 to 8.60	2.80 1.27 to 6.22	2.70 0.65 to 11.01	2.45 0.44 to 15.76	2.01 0.87 to 4.72	1.95 0.65 to 6.02	1.96 0.80 to 4.79	1.78 0.60 to 5.41	1.78 0.81 to 4.09	1.55 0.70 to 3.50	1.56 0.39 to 6.38	1.53 0.66 to 3.69	1.47 0.44 to 5.14	1.43 0.46 to 4.63	1.41 0.63 to 3.27	1.30 0.39 to 4.64	1.28 0.57 to 2.94	1.26 0.12 to 7.88	1.21 0.54 to 2.78	1.16 0.34 to 3.86	1.06 0.44 to 2.53	SAFIGL_PO	0.99 0.09 to 6.19	0.98 0.24 to 3.52	0.95 0.40 to 2.37	0.84 0.31 to 2.31	0.78 0.25 to 2.36	0.56 0.11 to 2.48	0.51 0.09 to 2.15	0.48 0.09 to 2.11	0.43 0.10 to 1.66
ECC500_PO	5.12 0.99 to 51.01	267 17.89 to 10547	68.78 3.12 to 4524	39.95 4.83 to 537	32.04 3.21 to 569	30.13 4.69 to 351	31.60 2.60 to 653	27.07 4.41 to 318	22.64 2.99 to 260	20.61 3.06 to 236	20.34 2.17 to 328	17.21 3.23 to 173	17.51 0.35 to 1999	13.89 2.29 to 151	12.84 2.09 to 140	12.43 1.55 to 175	10.43 1.28 to 138	7.95 0.99 to 99.86	7.52 1.19 to 86.08	7.23 1.10 to 83.10	7.05 1.35 to 72.37	7.02 1.10 to 84.68	6.91 0.68 to 123	6.59 0.49 to 182	5.90 0.83 to 68.33	5.54 0.47 to 98.28	4.88 0.23 to 103	4.17 0.73 to 43.36	3.36 0.60 to 35.97	2.79 0.52 to 28.95	2.84 0.33 to 36.22	2.57 0.27 to 40.85	2.00 0.38 to 20.99	1.99 0.30 to 22.78	1.98 0.36 to 20.26	1.78 0.29 to 21.66	1.79 0.34 to 18.03	1.55 0.30 to 15.86	1.64 0.21 to 20.69	1.54 0.28 to 16.61	1.53 0.21 to 17.26	1.45 0.21 to 17.02	1.41 0.26 to 14.27	1.36 0.20 to 15.71	1.28 0.23 to 12.97	1.28 0.08 to 22.09	1.20 0.23 to 12.17	1.17 0.17 to 13.73	1.06 0.19 to 11.15	1.01 0.16 to 10.76	ECC500_PO	1.00 0.13 to 12.83	0.96 0.17 to 10.20	0.84 0.14 to 9.16	0.79 0.12 to 8.87	0.58 0.06 to 7.59	0.53 0.05 to 6.46	0.49 0.05 to 6.78	0.44 0.06 to 5.73
PEGLOX_SC	5.23 1.76 to 17.42	255 25.16 to 6331	64.59 4.35 to 3026	39.95 8.08 to 219	30.90 5.22 to 261	30.41 8.08 to 128	30.06 4.19 to 357	27.59 7.71 to 108	22.43 5.00 to 107	20.77 5.09 to 96.84	19.46 3.03 to 172	17.49 5.77 to 60.05	16.55 0.44 to 1210	14.02 4.00 to 55.47	12.95 3.65 to 50.35	12.42 2.40 to 79.22	10.42 2.12 to 54.60	7.93 1.55 to 44.69	7.64 2.09 to 31.09	7.30 1.73 to 33.05	7.24 2.31 to 25.14	7.05 1.83 to 30.39	6.88 1.03 to 63.81	6.30 0.66 to 103	5.95 1.42 to 27.03	5.38 0.72 to 48.01	4.83 0.31 to 50.86	4.26 1.29 to 15.26	3.44 1.02 to 12.65	2.85 0.92 to 9.89	2.80 0.54 to 14.35	2.56 0.38 to 19.16	2.07 0.66 to 6.96	2.01 0.53 to 8.37	1.99 0.61 to 7.19	1.83 0.65 to 5.71	1.83 0.61 to 6.01	1.58 0.53 to 5.23	1.62 0.33 to 8.46	1.56 0.50 to 5.43	1.54 0.35 to 7.11	1.47 0.36 to 6.42	1.43 0.47 to 4.92	1.36 0.31 to 6.41	1.31 0.42 to 4.41	1.27 0.11 to 10.01	1.25 0.40 to 4.19	1.20 0.29 to 5.41	1.08 0.34 to 3.84	1.03 0.28 to 4.16	1.00 0.08 to 7.96	PEGLOX_SC	0.98 0.30 to 3.67	0.86 0.24 to 3.22	0.80 0.20 to 3.28	0.57 0.10 to 3.29	0.53 0.08 to 2.83	0.49 0.07 to 2.71	0.44 0.08 to 2.20
TASP_SC	5.35 3.38 to 8.53	253 33.87 to 5773	63.69 5.52 to 2629	39.90 11.84 to 160	31.01 6.86 to 197	30.93 13.46 to 78.19	29.79 5.50 to 300	28.11 12.87 to 63.74	22.81 7.62 to 72.58	21.09 8.23 to 56.48	19.27 4.43 to 124	18.02 10.68 to 30.54	16.69 0.53 to 1124	14.33 6.72 to 31.17	13.22 6.24 to 29.28	12.41 3.38 to 58.76	10.76 3.02 to 37.49	8.06 2.33 to 30.33	7.85 3.18 to 19.34	7.46 2.66 to 21.05	7.37 4.50 to 12.39	7.15 2.97 to 18.21	6.83 1.45 to 47.26	6.31 0.88 to 84.02	6.00 2.04 to 17.89	5.37 0.95 to 39.32	4.96 0.36 to 41.31	4.33 2.23 to 8.48	3.50 1.85 to 6.71	2.92 1.68 to 5.10	2.89 0.82 to 9.78	2.59 0.51 to 14.09	2.12 1.22 to 3.59	2.05 0.82 to 5.15	2.06 1.10 to 3.69	1.87 0.76 to 4.56	1.88 1.12 to 3.13	1.63 0.99 to 2.65	1.63 0.48 to 5.88	1.60 0.90 to 2.84	1.56 0.53 to 4.41	1.50 0.57 to 3.94	1.48 0.88 to 2.48	1.37 0.48 to 3.92	1.34 0.83 to 2.18	1.31 0.14 to 7.24	1.27 0.77 to 2.12	1.22 0.43 to 3.33	1.11 0.60 to 2.05	1.05 0.42 to 2.53	1.04 0.10 to 6.02	1.02 0.27 to 3.37	TASP_SC	0.88 0.40 to 1.94	0.81 0.33 to 1.95	0.60 0.13 to 2.24	0.53 0.11 to 1.93	0.51 0.10 to 1.88	0.45 0.12 to 1.46
COTA_SC	6.09 3.25 to 11.74	289 36.70 to 6575	72.39 6.19 to 2886	45.60 12.21 to 194	35.47 7.47 to 237	35.35 13.16 to 102	33.74 6.05 to 348	31.98 13.02 to 82.19	25.75 7.61 to 89.40	23.95 8.45 to 73.79	22.36 4.80 to 148	20.48 10.28 to 41.53	18.87 0.59 to 1250	16.30 6.69 to 41.17	15.04 6.28 to 36.64	14.08 3.64 to 68.46	12.20 3.25 to 46.50	9.19 2.41 to 37.22	8.86 3.28 to 25.30	8.43 2.79 to 26.05	8.38 4.24 to 17.10	8.16 3.01 to 23.50	7.75 1.54 to 56.75	7.15 0.94 to 104	6.87 2.16 to 21.96	6.17 1.03 to 45.31	5.65 0.41 to 50.97	4.91 2.24 to 10.98	4.00 1.82 to 8.73	3.32 1.68 to 6.76	3.25 0.84 to 11.89	2.93 0.56 to 17.06	2.41 1.20 to 4.89	2.34 0.86 to 6.48	2.33 1.08 to 4.99	2.13 0.80 to 5.73	2.13 1.09 to 4.23	1.85 0.98 to 3.52	1.86 0.52 to 7.00	1.83 0.88 to 3.71	1.77 0.57 to 5.47	1.71 0.59 to 4.94	1.67 0.84 to 3.35	1.56 0.49 to 4.94	1.52 0.77 to 3.08	1.50 0.15 to 8.69	1.44 0.74 to 2.89	1.40 0.43 to 4.37	1.26 0.59 to 2.67	1.19 0.43 to 3.26	1.19 0.11 to 6.94	1.16 0.31 to 4.10	1.14 0.52 to 2.51	COTA_SC	0.91 0.33 to 2.55	0.68 0.14 to 2.75	0.61 0.12 to 2.42	0.58 0.11 to 2.35	0.51 0.13 to 1.81
LOTI_PO	6.61 3.06 to 14.62	316 37.86 to 7139	79.41 6.21 to 3132	49.45 12.04 to 220	38.96 7.42 to 262	38.19 12.89 to 123	36.86 6.17 to 387	34.89 12.44 to 99.47	28.13 7.84 to 103	25.98 8.16 to 87.28	24.00 4.76 to 167	22.12 9.87 to 52.18	20.69 0.61 to 1359	17.60 6.62 to 48.81	16.42 6.00 to 45.13	15.47 3.69 to 81.33	13.24 3.18 to 54.63	9.83 2.49 to 43.18	9.60 3.24 to 29.72	9.25 2.74 to 31.60	9.07 3.98 to 21.14	8.87 2.98 to 26.80	8.39 1.62 to 66.76	7.88 0.98 to 114	7.47 2.10 to 26.47	6.72 1.00 to 52.74	6.05 0.43 to 55.25	5.34 2.12 to 13.77	4.33 1.75 to 10.93	3.61 1.55 to 8.39	3.54 0.86 to 13.83	3.20 0.56 to 20.34	2.59 1.20 to 5.75	2.54 0.84 to 7.67	2.54 1.06 to 6.08	2.29 0.78 to 7.16	2.32 1.03 to 5.24	1.99 0.91 to 4.53	2.02 0.49 to 8.16	1.97 0.84 to 4.65	1.93 0.56 to 6.59	1.85 0.58 to 5.98	1.82 0.80 to 4.18	1.69 0.49 to 5.92	1.66 0.73 to 3.78	1.61 0.16 to 10.13	1.57 0.70 to 3.55	1.52 0.43 to 4.98	1.36 0.58 to 3.30	1.29 0.42 to 3.93	1.26 0.11 to 8.21	1.25 0.31 to 4.96	1.23 0.51 to 3.07	1.09 0.39 to 2.99	LOTI_PO	0.74 0.15 to 3.26	0.66 0.13 to 2.76	0.63 0.12 to 2.71	0.56 0.12 to 2.18
HRS7535_PO	8.90 2.69 to 37.84	441 40.98 to 12601	111 7.09 to 4949	67.33 11.86 to 453	52.53 7.82 to 498	51.75 12.09 to 274	51.93 6.27 to 710	46.65 11.57 to 233	38.05 7.61 to 229	35.13 7.95 to 193	33.62 4.98 to 315	29.91 8.59 to 132	28.57 0.74 to 2262	23.85 5.94 to 115	21.92 5.56 to 106	21.13 3.56 to 163	18.10 3.26 to 110	13.35 2.45 to 89.48	13.13 3.02 to 64.08	12.37 2.64 to 67.73	12.26 3.50 to 53.02	12.09 2.83 to 62.89	11.68 1.63 to 119	10.76 1.05 to 201	10.04 2.08 to 58.27	9.07 1.08 to 95.84	8.30 0.51 to 99.68	7.16 1.89 to 33.06	5.85 1.59 to 26.19	4.88 1.40 to 20.93	4.80 0.84 to 29.76	4.36 0.60 to 39.28	3.50 1.03 to 15.53	3.45 0.79 to 17.67	3.40 0.94 to 15.15	3.15 0.74 to 15.55	3.11 0.90 to 13.47	2.69 0.78 to 11.46	2.73 0.50 to 17.80	2.66 0.75 to 11.99	2.62 0.52 to 14.79	2.50 0.55 to 13.02	2.44 0.71 to 10.75	2.30 0.47 to 13.24	2.22 0.65 to 9.59	2.18 0.17 to 19.47	2.11 0.61 to 9.08	2.03 0.45 to 10.75	1.83 0.51 to 8.31	1.77 0.40 to 8.85	1.71 0.13 to 15.58	1.75 0.30 to 10.13	1.66 0.45 to 7.54	1.47 0.36 to 6.97	1.35 0.31 to 6.88	HRS7535_PO	0.89 0.13 to 5.89	0.84 0.12 to 5.59	0.75 0.13 to 4.39
VISEPE_SC	9.97 2.99 to 45.99	501 44.52 to 14300	125 7.74 to 5848	76.35 13.67 to 568	59.92 8.73 to 571	57.91 14.28 to 342	57.49 6.93 to 792	53.05 13.57 to 270	42.99 8.82 to 261	39.57 8.74 to 232	38.22 5.36 to 379	33.65 9.55 to 167	31.83 0.82 to 2642	26.90 6.81 to 143	24.99 6.30 to 125	24.07 4.28 to 180	20.43 3.72 to 142	15.20 2.77 to 99.00	14.86 3.40 to 82.88	14.01 3.06 to 79.82	13.72 3.98 to 64.73	13.58 3.28 to 75.92	12.91 1.91 to 146	12.29 1.21 to 243	11.47 2.35 to 72.08	10.32 1.31 to 120	9.27 0.54 to 117	8.14 2.18 to 39.93	6.58 1.76 to 32.94	5.45 1.57 to 26.29	5.43 0.97 to 36.26	4.96 0.68 to 47.39	3.95 1.13 to 17.91	3.87 0.90 to 22.24	3.83 1.07 to 19.02	3.53 0.81 to 18.97	3.51 1.01 to 17.00	3.03 0.89 to 13.92	3.11 0.58 to 19.76	3.00 0.85 to 14.47	2.95 0.62 to 17.80	2.82 0.64 to 16.32	2.74 0.80 to 13.18	2.59 0.55 to 16.24	2.51 0.73 to 11.93	2.50 0.19 to 24.04	2.36 0.70 to 11.20	2.29 0.49 to 13.54	2.07 0.58 to 9.95	1.97 0.46 to 10.70	1.89 0.15 to 19.58	1.90 0.35 to 12.70	1.87 0.52 to 9.11	1.65 0.41 to 8.34	1.52 0.36 to 8.00	1.12 0.17 to 7.67	VISEPE_SC	0.96 0.13 to 6.64	0.87 0.14 to 5.44
DANU_PO	10.41 3.05 to 48.38	517 47.94 to 15371	133 8.07 to 5829	80.76 14.09 to 559	63.19 8.61 to 643	61.66 14.19 to 347	60.89 7.40 to 904	55.99 13.82 to 282	45.04 9.33 to 281	41.67 9.30 to 249	39.81 5.70 to 397	34.99 10.00 to 170	34.33 0.88 to 3082	28.60 7.19 to 146	25.90 6.61 to 136	25.31 4.23 to 202	21.26 3.93 to 151	16.09 2.89 to 114	15.33 3.59 to 86.69	14.82 3.08 to 87.44	14.41 4.16 to 69.22	14.18 3.37 to 78.80	13.91 1.91 to 146	12.95 1.31 to 242	12.05 2.42 to 75.42	11.00 1.36 to 117	9.73 0.59 to 124	8.50 2.25 to 42.36	6.82 1.85 to 34.37	5.69 1.61 to 26.90	5.69 1.03 to 38.44	5.31 0.69 to 48.63	4.12 1.18 to 19.58	4.03 0.94 to 21.87	4.00 1.09 to 19.51	3.67 0.88 to 20.35	3.65 1.05 to 17.08	3.18 0.92 to 14.68	3.31 0.61 to 21.92	3.11 0.87 to 15.09	3.05 0.64 to 17.86	2.97 0.65 to 17.59	2.84 0.82 to 13.67	2.71 0.57 to 16.68	2.61 0.75 to 12.33	2.64 0.20 to 24.57	2.46 0.72 to 11.71	2.43 0.51 to 14.19	2.17 0.61 to 10.74	2.07 0.47 to 11.45	2.05 0.15 to 19.49	2.02 0.37 to 13.47	1.96 0.53 to 9.62	1.72 0.42 to 8.82	1.60 0.37 to 8.54	1.19 0.18 to 8.23	1.05 0.15 to 7.57	DANU_PO	0.88 0.16 to 5.55
EFPE_SC	11.74 4.09 to 41.74	573 60.78 to 15955	145 10.14 to 7079	90.00 18.00 to 554	70.30 11.38 to 630	68.71 17.94 to 320	67.65 9.49 to 830	62.47 17.42 to 263	50.81 11.12 to 271	47.01 11.33 to 219	44.14 7.28 to 394	39.74 13.13 to 146	37.70 0.99 to 2921	31.68 9.11 to 131	29.34 8.58 to 125	27.79 5.48 to 195	23.89 4.97 to 128	17.89 3.56 to 105	17.39 4.62 to 76.11	16.54 4.01 to 80.73	16.25 5.36 to 60.05	16.01 4.26 to 67.90	15.15 2.35 to 148	14.37 1.52 to 233	13.39 3.13 to 65.28	12.10 1.59 to 125	10.95 0.69 to 125	9.55 2.97 to 37.60	7.72 2.46 to 29.83	6.48 2.11 to 24.05	6.44 1.28 to 34.51	5.85 0.86 to 45.08	4.64 1.53 to 17.06	4.55 1.21 to 19.79	4.50 1.44 to 16.94	4.16 1.10 to 18.38	4.10 1.41 to 14.82	3.55 1.20 to 13.00	3.61 0.74 to 20.11	3.52 1.14 to 13.51	3.52 0.79 to 16.13	3.34 0.85 to 15.41	3.24 1.10 to 11.85	3.06 0.71 to 15.15	2.95 0.98 to 10.81	2.96 0.26 to 23.86	2.78 0.94 to 10.17	2.73 0.64 to 12.85	2.42 0.78 to 9.24	2.34 0.60 to 10.25	2.30 0.17 to 18.09	2.26 0.45 to 12.20	2.21 0.68 to 8.37	1.94 0.55 to 7.99	1.79 0.46 to 8.02	1.32 0.23 to 7.55	1.16 0.18 to 7.26	1.14 0.18 to 6.35	EFPE_SC

Heterogeneity, fit and convergence

Bayesian random effects (primary)

Heterogeneity (tau): 0.367 (95% CrI 0.269 to 0.481), log scale
Residual deviance: 459.3 for 413 data points
DIC: 762.7 (pD 303.5)
Largest R-hat: 1.002
Smallest ESS: bulk 1,357, tail 2,689
Divergent transitions: 0
Convergence: All criteria met
Priors: PR02 N(0, 5^2); PR05 N(0, 2.5^2); PR09 log normal(-2.1, 1.58^2) on tau^2 (Adverse events, pharm vs pharm)

Inconsistency

Do trials comparing two treatments directly agree with the indirect evidence through other treatments?

No comparison here has both direct and indirect evidence, so inconsistency cannot be checked by node splitting.

Small study effects

A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.

Fewer than ten trial comparisons, too few to judge funnel plot asymmetry.

Baseline characteristics of the trials

The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.

Baseline effect modifiers and prognostic factors per trial
Trial	Sex (percent female) effect modifier, prognostic factor; 188 of 194
NCT01149421 S000784	48.08
NCT00434954 S000790	30.36
NCT02229396 S000791	52
NCT03131687 S000010	46.85
NCT00754988 S000027	44.91
NCT05407961 S000034	23.57 100 minus male share
NCT02325960 S000058	37.78
NCT00518115 S000060	51.52
NCT01296412 S000080	45 100 minus male share
DUAL™ I China S000081	40.67
NCT00838916 S000099	43.94
SURPASS-6 S000108	57.68
PIONEER 4 S000133	48
NCT04965506 S000140	40.79
MAGNA VICTORIA S000142	59.74
REWIND S000147	46.35
COMBINE 2 S000155	41.87
SCALE™ Insulin S000159	52.27
Lixilan-O-AP S000170	47.4
NCT01476475 S000191	48.92
OUTSTAND-1 S000213	33.09
PB119 S000217	26.74
NCT01001104 S000232	26.19
PIONEER 10 S000234	25.74
NCT02846233 S000236	40.91
AWARD-7 S000237	47.69
NCT01584232 S000246	28.51
NCT03235050 S000257	53.72
NCT04235959 S000277	45.83
AWARD-10 S000305	49.99
SUSTAIN™ 3 S000329	44.53
NCT00393718 S000330	32.75
EGO S000337	49.24
NCT00765817 S000345	42.87
NCT01029886 S000352	45.49
LIXILAN JP-L S000356	not reported
SUSTAIN 11 S000363	48.86
NCT02765399 S000370	26.09
SUSTAIN 7 S000372	55.12
NCT00791479 S000376	55.09
REMODEL S000395	23.56
NCT00637273 S000402	48.02
SURPASS-1 S000407	48.31
NCT00717457 S000414	46.98 100 minus male share
NCT00976937 S000415	59.9 100 minus male share
NCT00516074 S000435	44.44
ACHIEVE-3 S000438	48.59
NCT00082407 S000441	48.98
AWARD-9 S000446	42.33
NCT05579977 S000448	52.05
COMBINE 1 S000458	38.11
SUSTAIN 9 S000483	41.72
GETGOAL-L-ASIA S000488	52.09
NCT04867785 S000489	55.52
GETGOAL-S S000491	49.48
LIRA-PRIME S000508	47.55
PIONEER 12 S000522	41.7
NCT06589765 S000558	35.68
SUSTAIN 10 S000584	43.33
NCT01175473 S000587	33.12
NCT03951753 S000593	26.5
NCT00960661 S000609	39.09
NCT00935532 S000632	32.08
NCT02008682 S000650	40.35
NCT03555994 S000670	33.33
NCT02229383 S000703	52.04 100 minus male share
NCT02081118 S000719	54.01
NCT00577824 S000752	31.49
ATTAIN-2 S000754	46.93
NCT02973321 S000763	48.31
LIRAVIS S000773	71.4
GetGoal-Duo1 S000792	50.22
NCT01558271 S000837	19
NCT00849017 S000852	44.88 100 minus male share
NCT01147627 S000864	36.06
NCT05759897 S000877	40.68
SUSTAIN™1 S000878	45.62
GetGoal-O S000904	48
NCT04093752 S000909	43.62
NCT01617434 S000926	43.16
NCT00135330 S000943	48.91
LIRA-Ramadan™ S000963	50.75
NCT02200991 S001003	37.5 100 minus male share
NCT00097500 S001020	34.78
ACHIEVE-5 S001044	47.07
NCT00894322 S001058	31.43
AWARD-CHN1 S001064	45.71
AWARD-8 S001068	55.86
NCT01733758 S001075	not reported
NCT00359762 S001097	46
LIRA-SWITCH™ S001119	40.5
LixiLan-G S001125	47.47
AWARD-2 S001130	48.52
DUAL™ VIII S001131	45.16
DURATION-NEO-2 S001157	47.12
NCT05514535 S001161	44.19
AWARD-6 S001184	52.09
GetGoal-M-Asia S001185	50.64
NCT03985293 S001191	49.21
NCT00701935 S001193	47.5
NCT01191268 S001198	46.49
LixiLan-O S001199	49.44
GETGOAL-P S001204	47.52
SUSTAIN™ 4 S001219	not reported
NCT00375492 S001222	62.37
NCT04504396 S001230	39.7
DUALTM IX S001236	41.2 100 minus male share
SURPASS-4 S001287	37.51
NCT00877890 S001308	42.13
SUSTAIN S001311	42.5
NCT00360334 S001323	31.49
DUAL™ V S001328	49.73
NCT04552470 S001336	13.51
NCT01003184 S001355	32.88
STRIDE S001363	24.62
SOLID-DKD S001370	26.07
LixiLan-L S001409	53.26
NCT02324842 S001422	37.78
NCT00917267 S001437	not reported
GETGOAL-X S001439	46.32
NCT00299871 S001455	50.18 100 minus male share
NCT02212067 S001486	31.97 100 minus male share
SUSTAIN™ S001498	28.47
LEAD-2 S001502	41.77
NCT01620489 S001504	49.1
NCT05486065 S001555	48.69
GETGOAL-F1 S001563	55.59
SURPASS-3 S001591	44.04
NCT00460941 S001597	56.5
SURPASS-5 S001608	44.42
NCT03322631 S001634	2.1
NCT00744926 S001638	not reported
NCT00603239 S001737	40.61
PIONEER 1 S001741	49.22
NCT02420262 S001760	55.14
NCT00641056 S001768	45.61
ELEGANT S001780	38
NCT01126580 S001786	56.26
PIONEER 11 S001791	36.27
NCT01272232 S001792	49.76
NCT00943917 S001812	50.32
SUSTAIN 8 S001847	46.19
SUSTAIN™ 5 S001872	43.83
NCT02229227 S001887	54.27
NCT00382239 S001906	31.14 100 minus male share
SUSTAIN™ 6 S001933	39.28
SURPASS-SWITCH S001940	48.18
PIONEER 9 S001943	21.4
AGAC2 S001949	43.29
ACHIEVE-1 S001950	48.12
NCT01632163 S001963	54.65 100 minus male share
DUAL™ I Japan S001965	29.07
NCT05086445 S001999	3.33 100 minus male share
NCT00423501 S002003	51.83
LIXILAN JP-O1 S002018	35.85
GETGOAL-L S002023	53.83
PIONEER 5 S002025	51.85
DUAL™ II Japan S002038	36.67
NCT03550378 S002039	48.8
AMPLITUDE-M S002081	46.06
SUSTAIN™ S002082	23.72
NCT02288273 S002087	43.99 100 minus male share
LEAD-5 S002098	43.38
Lixilan-L-CN S002110	41.81 100 minus male share
NCT04998032 S002121	46.97
AWARD-1 S002153	41.51
GETGOAL-M S002188	58.44
NCT03311724 S002256	40.54
NCT05048719 S002265	40.99
PIONEER 3 S002267	47.16
DUAL™ II S002285	43.58
NCT04466904 S002331	42
GETGOAL-MONO S002333	47.28
NCT02113332 S002357	35.47
NCT00700817 S002361	47.07
PIONEER 8 S002369	45.96
NCT06256523 S002776	41.95
S002858 S002858	35.35
S002904 S002904	36.67
S002928 S002928	32.37
S002946 S002946	18.7 100 minus male share
S002947 S002947	35.85
S002951 S002951	36.57
S002969 S002969	77.78
NCT05654831 S002988	44.85 100 minus male share
S002991 S002991	45
S002992 S002992	50.15
S003009 S003009	48.75
S003023 S003023	35.05 100 minus male share
S003041 S003041	28.57
S003047 S003047	21.73 100 minus male share
S003058 S003058	33.33
S003072 S003072	33.61
S003079 S003079	not reported

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.

FlagBaseline, Sex: design means range from 23.6 (DULA_SC vs DULAMACU_SC vs OTHER_ACTIVE_macupatide) to 57.7 (INS_LISPRO vs TIRZ_SC) percent female; threshold 15
FlagEligibility, hba1c entry range: a design requires hba1c 1000 or more while another admits only 8 or less
FlagEligibility, bmi entry range: a design requires bmi 50 or more while another admits only 30 or less
NoteOutcome assessment, time point: selected time points span 0.43 to 365.26 weeks
NoteOutcome assessment, analysis set: mixed: completers 3, full_analysis 8, modified_itt 13, other 3, other;safety 1, randomized 12, safety 154
NoteOutcome assessment, definition: mixed: ADA 2018 level 2 (below 3.0 mmol/L); level 3 row zero in all arms 1, ADA 2018 level 2, glucose below 3.0 mmol/L; level 3 printed as zero in all arms 1, adverse event term hypoglycemia, threshold not stated 1, all hypoglycemia, PG 70 mg/dL or less and/or symptoms, treatment period 1, any hypoglycemia, blood glucose below 70 mg/dL 1, Any signs or symptoms of hypoglycemia regardless of glucose 1, confirmed: severe or plasma glucose below 3.1 mmol/L 1, documented plasma glucose below 3.0 mmol/L regardless of symptoms 1, Documented symptomatic, plasma glucose 3.9 mmol/L or lower 1, glucose below 3.0 mmol/L; no severe events in any arm 1, Grade 1 or 2 hypoglycemia below 3.9 mmol/L 1, Hypoglycaemia reported as treatment emergent adverse event 1, Hypoglycemia adverse event of special interest 1, hypoglycemia adverse event term, any severity 1, Hypoglycemia adverse event term;Severe hypoglycemia, undefined 1, hypoglycemia adverse event, definition not stated 1, hypoglycemia adverse reaction, undefined 1, hypoglycemia below 3.0 mmol/L or requiring assistance 1, hypoglycemia glucose 3.9 mmol/L or lower; both events mild 1, Hypoglycemia preferred term, mostly mild by investigator 1, hypoglycemia reported as serious adverse event; level not stated 1, hypoglycemia requiring medical assistance 1, hypoglycemia, definition not stated 1, investigator reported symptomatic hypoglycemia 1, level 2 hypoglycemia, glucose below 54 mg/dL 1, level 3 severe hypoglycemia 2, minor (symptomatic, glucose below 54 mg/dL) or major hypoglycemia 1, minor: symptomatic, glucose below 3.0 mmol/L, not major 1, minor: symptoms with glucose below 3 mmol/L, self treated or resolved 1, not stated 138, participants with serious adverse events 2, plasma glucose 54 mg/dL or lower 1, serious acute kidney injury 1, serious adverse event term hypoglycaemia 1, serious adverse events 1, serious hypoglycaemia adverse event 1, Severe (ADA) or glucose confirmed below 3.1 mmol/L with symptoms 1, severe (ADA) or symptomatic with plasma glucose below 3.1 mmol/L 1, severe hypoglycemia 1, severe hypoglycemia needing assistance of another person 1, Severe hypoglycemia needing medical treatment 1, severe hypoglycemia needing third party assistance 1, Severe hypoglycemia requiring assistance of another person 1, severe hypoglycemia with severe cognitive impairment needing medical treatment 1, severe or blood glucose confirmed below 3.1 mmol/L with or without symptoms 1, severe symptomatic hypoglycemia needing assistance 1, severe, requiring assistance of another person 1, severe: third party assistance with glucose below 2.8 mmol/L or prompt recovery 1, symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery 1, symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery with carbohydrate 1, Symptomatic hypoglycemia with glucose below 60 mg/dL or symptoms without measurement 1, symptomatic hypoglycemia with plasma glucose below 3.3 mmol/L or prompt recovery with carbohydrate 1, TEAE leading to death 1, TEAE preferred term hypoglycemia, not necessarily protocol defined 1, Zero implied by no hypoglycemia of any kind 1
NoteOutcome assessment, adjudicated: mixed: not stated 192, yes 2
NoteOutcome assessment, proportion method: mixed: not stated 190, observed 4
NoteOutcome assessment, intercurrent events (discontinuation): mixed: not stated 187, treatment_policy 1, while_on_treatment 6
NoteOutcome assessment, intercurrent events (rescue): mixed: hypothetical 1, not stated 189, treatment_policy 4
NoteRisk of bias, blinding: mixed: double_blind 111, not_reported 1, open_label 75, single_blind 7
NoteRisk of bias, funding: mixed: industry 178, mixed 6, non_industry 8, not_reported 2
NoteData handling, input conversions: arms_combined 81, count_from_percent 13, nonserious_only 159, printed_denominator 26

Comparability items per trial
Trial	time weeks	analysis set	definition	instrument	adjudicated	proportion method	intercurrent events (discontinuation)	intercurrent events (rescue)	blinding	funding	start year	Eligibility
NCT01149421	26	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2010	adults 18 or older; HbA1c 7 to 9.5 percent; stable oral agents
NCT00434954	26	full_analysis	not stated	not stated	not stated	observed	not stated	not stated	open_label	industry	2007	adults with T2D on metformin, HbA1c 6.5 to 10.0 percent
NCT02229396	104	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 or older; HbA1c 8.0 to 12.0 percent on metformin 1500 mg/d or more
NCT03131687	30	safety	severe hypoglycemia needing assistance of another person	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 50; diet and exercise or metformin
NCT00754988	156	safety	hypoglycemia adverse event, definition not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	age 18 to 75; HbA1c 7.0 to 10.0 percent; BMI 25 (23 Asian) to 45; metformin at least 1500 mg
NCT05407961	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	Age 18 to 70; BMI 23 to 45; HbA1c 7.0 to 10.0 on metformin or diet, 6.0 to 9.5 on DPP-4 or SGLT2 inhibitor (washed out)
NCT02325960	16	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	mixed	2015	age 18 to 70; BMI 24 or more; HbA1c 7.0 to 10.0 percent; metformin 1.5 g/day or more
NCT00518115	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2007	age 18 to 75; BMI 20 to 40; HbA1c 7 to 10 percent; drug naive or metformin
NCT01296412	26	safety	investigator reported symptomatic hypoglycemia	not stated	not stated	not stated	not stated	not stated	open_label	industry	2011	age 18 to 79; HbA1c 7.0 to 11.0 percent on metformin 1500 mg or more; eGFR 60 or more
DUAL™ I China	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2017	Chinese adults 18 y or older; HbA1c 7.0 to 10.0; BMI 40 or less; metformin with or without one OAD
NCT00838916	164	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	age 18 or older, HbA1c 7.0 to 10.0 percent, BMI 20 to 45, creatinine clearance above 60
SURPASS-6	56	safety	not stated	not stated	yes	not stated	while_on_treatment	not stated	open_label	industry	2020	adults 18 or older; HbA1c 7.5 to 11 percent; BMI 23 to 45; basal insulin at least 30 U/day with or without up to 2 oral drugs
PIONEER 4	57	safety	not stated	not stated	not stated	not stated	while_on_treatment	treatment_policy	double_blind	industry	2016	Age 18 or older; T2D on metformin with or without SGLT2i; HbA1c 7.0 to 9.5 percent; eGFR 60 or more
NCT04965506	24	safety	glucose below 3.0 mmol/L; no severe events in any arm	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	age 18 to 75; HbA1c 7.0 to 10.5 percent; BMI 20 to under 40; diet or metformin
MAGNA VICTORIA	26	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	mixed	2015	South Asian descent; age 18 to 74; BMI 23 or more; HbA1c 6.5 to 11.0 percent
REWIND	365.26	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2011	age 50 or older with T2D; HbA1c 9.5 percent or less; BMI 23 or more; CV disease or risk factors
COMBINE 2	57	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2022	adults T2D on GLP-1 RA with or without oral drugs; HbA1c 7.0 to 10.0 percent
SCALE™ Insulin	58	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 or older; BMI 27 or higher; HbA1c 6.0 to 10 percent; basal insulin plus up to 2 oral drugs
Lixilan-O-AP	24.43	safety	documented plasma glucose below 3.0 mmol/L regardless of symptoms	not stated	not stated	not stated	not stated	not stated	open_label	industry	2019	adults with T2D on metformin with or without a second OAD; HbA1c 7.5 to 11 percent, or 7 to 10 percent with a non SGLT2i second OAD
NCT01476475	24	safety	Documented symptomatic, plasma glucose 3.9 mmol/L or lower	not stated	not stated	not stated	not stated	not stated	open_label	industry	2011	Adults with T2D; HbA1c 7 to 10 percent on metformin at least 1.5 g/day; insulin naive
OUTSTAND-1	32	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2024	age 18 to 75; HbA1c 7.0 to 10.0 percent; BMI 19.0 to 40.0; diet and exercise only
PB119	24	safety	Severe hypoglycemia needing medical treatment	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2020	age 18 to 75; HbA1c 7.5 to 11.0 at screening and 7.0 to 10.5 at randomization; BMI 18.5 to 40; eGFR 60 or more; drug naive
NCT01001104	12	safety	all hypoglycemia, PG 70 mg/dL or less and/or symptoms, treatment period	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	Japanese T2D age 20 to 74; BMI 18.5 to 40; HbA1c 7.0 to 9.5 percent after lead in
PIONEER 10	57	safety	not stated	not stated	yes	not stated	while_on_treatment	treatment_policy	single_blind	industry	2017	Japanese adults 20 or older; T2D; HbA1c 7.0 to 10.5 percent on one oral glucose lowering drug
NCT02846233	16	randomized	any hypoglycemia, blood glucose below 70 mg/dL	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2016	age over 21; BMI 30 or more; HbA1c above 8 percent; eGFR above 45; basal plus prandial or premixed insulin
AWARD-7	52	safety	Hypoglycaemia reported as treatment emergent adverse event	not stated	not stated	not stated	treatment_policy	treatment_policy	single_blind	industry	2012	adults with T2D and CKD stage 3 to 4 (eGFR 15 to below 60); HbA1c 7.5 to 10.5 percent on insulin; maximal ACEI or ARB; BMI 23 to 45
NCT01584232	26	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2012	Japanese adults 20 years or older; BMI 18.5 to less than 35 kg/m2; HbA1c 7.0 to 10.0 percent; on sulfonylurea and/or biguanide
NCT03235050	58	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 or older; BMI 25 or higher; HbA1c 7.0 to 10.5 percent; on metformin
NCT04235959	28	safety	hypoglycemia glucose 3.9 mmol/L or lower; both events mild	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2020	Chinese adults 20 to 70 years, HbA1c 7.0 to 10.5 diet only or 6.5 to 10.0 on one OAM, BMI 23 or more
AWARD-10	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2015	T2D; HbA1c 7.0 to 9.5 percent; BMI 45 or lower; SGLT2i with or without metformin
SUSTAIN™ 3	62	safety	not stated	not stated	not stated	not stated	while_on_treatment	not stated	open_label	industry	2013	age 18 or older; T2D on stable 1 to 2 oral drugs; HbA1c 7.0 to 10.5 percent; eGFR 60 or more
NCT00393718	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 20 or older; HbA1c 7.4 to 10.4 percent NGSP; with or without prior oral agents
EGO	16	safety	serious adverse events	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	overweight or obese adults with type 2 diabetes
NCT00765817	30	full_analysis	minor: symptoms with glucose below 3 mmol/L, self treated or resolved	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults 18 or older; insulin glargine 20 U/d or more alone or with metformin or pioglitazone; HbA1c 7.1 to 10.5 percent; BMI 45 or less
NCT01029886	26	modified_itt	not stated	not stated	not stated	not stated	while_on_treatment	not stated	open_label	industry	2010	adults 18 or older with type 2 diabetes on oral agents, HbA1c 7.1 to 11.0 percent, BMI 45 or less
LIXILAN JP-L	26.43	randomized	not stated	not stated	not stated	not stated	while_on_treatment	treatment_policy	open_label	industry	2016	Japanese adults; T2D over 1 year; HbA1c 7.5 to 9.5 on basal insulin plus 1 or 2 oral drugs
SUSTAIN 11	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2018	adults; HbA1c above 7.5 to 10.0 percent on insulin glargine plus metformin
NCT02765399	16	safety	not stated	not stated	not stated	not stated	not stated	not stated	single_blind	mixed	2015	age 30 to 75; BMI 27 to 40; HbA1c 6 to 9 percent; lifestyle or metformin
SUSTAIN 7	45	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2016	age 18 or older; HbA1c 7.0 to 10.5 percent; eGFR 60 or higher; metformin background
NCT00791479	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults with type 2 diabetes on no background glucose lowering drug
REMODEL	57	randomized	serious acute kidney injury	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	T2D with HbA1c 9.0 percent or less; eGFR 30 to 75; UACR 20 to under 5000 mg/g
NCT00637273	26	modified_itt	not stated	not stated	not stated	observed	not stated	not stated	double_blind	industry	2008	age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 25 to 45; stable metformin
SURPASS-1	44	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	adults; HbA1c 7.0 to 9.5 percent; BMI 23 or higher; no glucose lowering drug in prior 90 days
NCT00717457	104	safety	adverse event term hypoglycemia, threshold not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2008	age 18 to 75; HbA1c 7 to 10 percent; BMI 25 to 45 (above 23 for Asians); metformin with or without TZD
NCT00976937	24	safety	severe symptomatic hypoglycemia needing assistance	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	age 18 to under 50; BMI 30 or more; HbA1c 7.0 to 10 percent; metformin at least 1.5 g/day
NCT00516074	12	modified_itt	severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2007	age 18 to 75; HbA1c 6.5 to 9.5 percent; BMI 25 to 40; metformin and/or thiazolidinedione
ACHIEVE-3	57	safety	hypoglycemia reported as serious adverse event; level not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2023	adults T2D on metformin; HbA1c 7.0 to 10.5 percent
NCT00082407	52	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2003	Age 30 to 75; HbA1c 7.0 to 11.0 on metformin plus sulfonylurea; BMI 25 to 40
AWARD-9	28	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	adults with T2D on basal insulin glargine with or without metformin
NCT05579977	28	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	age 18 to 75; T2D cohort on metformin, HbA1c 7.0 to 10.0, BMI 23 or more; obesity cohort BMI 30 or more without diabetes
COMBINE 1	57	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2022	adults 18+; HbA1c 7.0-10.0%; BMI 40 or less; basal insulin 20-80 U/day; eGFR 30 or more
SUSTAIN 9	36	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	adults 18 or older (20 in Japan); HbA1c 7.0 to 10.5 percent; stable SGLT2i with or without metformin or SU
GETGOAL-L-ASIA	24	safety	symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	age 25 to 81; type 2 diabetes at least 1 year; stable basal insulin at least 10 U/day with or without sulfonylurea; HbA1c 7 to 10 percent
NCT04867785	40	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	age 18 to 75; HbA1c 7.0 to 10.5 percent; BMI 25 to 50; diet and exercise or stable metformin
GETGOAL-S	120	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults on sulfonylurea with or without metformin; HbA1c 7 to 10 percent
LIRA-PRIME	105	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2016	adults; HbA1c 7.5 to 9.0 percent; stable metformin monotherapy
PIONEER 12	31	safety	ADA 2018 level 2, glucose below 3.0 mmol/L; level 3 printed as zero in all arms	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	adults with type 2 diabetes on metformin, HbA1c 7.0 to 10.5 percent
NCT06589765	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2024	age 18 to 75; HbA1c 7.5 to 11.0 percent; BMI 19 to 40; metformin monotherapy; eGFR 45 or more
SUSTAIN 10	35	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2017	adults with T2D, HbA1c 7.0 to 11.0 percent on 1 to 3 oral drugs
NCT01175473	4.43	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2010	age 37 to 74; HbA1c 6.5 to 9.0 percent; BMI above 20 and below 37; metformin 1.5 g/day or more
NCT03951753	32	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	age 20 to 74; BMI 25 to 45; metformin with or without one other oral agent
NCT00960661	30	other	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	age 18 or older; T2D on insulin glargine and metformin with or without sulfonylurea; HbA1c 7.0 to 10.0; BMI 25.0 (23.0 in South Korea) to 45.0; HbA1c above 7.0 after optimization
NCT00935532	26	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	type 2 diabetes on biguanide with or without thiazolidinedione
NCT02008682	26	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2013	Chinese adults 18 to 80; HbA1c 7.0 to 10.0 on metformin; BMI 45 or lower
NCT03555994	9	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2018	adults; BMI 27 to 40; HbA1c 8.0 or lower on metformin alone
NCT02229383	38	safety	minor: symptomatic, glucose below 3.0 mmol/L, not major	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	adults; insulin glargine 20 U/d or more with or without metformin; HbA1c 7.0 to 10.5 percent at randomization
NCT02081118	22	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 to under 75; metformin; HbA1c 7.0 to 10 percent; BMI under 40
NCT00577824	24	full_analysis	Any signs or symptoms of hypoglycemia regardless of glucose	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	age 20 to 75; HbA1c 7.0 to 10.0 percent JDS; weight 50 kg or more; sulfonylurea based oral therapy
ATTAIN-2	74	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2023	adults with type 2 diabetes; BMI 27 or higher; HbA1c 7.0 to 10.0 percent
NCT02973321	26.4	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2016	adults with type 2 diabetes and overweight or obesity
LIRAVIS	2	randomized	not stated	not stated	not stated	not stated	not stated	not stated	single_blind	not_reported	2016	adults with type 2 diabetes on one or two oral drugs; HbA1c 7 percent or more; eGFR 30 or more; incretin naive
GetGoal-Duo1	24.43	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	T2D on metformin 1.5 g or more with or without SU, glinide or TZD, HbA1c 7 to 10, BMI over 20; HbA1c 7 to 9 after run in
NCT01558271	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	Japanese; age 20 or more; BMI 18.5 to 35; HbA1c 7.0 to 10.0 percent; OAM naive or OAM stopped
NCT00849017	164	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2009	age 18 or older; HbA1c 7.0 to 10.0 percent; BMI 20 to 45; diet and exercise only
NCT01147627	48	randomized	not stated	not stated	not stated	not stated	not stated	not stated	open_label	mixed	2010	newly diagnosed drug naive T2D; age 30 to 70; HbA1c 7 to 10 percent; BMI 20 to 35
NCT05759897	16	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2023	age 18 to 75; BMI 19.0 to 40.0; HbA1c 7.5 to 11.0 on stable metformin
SUSTAIN™1	35	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 or older (20 in Japan); HbA1c 7.0 to 10.0 percent; drug naive on diet and exercise; eGFR 30 or more
GetGoal-O	24.43	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2013	age 70 or older; type 2 diabetes uncontrolled on basal insulin and/or oral drugs; eGFR 30 or higher
NCT04093752	44	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2019	adults with T2D on metformin with or without sulfonylurea
NCT01617434	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	age 18 to 80; HbA1c 7.0 to 10.0 percent; BMI 20 to 45; basal insulin analogue 20 U or more with or without metformin
NCT00135330	20	randomized	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2005	age 18 to 75; BMI 25 to 40; HbA1c 6.8 to 10.0 percent; stable metformin only
LIRA-Ramadan™	30	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	age 18 to 80; HbA1c 7 to 10 percent; BMI 20 or more; metformin plus sulfonylurea; intent to fast in Ramadan
NCT02200991	4.43	safety	severe hypoglycemia needing third party assistance	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	age 20 to 75; T2D 5 years or more; HbA1c 7.0 to 10.0; FBG 180 mg/dL or less; stable glargine
NCT00097500	64	other;safety	Hypoglycemia adverse event term;Severe hypoglycemia, undefined	not stated	not stated	not stated	not stated	not stated	open_label	industry	2004	age 30 to 75; HbA1c 6.5 to 9.5 percent; BMI 25 to 40; on metformin
ACHIEVE-5	42	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2023	adults with T2D on insulin glargine with or without metformin or SGLT2 inhibitor
NCT00894322	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	single_blind	industry	2009	adults with T2D on diet and exercise, metformin, TZD or both
AWARD-CHN1	26	safety	severe, requiring assistance of another person	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	age 18 or older; BMI 19 to 35 kg/m2; HbA1c 7.0 to 10.5 percent OAM naive or 6.5 to 10.0 percent on OAM monotherapy
AWARD-8	24	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2013	age 18 or older; BMI up to 45; HbA1c 7.5 to 9.5 percent on sulfonylurea at least half maximal dose
NCT01733758	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2013	Japanese adults; diet and exercise with or without one oral drug; HbA1c 7 to 10 percent after washout
NCT00359762	234.81	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2006	age 18 to 85; BMI 25 to below 40; HbA1c 6.5 to below 9.0 percent on maximum tolerated metformin
LIRA-SWITCH™	27	safety	confirmed: severe or plasma glucose below 3.1 mmol/L	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2013	age 18 or more; HbA1c 7.5 to 9.5 percent; BMI 20 or more; on sitagliptin 100 mg and metformin for 90 days or more
LixiLan-G	26	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2016	T2D 1 year or more; HbA1c 7 to 9 percent; BMI over 20 to 40; maximum tolerated GLP-1 RA plus metformin
AWARD-2	78	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2010	type 2 diabetes on metformin and glimepiride
DUAL™ VIII	108.29	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2016	adults with type 2 diabetes uncontrolled on oral drugs, insulin naive
DURATION-NEO-2	28	safety	minor (symptomatic, glucose below 54 mg/dL) or major hypoglycemia	not stated	not stated	not stated	not stated	not stated	open_label	industry	2013	age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 45 or lower; metformin 1500 mg or more
NCT05514535	45	safety	level 3 severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	open_label	industry	2022	adults with T2D, BMI 25 or more, HbA1c 7 to 10 percent, basal insulin up to 40 U/day plus metformin with or without SGLT2i
AWARD-6	30	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2012	adults; HbA1c 7 to 10 percent; metformin 1500 mg/day or more
GetGoal-M-Asia	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2010	Asian adults with type 2 diabetes on metformin with or without sulfonylurea
NCT03985293	20	safety	TEAE preferred term hypoglycemia, not necessarily protocol defined	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	age 18 to 75; HbA1c 7 to 10.5 percent; BMI 22.5 (Asia) or 24.5 to 45.4; metformin or diet and exercise
NCT00701935	26.07	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults with T2D on metformin
NCT01191268	56	safety	participants with serious adverse events	not stated	not stated	not stated	not stated	not stated	open_label	industry	2010	adults with type 2 diabetes on conventional insulin with or without metformin
LixiLan-O	30.29	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	adults; HbA1c 7.5 to 10% on metformin or 7 to 9% on metformin plus second OAD; 7 to 10% after run in
GETGOAL-P	132	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	type 2 diabetes on pioglitazone 30 mg or more with or without metformin; HbA1c 7 percent or more
SUSTAIN™ 4	35	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	adults with T2D, insulin naive, on metformin with or without SU; HbA1c 7.0 to 10.0 percent
NCT00375492	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	type 2 diabetes; weight loss trial
NCT04504396	24	safety	severe hypoglycemia with severe cognitive impairment needing medical treatment	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2020	age 18 to 75; HbA1c 7.0 to 10.5 percent; BMI 40 or lower; eGFR 60 or higher; metformin monotherapy at least 1000 mg
DUALTM IX	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2016	adults; insulin naive type 2 diabetes on SGLT2 inhibitor with or without other oral drugs; HbA1c 7.0 to 11.0 percent; BMI 20 to 40
SURPASS-4	108	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2018	age 18 or older; HbA1c 7.5 to 10.5 percent; BMI 25 or more; increased cardiovascular risk; 1 to 3 oral agents
NCT00877890	24	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 25 to 45
SUSTAIN	35	safety	Severe (ADA) or glucose confirmed below 3.1 mmol/L with symptoms	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	Adults 18 or older, HbA1c 7.0 to 10.5 percent on metformin monotherapy, eGFR 60 or more
NCT00360334	26	full_analysis	severe: third party assistance with glucose below 2.8 mmol/L or prompt recovery	not stated	not stated	not stated	not stated	not stated	open_label	industry	2006	BMI above 27; HbA1c 7.5 to 10.0 percent; 2 or 3 oral drugs; at least one CV risk factor
DUAL™ V	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2013	T2D uncontrolled on insulin glargine 20 to 50 U plus metformin
NCT04552470	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2020	Japanese adults 20 to 70, diet and exercise only, HbA1c 7 to 10.5 percent, BMI 22.5 to 45.4
NCT01003184	26	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	age 18 or older; HbA1c 7.1 to 10.0 percent; BMI 25 to 45; metformin with or without SU
STRIDE	57	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2020	age 18 or more; type 2 diabetes; symptomatic PAD Fontaine IIa; ABI 0.90 or less or TBI 0.70 or less
SOLID-DKD	18	safety	level 3 severe hypoglycemia	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2024	age 18 to 75; T2D with UACR 300 to below 3000 mg/g; eGFR 30 or more; HbA1c 6.5 to 10; BMI 20 to 40
LixiLan-L	30	safety	serious hypoglycaemia adverse event	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	adults with T2D on basal insulin 15 to 40 U/d; HbA1c 7 to 10% and glargine 20 to 50 U after run in
NCT02324842	17.38	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	T2DM, HbA1c 7 to 11 percent, eGFR 60 or more, drug naive or metformin with or without SU
NCT00917267	36	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	Asian adults 20 or older; HbA1c 7 to 11; BMI 21 to 35; on oral drugs
GETGOAL-X	116	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2008	age 21 to 84; HbA1c 7 to 10 percent; metformin at least 1.5 g/day
NCT00299871	13.43	safety	symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery with carbohydrate	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 30 to 75; HbA1c 7.0 to below 9.0 percent on metformin at least 1000 mg/day
NCT02212067	17	randomized	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 to 64; HbA1c 6.5 to 9.0 percent; BMI 20 to 35; diet and exercise or metformin
SUSTAIN™	62	safety	severe (ADA) or symptomatic with plasma glucose below 3.1 mmol/L	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	Japanese adults 20 or older; HbA1c 7.0 to 10.5 percent; diet and exercise or OAD monotherapy; eGFR 30 or more
LEAD-2	104.28	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 18 to 80; HbA1c 7 to 11 percent on one OAD or 7 to 10 on combination; BMI 40 or less; no recent insulin
NCT01620489	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	type 2 diabetes; eGFR 30 to 59 mL/min/1.73m2 (MDRD); oral drugs and/or insulin
NCT05486065	49	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	age 18 to 64; HbA1c 7.0 to 10.5; BMI 27 or more; on metformin
GETGOAL-F1	112	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults with T2D on metformin
SURPASS-3	56	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2019	insulin naive; HbA1c 7.0 to 10.5 percent; BMI at least 25; metformin with or without SGLT2i; eGFR above 45
NCT00460941	8	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2007	age 18 to 75; HbA1c 7.0 to 9.5 percent on metformin; BMI above 25 to 45
SURPASS-5	44	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	HbA1c 7.0 to 10.5 percent; BMI 23 or higher; insulin glargine above 0.25 U/kg or 20 U daily with or without metformin
NCT03322631	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	Japanese adults 20 to 70; T2D 1 year or more on diet or metformin or DPP-4 inhibitor (washed out); BMI 20 to 35
NCT00744926	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	age 18 to 80; drug naive; HbA1c 6.5 to 10 percent; BMI 25 to 45
NCT00603239	26	safety	participants with serious adverse events	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	type 2 diabetes on a thiazolidinedione with or without metformin
PIONEER 1	31	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2016	adults with type 2 diabetes on diet and exercise only; HbA1c 7.0 to 9.5 percent
NCT02420262	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2015	age 18 or older; HbA1c 7.0 to 10.0; BMI up to 40; glargine 20 to 50 U plus metformin
NCT00641056	84	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2008	age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 25 to 45; metformin with or without sulfonylurea
ELEGANT	26	randomized	Grade 1 or 2 hypoglycemia below 3.9 mmol/L	not stated	not stated	not stated	not stated	not stated	open_label	industry	2012	age 18 to 75; BMI 25 or more; HbA1c 6.5 to 8.5 percent; insulin 3 to 16 months with 4 percent weight gain
NCT01126580	52	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2010	type 2 diabetes on diet and exercise or one oral drug; registry gives no ranges
PIONEER 11	31	safety	ADA 2018 level 2 (below 3.0 mmol/L); level 3 row zero in all arms	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2019	age 18 or older; HbA1c 7.0 to 10.0 percent at screening, 7.0 to 9.5 at randomization; no glucose lowering drugs; eGFR 60 or more
NCT01272232	68	safety	hypoglycemia adverse event term, any severity	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2011	adults with T2D, BMI 27 or more, HbA1c 7.0 to 10.0 percent, diet alone or up to 3 oral drugs
NCT00943917	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2009	age 18 to 70; HbA1c 7 to 10 percent; BMI 40 or less; stable metformin 3 months
SUSTAIN 8	57	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 or older; HbA1c 7.0 to 10.5 percent; eGFR 60 or higher; metformin 1500 mg or maximum tolerated
SUSTAIN™ 5	35	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 or older (20 in Japan); HbA1c 7.0 to 10.0 percent; stable basal insulin with or without metformin; eGFR 30 or more
NCT02229227	26	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	age 18 to 75; HbA1c 7.0 to 9.5 percent at screening; BMI 40 or less; basal plus prandial insulin
NCT00382239	12	full_analysis	Hypoglycemia preferred term, mostly mild by investigator	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 20 to 75; HbA1c 7 to 10 percent on sulfonylurea based therapy; weight 50 kg or more
SUSTAIN™ 6	109	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2013	T2D HbA1c 7.0 or more; age 50 or more with CVD, CHF or CKD stage 3 or more, or age 60 or more with CV risk factor
SURPASS-SWITCH	44	modified_itt	level 2 hypoglycemia, glucose below 54 mg/dL	not stated	not stated	observed	not stated	not stated	open_label	industry	2022	age 18 or older; HbA1c 7.0 to 9.5 percent; BMI 25 or more; stable dulaglutide 0.75 or 1.5 mg
PIONEER 9	57	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	Japanese adults 20 y or older; HbA1c 6.5 to 9.5 on one oral drug washed out, or 7.0 to 10.0 on diet and exercise
AGAC2	0.43	randomized	not stated	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2011	age over 20, T2DM over 2 years, A1C 8 to 12 percent, premixed insulin twice daily over 0.6 U/kg/day
ACHIEVE-1	42	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2023	adults with type 2 diabetes on diet and exercise alone; HbA1c 7.0 to 9.5 percent
NCT01632163	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2012	adults; T2D at least 1 year; HbA1c 7 to 10.5 at screening, 7 to 9.5 after run in; basal insulin at least 15 U
DUAL™ I Japan	53	safety	severe or blood glucose confirmed below 3.1 mmol/L with or without symptoms	not stated	not stated	not stated	not stated	not stated	open_label	industry	2015	Japanese adults 20 or older; HbA1c 7.0 to 11.0 percent; BMI at least 20; insulin naive on one oral drug
NCT05086445	14	safety	Hypoglycemia adverse event of special interest	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	Japanese; age 20 to 70; BMI 20 to 35; HbA1c 7.0 to 10.0 diet only or 6.5 to 9.0 on one OAM, withdrawn 28 days
NCT00423501	12	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2007	age 18 to 75; metformin 1500 mg or more; HbA1c 7 to 9.5 percent; BMI 25 to 45
LIXILAN JP-O1	52.43	safety	TEAE leading to death	not stated	not stated	not stated	not stated	not stated	open_label	industry	2016	insulin naive Japanese adults; HbA1c 7.5 to 10%; FPG 13.8 mmol/L or less; one or two OADs
GETGOAL-L	125	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	adults; HbA1c 7.0 to 10.0 percent; stable basal insulin with or without metformin
PIONEER 5	31	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2016	type 2 diabetes; HbA1c 7.0 to 9.5 percent; moderate renal impairment
DUAL™ II Japan	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2016	Japanese adults; BMI 23 kg/m2 or more; HbA1c 7.5 to 11.0 percent; basal or premix insulin 20 to 50 U with metformin
NCT03550378	8.43	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2018	age 18 to 84; BMI 25 to 45; eGFR 30 to 59; HbA1c 6.5 to 10.5 percent
AMPLITUDE-M	56	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	type 2 diabetes on diet and exercise, HbA1c 7 to 10 percent, no glucose lowering drug in prior 3 months
SUSTAIN™	35	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	Japanese; age 20 or older; HbA1c 6.5 to 9.5 percent on one OAD or 7.0 to 10.5 percent on diet and exercise
NCT02288273	14	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2014	age 18 to 75; T2D on metformin 1500 mg or more; HbA1c 7.0 to 10.0 percent; BMI 45 or less
LEAD-5	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 18 to 80; HbA1c 7.5 to 10 on monotherapy or 7 to 10 on combination; BMI 45 or lower
Lixilan-L-CN	30.43	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2019	Chinese adults; HbA1c 7.0 to 10.5 percent; basal insulin 10 to 25 U/day with up to 2 oral drugs; FPG at most 8.9 mmol/L
NCT04998032	24	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	age 18 to 75; metformin monotherapy; HbA1c 7.5 to 10.5 at randomization; BMI 18.5 to 40; eGFR 60 or higher
AWARD-1	56	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2010	adults with type 2 diabetes on metformin and pioglitazone
GETGOAL-M	76.43	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	type 2 diabetes on metformin 1.5 g/day or more for 3 months; HbA1c 7 to 10 percent; FPG 13.9 mmol/L or less
NCT03311724	16	modified_itt	plasma glucose 54 mg/dL or lower	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 45; diet or stable metformin
NCT05048719	28	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	adults with type 2 diabetes, HbA1c 7.0 to 10.5 percent, BMI 23 or more, diet or metformin
PIONEER 3	83	safety	serious adverse event term hypoglycaemia	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2016	adults with T2D; HbA1c 7.0 to 10.5 percent; metformin with or without sulfonylurea
DUAL™ II	27	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2011	HbA1c 7.5 to 10 percent; BMI 27 or higher; basal insulin 20 to 40 U plus metformin with or without SU or glinides
NCT04466904	20	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2020	age 18 to 75; T2D on diet and exercise or stable metformin; HbA1c 7.5 to 11.0 percent; BMI 20 to 35
GETGOAL-MONO	12.43	safety	symptomatic hypoglycemia with plasma glucose below 3.3 mmol/L or prompt recovery with carbohydrate	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2008	age 20 to 85; HbA1c 7.0 to 10.0 percent; no glucose lowering drug for 3 months
NCT02113332	24	full_analysis	Severe hypoglycemia requiring assistance of another person	not stated	not stated	not stated	not stated	hypothetical	double_blind	industry	2013	T2D on multiple daily insulin injections; HbA1c 7.5 to 11.5 percent; BMI 27.5 to 45 kg/m2
NCT00700817	52	other	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2008	age 18 to 80; HbA1c 7.5 to 10%; BMI 45 or less; metformin 1500 mg/day or more for 3 months
PIONEER 8	57	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2017	adults with type 2 diabetes on basal, premixed or basal bolus insulin with or without metformin
NCT06256523	29	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	age 18 to 65; HbA1c 7.0 to 10.0 percent; BMI 18.5 to 35; eGFR 60 or more
S002858	24	randomized	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry		T2D age over 35; clinical CKD; eGFR above 30 mL/min; stable ACE inhibitor or ARB
S002904	12	full_analysis	hypoglycemia, definition not stated	not stated	not stated	not stated	not stated	not stated	open_label	mixed	2014	age 20 or older; HbA1c 8.0 percent or more; diet or oral drugs; no insulin or GLP-1 RA
S002928	24	safety	hypoglycemia below 3.0 mmol/L or requiring assistance	not stated	not stated	not stated	not stated	not stated	single_blind	non_industry	2022	age 18 to 65; BMI 50 or more; type 2 diabetes
S002946	26	randomized	Zero implied by no hypoglycemia of any kind	not stated	not stated	not stated	not stated	not stated	open_label	not_reported	2020	age over 20; T2D on liraglutide 0.6 or 0.9 mg; no new diabetes drug for 3 months
S002947	25	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2021	age 18 to 65; HbA1c 7.0 to 10.5 percent; BMI 20 to 35; diet or one oral agent washed out
S002951	16	safety	not stated	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2022	age 18 to 65; BMI 25 or more; HbA1c 7.0 to 10.0 percent; lifestyle or one OAD
S002969	52.14	randomized	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2018	age 18 to 70; BMI 30 to 50; HbA1c 48 to below 97 mmol/mol; T2DM under 10 years; undergoing LAGB
NCT05654831	4.86	safety	not stated	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2022	MAD: age 18 to 70; BMI 24 to 40; HbA1c 7.0 to 10.5 percent; T2DM on metformin or lifestyle
S002991	13.04	other	hypoglycemia adverse reaction, undefined	not stated	not stated	not stated	not stated	not stated	not_reported	non_industry	2023	age 65 or older; newly diagnosed T2D; UACR 30 to 300 mg/g; eGFR 60 to 90
S002992	26	safety	not stated	not stated	not stated	observed	not stated	not stated	open_label	industry		adults 18 or older; HbA1c 7.5 to 10 percent; BMI 20 to less than 40; basal insulin 20 to 50 U plus metformin with or without SGLT2i
S003009	24	completers	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2023	age 18 or more; HbA1c 7.0 to 10.0 percent; eGFR 30 to 90; UACR above 30 to 5000 mg/g
S003023	0.43	modified_itt	not stated	not stated	not stated	not stated	not stated	not stated	single_blind	non_industry		age 20 to 80, T2D not on insulin, elective CABG or valve surgery with cardiopulmonary bypass
S003041	2	full_analysis	not stated	not stated	not stated	not stated	not stated	not stated	open_label	industry	2014	Japanese; age 40 to 70; BMI below 30; HbA1c 6.0 to 8.5 percent
S003047	6.57	safety	Symptomatic hypoglycemia with glucose below 60 mg/dL or symptoms without measurement	not stated	not stated	not stated	not stated	not stated	double_blind	industry	2006	age 20 to 75; HbA1c 7.0 to 10.0 percent; BMI 35 or less; sulfonylurea with or without metformin
S003058	12	completers	not stated	not stated	not stated	not stated	not stated	not stated	open_label	non_industry		age 20 to 90; HbA1c 7.0 to 10.0 percent; on insulin glargine plus sitagliptin 50 mg at least 8 weeks
S003072	14	completers	not stated	not stated	not stated	not stated	not stated	not stated	open_label	mixed	2011	age 20 to 80; HbA1c above 6.9 percent on sitagliptin 50 mg for 3 months or more
S003079	5	safety	hypoglycemia requiring medical assistance	not stated	not stated	not stated	not stated	not stated	open_label	non_industry	2010	age 18 to 80, HbA1c 7.5 to 12 percent, BMI 21 to 35, T2D at least 6 months

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.

Trial data entering this analysis
Trial	Arm	Treatment	Week	Data	Events / N	Flags	Source
NCT03131687	A1	PLACEBO	30	arm, events	3 / 51		R0016215:Table 3
NCT03131687	A2+A3+A4+A5	TIRZ_SC	30	arm, events	45 / 213	arms_combined	R0016215:Table 3
NCT03131687	A6	DULA_SC	30	arm, events	16 / 54		R0016215:Table 3
NCT00754988	A2+A3	TASP_SC	156	arm, events	207 / 388	arms_combined	R0022521:Table 2
NCT00754988	A4	SITAGLIPTIN	156	arm, events	32 / 185		R0022521:Table 2
NCT05407961	A1	OTHER_ACTIVE_macupatide	12	arm, events	1 / 15		R0015193:Table 2
NCT05407961	A2	DULA_SC	12	arm, events	5 / 29		R0015193:Table 2
NCT05407961	A3	DULAMACU_SC	12	arm, events	2 / 28		R0015193:Table 2
NCT02325960	A1	EXEN_SC	16	arm, events	3 / 22		R0024438:Results
NCT02325960	A2	INS_GLARGINE	16	arm, events	0 / 23		R0024438:Results
NCT00518115	A1	PLACEBO	24	arm, events	6 / 52	nonserious_only	registry:adverse_events
NCT00518115	A10+A3+A4+A5+A6+A7+A8+A9	ALBI_SC	24	arm, events	87 / 274	nonserious_only;arms_combined	registry:adverse_events
NCT00518115	A2	EXEN_SC	24	arm, events	14 / 35	nonserious_only	registry:adverse_events
NCT01296412	A1	SITAGLIPTIN	26	arm, events	10 / 326		R0026295:Table 3
NCT01296412	A2	LIRA_SC	26	arm, events	63 / 327		R0026295:Table 3
DUAL™ I China	A1	IDEGLIRA_SC	27	arm, events	14 / 361		R0012560:Table 3
DUAL™ I China	A2	INS_DEGLUDEC	27	arm, events	1 / 179		R0012560:Table 3
DUAL™ I China	A3	LIRA_SC	27	arm, events	21 / 180		R0012560:Table 3
NCT00838916	A1	ALBI_SC	164	arm, events	67 / 516	nonserious_only	registry:adverse_events
NCT00838916	A2	INS_GLARGINE	164	arm, events	18 / 263	nonserious_only	registry:adverse_events
SURPASS-6	A1+A2+A3	TIRZ_SC	56	arm, events	143 / 717	arms_combined	R0009666:Table 3
SURPASS-6	A4	INS_LISPRO	56	arm, events	8 / 711		R0009666:Table 3
PIONEER 4	A1	SEMA_PO	57	arm, events	56 / 285		R0015836:Table 3
PIONEER 4	A2	LIRA_SC	57	arm, events	51 / 284		R0015836:Table 3
PIONEER 4	A3	PLACEBO	57	arm, events	5 / 142		R0015836:Table 3
NCT04965506	A1+A2+A3	MAZD_SC	24	arm, events	35 / 149	arms_combined	R0012443:Table 2
NCT04965506	A4	DULA_SC	24	arm, events	15 / 50		R0012443:Table 2
NCT04965506	A5	PLACEBO	24	arm, events	3 / 51		R0012443:Table 2
MAGNA VICTORIA	A1	LIRA_SC	26	arm, events	16 / 22	count_from_percent	R0020542:Results
MAGNA VICTORIA	A2	PLACEBO	26	arm, events	10 / 25	count_from_percent	R0020542:Results
REWIND	A1	PLACEBO	365.26	arm, events	269 / 4,952	nonserious_only	registry:adverse_events
REWIND	A2	DULA_SC	365.26	arm, events	735 / 4,949	nonserious_only	registry:adverse_events
COMBINE 2	A1	ICOSEMA_SC	57	arm, events	40 / 342		R0005851:Table 4
COMBINE 2	A2	SEMA_SC	57	arm, events	39 / 341		R0005851:Table 4
SCALE™ Insulin	A1	LIRA_SC	58	arm, events	58 / 198		R0024063:Table 3
SCALE™ Insulin	A2	PLACEBO	58	arm, events	23 / 198		R0024063:Table 3
Lixilan-O-AP	A1	IGLARLIXI_SC	24.43	arm, events	48 / 351		R0013321:Table 3
Lixilan-O-AP	A2	INS_GLARGINE	24.43	arm, events	2 / 350		R0013321:Table 3
Lixilan-O-AP	A3	LIXI_SC	24.43	arm, events	36 / 177		R0013321:Table 3
NCT01476475	A1	IGLARLIXI_SC	24	arm, events	12 / 161		R0021236:Table 2
NCT01476475	A2	INS_GLARGINE	24	arm, events	0 / 162		R0021236:Table 2
OUTSTAND-1	A1+A2+A3	SAFIGL_PO	32	arm, events	76 / 212	arms_combined	R0011607:Table 3
OUTSTAND-1	A4	PLACEBO	32	arm, events	5 / 72		R0011607:Table 3
PB119	A1	VISEPE_SC	24	arm, events	11 / 137		R0011471:Table 4
PB119	A2	PLACEBO	24	arm, events	1 / 136		R0011471:Table 4
NCT01001104	A1	PLACEBO	12	arm, events	0 / 37		R0015000:Table 3
NCT01001104	A2+A3+A4	DULA_SC	12	arm, events	8 / 108	arms_combined	R0015000:Table 3
PIONEER 10	A1+A2+A3	SEMA_PO	57	arm, events	30 / 393	arms_combined	R0018421:Table 2
PIONEER 10	A4	DULA_SC	57	arm, events	6 / 65		R0018421:Table 2
NCT02846233	A1	DULA_SC	16	arm, events	9 / 12		R0028441:Table 5
NCT02846233	A2	OTHER_ACTIVE_basal_bolus_insulin	16	arm, events	0 / 10		R0028441:Table 5
AWARD-7	A1	INS_GLARGINE	52	arm, events	9 / 194		R0017387:Table 2
AWARD-7	A2+A3	DULA_SC	52	arm, events	65 / 383	arms_combined	R0017387:Table 2
NCT01584232	A1	DULA_SC	26	arm, events	17 / 181		R0016159:Table 3
NCT01584232	A2	INS_GLARGINE	26	arm, events	2 / 180		R0016159:Table 3
NCT03235050	A1	PLACEBO	58	arm, events	12 / 112	nonserious_only	registry:adverse_events
NCT03235050	A2	LIRA_SC	58	arm, events	17 / 110	nonserious_only	registry:adverse_events
NCT03235050	A3+A4+A5	COTA_SC	58	arm, events	213 / 612	nonserious_only;arms_combined	registry:adverse_events
NCT04235959	A1	PLACEBO	28	arm, events	0 / 4		R0019570:Table 2
NCT04235959	A3	TIRZ_SC	28	arm, events	4 / 10		R0019570:Table 2
AWARD-10	A1+A2	DULA_SC	24	arm, events	28 / 284	arms_combined	R0020348:p1
AWARD-10	A3	PLACEBO	24	arm, events	5 / 140		R0020348:p1
SUSTAIN™ 3	A1	SEMA_SC	62	arm, events	90 / 406	nonserious_only	registry:adverse_events
SUSTAIN™ 3	A2	EXENER_SC	62	arm, events	48 / 407	nonserious_only	registry:adverse_events
NCT00393718	A1	LIRA_SC	52	arm, events	14 / 272		R0022766:Table 4
NCT00393718	A2	GLIBENCLAMIDE	52	arm, events	2 / 139		R0022766:Table 4
EGO	A1+A2+A3	DULA_SC	16	arm, events	29 / 196	nonserious_only;arms_combined	registry:adverse_events
EGO	A4	PLACEBO	16	arm, events	5 / 66	nonserious_only	registry:adverse_events
NCT00765817	A1	EXEN_SC	30	arm, events	56 / 138		R0027069:Table 3
NCT00765817	A2	PLACEBO	30	arm, events	10 / 123		R0027069:Table 3
NCT01029886	A1	EXENER_SC	26	arm, events	43 / 461		R0016299:Table 3
NCT01029886	A2	LIRA_SC	26	arm, events	93 / 451		R0016299:Table 3
LIXILAN JP-L	A1	IGLARLIXI_SC	26.43	arm, events	43 / 255		R0008233:Supplement Table S1
LIXILAN JP-L	A2	INS_GLARGINE	26.43	arm, events	2 / 257		R0008233:Supplement Table S1
SUSTAIN 11	A1	SEMA_SC	52	arm, events	129 / 874		R0022346:Table 3
SUSTAIN 11	A2	INS_ASPART	52	arm, events	7 / 874		R0022346:Table 3
NCT02765399	A1	LIRA_SC	16	arm, events	4 / 16		registry:adverse_events
NCT02765399	A2	PLACEBO	16	arm, events	1 / 7		registry:adverse_events
SUSTAIN 7	A1+A2	SEMA_SC	45	arm, events	130 / 601	nonserious_only;arms_combined	registry:adverse_events
SUSTAIN 7	A3+A4	DULA_SC	45	arm, events	99 / 600	nonserious_only;arms_combined	registry:adverse_events
NCT00791479	A1+A2+A3+A4+A5	DULA_SC	12	arm, events	10 / 135	nonserious_only;arms_combined	registry:adverse_events
NCT00791479	A6	PLACEBO	12	arm, events	3 / 32	nonserious_only	registry:adverse_events
REMODEL	A1	SEMA_SC	57	arm, events	4 / 71	nonserious_only	registry:adverse_events
REMODEL	A2	PLACEBO	57	arm, events	2 / 35	nonserious_only	registry:adverse_events
NCT00637273	A1	EXENER_SC	26	arm, events	38 / 170	count_from_percent	R0024240:Table 4
NCT00637273	A2	SITAGLIPTIN	26	arm, events	17 / 172	count_from_percent	R0024240:Table 4
NCT00637273	A3	PIOGLITAZONE	26	arm, events	8 / 172	count_from_percent	R0024240:Table 4
SURPASS-1	A1+A2+A3	TIRZ_SC	44	arm, events	52 / 363	arms_combined	R0007531:Supplement Table S2
SURPASS-1	A4	PLACEBO	44	arm, events	7 / 115		R0007531:Supplement Table S2
NCT00717457	A1+A2	TASP_SC	104	arm, events	442 / 797	arms_combined	R0013639:Table 2
NCT00717457	A3	EXEN_SC	104	arm, events	135 / 392		R0013639:Table 2
NCT00976937	A1	LIXI_SC	24	arm, events	28 / 158		R0012687:Table 2
NCT00976937	A2	SITAGLIPTIN	24	arm, events	11 / 161		R0012687:Table 2
NCT00516074	A1	EXEN_SC	12	arm, events	10 / 28	count_from_percent	R0019195:Results
NCT00516074	A2	PLACEBO	12	arm, events	5 / 26	count_from_percent	R0019195:Results
ACHIEVE-3	A1+A2	ORFO_PO	57	arm, events	228 / 847	nonserious_only;arms_combined	registry:adverse_events
ACHIEVE-3	A3+A4	SEMA_PO	57	arm, events	146 / 851	nonserious_only;arms_combined	registry:adverse_events
NCT00082407	A1	EXEN_SC	52	arm, events	84 / 255		R0025791:Table 3
NCT00082407	A2	INS_PREMIX	52	arm, events	1 / 250		R0025791:Table 3
AWARD-9	A1	DULA_SC	28	arm, events	18 / 150	nonserious_only	registry:adverse_events
AWARD-9	A2	PLACEBO	28	arm, events	2 / 150	nonserious_only	registry:adverse_events
NCT05579977	A1+A8	PLACEBO	28	arm, events	11 / 139	arms_combined	R0004106:Table 2
NCT05579977	A10+A11+A12+A13+A2+A3+A4+A5+A6+A9	LOTI_PO	28	arm, events	256 / 690	arms_combined	R0004106:Table 2
NCT05579977	A7	SEMA_PO	28	arm, events	10 / 73		R0004106:Table 2
COMBINE 1	A1	ICOSEMA_SC	57	arm, events	153 / 646	nonserious_only	registry:adverse_events
COMBINE 1	A2	INS_ICODEC	57	arm, events	24 / 645	nonserious_only	registry:adverse_events
SUSTAIN 9	A1	SEMA_SC	36	arm, events	29 / 151	nonserious_only	registry:adverse_events
SUSTAIN 9	A2	PLACEBO	36	arm, events	5 / 151	nonserious_only	registry:adverse_events
GETGOAL-L-ASIA	A1	LIXI_SC	24	arm, events	61 / 154		R0022626:Table 2
GETGOAL-L-ASIA	A2	PLACEBO	24	arm, events	7 / 157		R0022626:Table 2
NCT04867785	A1	PLACEBO	40	arm, events	2 / 45	nonserious_only	registry:adverse_events
NCT04867785	A2	DULA_SC	40	arm, events	8 / 46	nonserious_only	registry:adverse_events
NCT04867785	A3+A4+A5+A6+A7+A8	RETA_SC	40	arm, events	36 / 190	nonserious_only;arms_combined	registry:adverse_events
GETGOAL-S	A1	PLACEBO	120	arm, events	25 / 286	nonserious_only	registry:adverse_events
GETGOAL-S	A2	LIXI_SC	120	arm, events	161 / 573	nonserious_only	registry:adverse_events
LIRA-PRIME	A1	LIRA_SC	105	arm, events	65 / 996	nonserious_only	registry:adverse_events
LIRA-PRIME	A2	OTHER_ACTIVE_investigator_choice_oral_drug	105	arm, events	15 / 995	nonserious_only	registry:adverse_events
PIONEER 12	A1+A2+A3	SEMA_PO	31	arm, events	119 / 1,082	arms_combined	R0019776:Table 3
PIONEER 12	A4	SITAGLIPTIN	31	arm, events	14 / 359		R0019776:Table 3
NCT06589765	A1+A2+A3	SAFIGL_PO	52	arm, events	218 / 608	arms_combined	R0029347:Table 3
NCT06589765	A4	DAPAGLIFLOZIN	52	arm, events	14 / 202		R0029347:Table 3
SUSTAIN 10	A1	SEMA_SC	35	arm, events	62 / 290	nonserious_only	registry:adverse_events
SUSTAIN 10	A2	LIRA_SC	35	arm, events	45 / 287	nonserious_only	registry:adverse_events
NCT01175473	A1	LIXI_SC	4.43	arm, events	17 / 77		R0022723:Table 3
NCT01175473	A2	LIRA_SC	4.43	arm, events	16 / 71		R0022723:Table 3
NCT03951753	A1	TIRZ_SC	32	arm, events	11 / 45	nonserious_only	registry:adverse_events
NCT03951753	A2	SEMA_SC	32	arm, events	13 / 44	nonserious_only	registry:adverse_events
NCT03951753	A3	PLACEBO	32	arm, events	7 / 28	nonserious_only	registry:adverse_events
NCT00960661	A1	EXEN_SC	30	arm, events	102 / 316		R0016788:Supplement Table 4
NCT00960661	A2	INS_LISPRO	30	arm, events	5 / 321		R0016788:Supplement Table 4
NCT00935532	A1	EXENER_SC	26	arm, events	27 / 215	nonserious_only	registry:adverse_events
NCT00935532	A2	INS_GLARGINE	26	arm, events	6 / 212	nonserious_only	registry:adverse_events
NCT02008682	A1	LIRA_SC	26	arm, events	27 / 184		R0025836:Table 2
NCT02008682	A2	SITAGLIPTIN	26	arm, events	1 / 184		R0025836:Table 2
NCT03555994	A1	PLACEBO	9	arm, events	0 / 11		R0005744:Table 2
NCT03555994	A2	LIRA_SC	9	arm, events	1 / 10		R0005744:Table 2
NCT03555994	A3	COTA_SC	9	arm, events	5 / 9		R0005744:Table 2
NCT02229383	A1	EXENER_SC	38	arm, events	12 / 233		R0014763:Table 3
NCT02229383	A2	PLACEBO	38	arm, events	9 / 231		R0014763:Table 3
NCT02081118	A1	PLACEBO	22	arm, events	1 / 51		R0009733:Table 3
NCT02081118	A2+A3+A4	EFPE_SC	22	arm, events	61 / 157	printed_denominator;arms_combined	R0009733:Table 3
NCT00577824	A1	PLACEBO	24	arm, events	3 / 36		R0018881:Table 2
NCT00577824	A2+A3	EXEN_SC	24	arm, events	44 / 145	arms_combined	R0018881:Table 2
ATTAIN-2	A1	PLACEBO	74	arm, events	53 / 630	nonserious_only	registry:adverse_events
ATTAIN-2	A2+A3+A4	ORFO_PO	74	arm, events	286 / 983	nonserious_only;arms_combined	registry:adverse_events
NCT02973321	A1	PLACEBO	26.4	arm, events	5 / 33	nonserious_only	registry:adverse_events
NCT02973321	A5	LIRA_SC	26.4	arm, events	21 / 67	nonserious_only	registry:adverse_events
LIRAVIS	A1	LIRA_SC	2	arm, events	2 / 7		R0055449:Table 5
LIRAVIS	A2	VILDAGLIPTIN	2	arm, events	3 / 7		R0055449:Table 5
NCT01149421	A1+A2	DULA_SC	26	arm, events	53 / 505	nonserious_only;arms_combined	registry:adverse_events
NCT01149421	A3	PLACEBO	26	arm, events	16 / 250	nonserious_only	registry:adverse_events
NCT00434954	A1	EXEN_SC	26	arm, events	34 / 248	count_from_percent	R0027127:Results
NCT00434954	A2	INS_PREMIX	26	arm, events	8 / 246	nonserious_only	registry:adverse_events
NCT02229396	A1	DAPAEXEN_SC	104	arm, events	13 / 231	nonserious_only	registry:adverse_events
NCT02229396	A2	EXENER_SC	104	arm, events	26 / 231	nonserious_only	registry:adverse_events
NCT02229396	A3	DAPAGLIFLOZIN	104	arm, events	10 / 233	nonserious_only	registry:adverse_events
GetGoal-Duo1	A1	PLACEBO	24.43	arm, events	11 / 223	nonserious_only	registry:adverse_events
GetGoal-Duo1	A2	LIXI_SC	24.43	arm, events	61 / 223	nonserious_only	registry:adverse_events
NCT01558271	A1	DULA_SC	52	arm, events	17 / 281		R0011754:Table 2
NCT01558271	A2	LIRA_SC	52	arm, events	11 / 141		R0011754:Table 2
NCT00849017	A1	PLACEBO	164	arm, events	10 / 105	nonserious_only	registry:adverse_events
NCT00849017	A2+A3	ALBI_SC	164	arm, events	25 / 204	nonserious_only;arms_combined	registry:adverse_events
NCT01147627	A1	EXEN_SC	48	arm, events	37 / 142	nonserious_only	registry:adverse_events
NCT01147627	A2	INS_PREMIX	48	arm, events	1 / 138	nonserious_only	registry:adverse_events
NCT01147627	A3	PIOGLITAZONE	48	arm, events	1 / 136	nonserious_only	registry:adverse_events
NCT05759897	A1	PLACEBO	16	arm, events	1 / 39	printed_denominator	R0002101:Table 3
NCT05759897	A2+A3+A4+A5	SAFIGL_PO	16	arm, events	27 / 155	printed_denominator;arms_combined	R0002101:Table 3
SUSTAIN™1	A1+A2	SEMA_SC	35	arm, events	57 / 259	nonserious_only;arms_combined	registry:adverse_events
SUSTAIN™1	A3	PLACEBO	35	arm, events	10 / 129	nonserious_only	registry:adverse_events
GetGoal-O	A1	LIXI_SC	24.43	arm, events	44 / 176	nonserious_only	registry:adverse_events
GetGoal-O	A2	PLACEBO	24.43	arm, events	13 / 174	nonserious_only	registry:adverse_events
NCT04093752	A1+A2+A3	TIRZ_SC	44	arm, events	194 / 687	nonserious_only;arms_combined	registry:adverse_events
NCT04093752	A4	INS_GLARGINE	44	arm, events	5 / 230	nonserious_only	registry:adverse_events
NCT01617434	A1	LIRA_SC	27	arm, events	50 / 226		R0026247:Table 3
NCT01617434	A2	PLACEBO	27	arm, events	7 / 225		R0026247:Table 3
NCT00135330	A1	EXEN_SC	20	arm, events	21 / 45	nonserious_only	registry:adverse_events
NCT00135330	A2	EXENROSI_SC	20	arm, events	22 / 47	nonserious_only	registry:adverse_events
NCT00135330	A3	ROSIGLITAZONE	20	arm, events	2 / 45	nonserious_only	registry:adverse_events
LIRA-Ramadan™	A1	LIRA_SC	30	arm, events	57 / 172		R0025756:Supplement Table S2
LIRA-Ramadan™	A2	OTHER_ACTIVE_sulfonylurea	30	arm, events	0 / 171		R0025756:Supplement Table S2
NCT02200991	A1	LIXI_SC	4.43	arm, events	22 / 69		R0024589:Table 3
NCT02200991	A2	SITAGLIPTIN	4.43	arm, events	0 / 67		R0024589:Table 3
NCT00097500	A1	EXEN_SC	64	arm, events	18 / 36	count_from_percent	R0027264:Results
NCT00097500	A2	INS_GLARGINE	64	arm, events	0 / 33	nonserious_only	registry:adverse_events
ACHIEVE-5	A1	PLACEBO	42	arm, events	6 / 141	nonserious_only	registry:adverse_events
ACHIEVE-5	A2+A3+A4	ORFO_PO	42	arm, events	107 / 405	nonserious_only;arms_combined	registry:adverse_events
NCT00894322	A1	EXENER_SC	12	arm, events	5 / 23	nonserious_only	registry:adverse_events
NCT00894322	A2	PLACEBO	12	arm, events	1 / 12	nonserious_only	registry:adverse_events
AWARD-CHN1	A1+A2	DULA_SC	26	arm, events	38 / 492	arms_combined	R0014229:Table 2
AWARD-CHN1	A3	GLIMEPIRIDE	26	arm, events	1 / 245		R0014229:Table 2
AWARD-8	A1	DULA_SC	24	arm, events	25 / 240		R0016038:Table 2
AWARD-8	A2	PLACEBO	24	arm, events	0 / 60		R0016038:Table 2
NCT01733758	A2+A3	ALBI_SC	52	arm, events	12 / 310	printed_denominator;arms_combined	R0010997:Table 3
NCT01733758	A4	LIRA_SC	52	arm, events	4 / 103	printed_denominator	R0010997:Table 3
NCT00359762	A1	EXEN_SC	234.81	arm, events	147 / 515	nonserious_only	registry:adverse_events
NCT00359762	A2	GLIMEPIRIDE	234.81	arm, events	11 / 514	nonserious_only	registry:adverse_events
LIRA-SWITCH™	A1	LIRA_SC	27	arm, events	44 / 203		R0025720:Table 1
LIRA-SWITCH™	A2	SITAGLIPTIN	27	arm, events	16 / 204		R0025720:Table 1
LixiLan-G	A1	IGLARLIXI_SC	26	arm, events	22 / 257	nonserious_only	registry:adverse_events
LixiLan-G	A2	GLP1RE_SC	26	arm, events	6 / 257	nonserious_only	registry:adverse_events
AWARD-2	A1+A2	DULA_SC	78	arm, events	64 / 545	nonserious_only;arms_combined	registry:adverse_events
AWARD-2	A3	INS_GLARGINE	78	arm, events	4 / 265	nonserious_only	registry:adverse_events
DUAL™ VIII	A1	IDEGLIRA_SC	108.29	arm, events	31 / 506	nonserious_only	registry:adverse_events
DUAL™ VIII	A2	INS_GLARGINE	108.29	arm, events	8 / 506	nonserious_only	registry:adverse_events
DURATION-NEO-2	A1	EXENER_SC	28	arm, events	16 / 182		R0010641:Table 3
DURATION-NEO-2	A2	SITAGLIPTIN	28	arm, events	2 / 122		R0010641:Table 3
DURATION-NEO-2	A3	PLACEBO	28	arm, events	0 / 61		R0010641:Table 3
NCT05514535	A1	SEMA_SC	45	arm, events	53 / 288		R0015842:Table 2
NCT05514535	A2	INS_GLARGINE	45	arm, events	2 / 285		R0015842:Table 2
AWARD-6	A1	DULA_SC	30	arm, events	61 / 299	nonserious_only	registry:adverse_events
AWARD-6	A2	LIRA_SC	30	arm, events	54 / 300	nonserious_only	registry:adverse_events
GetGoal-M-Asia	A1	PLACEBO	24	arm, events	5 / 195	nonserious_only	registry:adverse_events
GetGoal-M-Asia	A2	LIXI_SC	24	arm, events	32 / 196	nonserious_only	registry:adverse_events
NCT03985293	A1	PLACEBO	20	arm, events	2 / 66		R0006095:Table 3
NCT03985293	A2+A3+A4+A5+A6	DANU_PO	20	arm, events	66 / 346	arms_combined	R0006095:Table 3
NCT00701935	A1	EXEN_SC	26.07	arm, events	15 / 43	nonserious_only	registry:adverse_events
NCT00701935	A2	PLACEBO	26.07	arm, events	11 / 37	nonserious_only	registry:adverse_events
NCT01191268	A1+A2	DULA_SC	56	arm, events	128 / 588	nonserious_only;arms_combined	registry:adverse_events
NCT01191268	A3	INS_GLARGINE	56	arm, events	9 / 296	nonserious_only	registry:adverse_events
LixiLan-O	A1	IGLARLIXI_SC	30.29	arm, events	45 / 469		R0015993:Table 1
LixiLan-O	A2	INS_GLARGINE	30.29	arm, events	17 / 467		R0015993:Table 1
LixiLan-O	A3	LIXI_SC	30.29	arm, events	56 / 234		R0015993:Table 1
GETGOAL-P	A1	PLACEBO	132	arm, events	22 / 161	nonserious_only	registry:adverse_events
GETGOAL-P	A2	LIXI_SC	132	arm, events	84 / 323	nonserious_only	registry:adverse_events
SUSTAIN™ 4	A1+A2	SEMA_SC	35	arm, events	157 / 722	nonserious_only;printed_denominator;arms_combined	registry:adverse_events
SUSTAIN™ 4	A3	INS_GLARGINE	35	arm, events	12 / 360	nonserious_only;printed_denominator	registry:adverse_events
NCT00375492	A1	EXEN_SC	24	arm, events	43 / 96	nonserious_only	registry:adverse_events
NCT00375492	A2	PLACEBO	24	arm, events	19 / 98	nonserious_only	registry:adverse_events
NCT04504396	A1	VISEPE_SC	24	arm, events	13 / 310		R0009432:Table 3
NCT04504396	A2	PLACEBO	24	arm, events	1 / 310		R0009432:Table 3
DUALTM IX	A1	IDEGLIRA_SC	27	arm, events	12 / 210		R0014323:Supplement Table S4
DUALTM IX	A2	INS_GLARGINE	27	arm, events	1 / 210		R0014323:Supplement Table S4
SURPASS-4	A1+A2+A3	TIRZ_SC	108	arm, events	168 / 997	arms_combined	R0007531:Supplement Table S2
SURPASS-4	A4	INS_GLARGINE	108	arm, events	23 / 1,005		R0007531:Supplement Table S2
NCT00877890	A1	EXENER_SC	24	arm, events	18 / 129	nonserious_only	registry:adverse_events
NCT00877890	A2	EXEN_SC	24	arm, events	43 / 125	nonserious_only	registry:adverse_events
SUSTAIN	A1+A2	SEMA_SC	35	arm, events	61 / 578	arms_combined	R0014802:Table 3
SUSTAIN	A3	SITAGLIPTIN	35	arm, events	5 / 290		R0014802:Table 3
NCT00360334	A1	EXEN_SC	26	arm, events	57 / 118		R0024925:Table 3
NCT00360334	A2	INS_GLARGINE	26	arm, events	3 / 117		R0024925:Table 3
DUAL™ V	A1	IDEGLIRA_SC	27	arm, events	26 / 278	nonserious_only	registry:adverse_events
DUAL™ V	A2	INS_GLARGINE	27	arm, events	3 / 279	nonserious_only	registry:adverse_events
NCT04552470	A1	PLACEBO	12	arm, events	0 / 9		R0004540:Table 2
NCT04552470	A2+A3+A4	DANU_PO	12	arm, events	18 / 28	arms_combined	R0004540:Table 2
NCT01003184	A1	EXENER_SC	26	arm, events	20 / 111		R0027663:Table 2
NCT01003184	A2	INS_DETEMIR	26	arm, events	2 / 111		R0027663:Table 2
STRIDE	A1	SEMA_SC	57	arm, events	22 / 396	nonserious_only	registry:adverse_events
STRIDE	A2	PLACEBO	57	arm, events	3 / 396	nonserious_only	registry:adverse_events
SOLID-DKD	A1+A2	HRS7535_PO	18	arm, events	51 / 187	arms_combined	R0004355:Table 2
SOLID-DKD	A3	PLACEBO	18	arm, events	3 / 94		R0004355:Table 2
LixiLan-L	A1	IGLARLIXI_SC	30	arm, events	38 / 367	nonserious_only	registry:adverse_events
LixiLan-L	A2	INS_GLARGINE	30	arm, events	2 / 369	nonserious_only	registry:adverse_events
NCT02324842	A1	CANAGLIFLOZIN	17.38	arm, events	1 / 15	nonserious_only	registry:adverse_events
NCT02324842	A2	LIRA_SC	17.38	arm, events	9 / 15	nonserious_only	registry:adverse_events
NCT02324842	A3	CANALIRA_SC	17.38	arm, events	8 / 15	nonserious_only	registry:adverse_events
NCT00917267	A1	EXENER_SC	36	arm, events	32 / 340	nonserious_only;printed_denominator	registry:adverse_events
NCT00917267	A2	EXEN_SC	36	arm, events	73 / 338	nonserious_only;printed_denominator	registry:adverse_events
GETGOAL-X	A1	LIXI_SC	116	arm, events	91 / 320	nonserious_only	registry:adverse_events
GETGOAL-X	A2	EXEN_SC	116	arm, events	119 / 319	nonserious_only	registry:adverse_events
NCT00299871	A1	PLACEBO	13.43	arm, events	5 / 109		R0021613:Table 3
NCT00299871	A2+A3+A4+A5+A6+A7+A8+A9	LIXI_SC	13.43	arm, events	85 / 433	arms_combined	R0021613:Table 3
NCT02212067	A1	SEMA_SC	17	arm, events	7 / 37		R0021892:Results
NCT02212067	A2	PLACEBO	17	arm, events	2 / 38		R0021892:Results
SUSTAIN™	A1+A2	SEMA_SC	62	arm, events	75 / 480	arms_combined	R0025024:Table 2
SUSTAIN™	A3	OTHER_ACTIVE_additional_OAD	62	arm, events	1 / 121		R0025024:Table 2
LEAD-2	A1+A2+A3	LIRA_SC	104.28	arm, events	124 / 725	nonserious_only;arms_combined	registry:adverse_events
LEAD-2	A4	GLIMEPIRIDE	104.28	arm, events	10 / 244	nonserious_only	registry:adverse_events
LEAD-2	A5	PLACEBO	104.28	arm, events	5 / 122	nonserious_only	registry:adverse_events
NCT01620489	A1	LIRA_SC	27	arm, events	30 / 140	nonserious_only	registry:adverse_events
NCT01620489	A2	PLACEBO	27	arm, events	6 / 139	nonserious_only	registry:adverse_events
NCT05486065	A1+A2+A3	SEMA_SC	49	arm, events	61 / 185	nonserious_only;arms_combined	registry:adverse_events
NCT05486065	A4	PLACEBO	49	arm, events	9 / 60	nonserious_only	registry:adverse_events
GETGOAL-F1	A1	PLACEBO	112	arm, events	13 / 160	nonserious_only;printed_denominator	registry:adverse_events
GETGOAL-F1	A2+A3	LIXI_SC	112	arm, events	108 / 322	nonserious_only;arms_combined	registry:adverse_events
SURPASS-3	A1+A2+A3	TIRZ_SC	56	arm, events	207 / 1,079	arms_combined	R0015264:Table 2
SURPASS-3	A4	INS_DEGLUDEC	56	arm, events	6 / 365		R0007531:Supplement Table S2
NCT00460941	A1	PLACEBO	8	arm, events	4 / 32	printed_denominator	R0021258:Table 2
NCT00460941	A2+A3+A4	TASP_SC	8	arm, events	40 / 97	printed_denominator;arms_combined	R0021258:Table 2
SURPASS-5	A1+A2+A3	TIRZ_SC	44	arm, events	58 / 355	arms_combined	R0007531:Supplement Table S2
SURPASS-5	A4	PLACEBO	44	arm, events	3 / 120		R0007531:Supplement Table S2
NCT03322631	A1	PLACEBO	12	arm, events	0 / 9		R0021917:Table 2
NCT03322631	A2+A3+A4	TIRZ_SC	12	arm, events	3 / 39	arms_combined	R0021917:Table 2
NCT00744926	A1	PLACEBO	24	arm, events	5 / 123	printed_denominator	R0025346:Table 1
NCT00744926	A2+A3	TASP_SC	24	arm, events	70 / 245	printed_denominator;arms_combined	R0025346:Table 1
NCT00603239	A1	EXEN_SC	26	arm, events	13 / 111	nonserious_only	registry:adverse_events
NCT00603239	A2	PLACEBO	26	arm, events	1 / 54	nonserious_only	registry:adverse_events
PIONEER 1	A1+A2+A3	SEMA_PO	31	arm, events	51 / 525	nonserious_only;arms_combined	registry:adverse_events
PIONEER 1	A4	PLACEBO	31	arm, events	10 / 178	nonserious_only	registry:adverse_events
NCT02420262	A1	IDEGLIRA_SC	27	arm, events	28 / 252	nonserious_only	registry:adverse_events
NCT02420262	A2	OTHER_ACTIVE_basal_bolus_insulin	27	arm, events	4 / 254	nonserious_only	registry:adverse_events
NCT00641056	A1	EXENER_SC	84	arm, events	34 / 233		R0027747:Table 1
NCT00641056	A2	INS_GLARGINE	84	arm, events	3 / 234		R0027747:Table 1
ELEGANT	A1	LIRA_SC	26	arm, events	11 / 26		R0025175:Table 3
ELEGANT	A2	STANDARD_CARE	26	arm, events	3 / 24		R0025175:Table 3
NCT01126580	A1+A2	DULA_SC	52	arm, events	84 / 539	nonserious_only;arms_combined	registry:adverse_events
NCT01126580	A3	METFORMIN	52	arm, events	43 / 268	nonserious_only	registry:adverse_events
PIONEER 11	A1+A2+A3	SEMA_PO	31	arm, events	18 / 390	arms_combined	R0019663:Table 3
PIONEER 11	A4	PLACEBO	31	arm, events	2 / 131		R0019663:Table 3
NCT01272232	A1+A2	LIRA_SC	68	arm, events	204 / 634	nonserious_only;arms_combined	registry:adverse_events
NCT01272232	A3	PLACEBO	68	arm, events	29 / 212	nonserious_only	registry:adverse_events
NCT00943917	A1+A2	EXENIMP_IMPLANT	12	arm, events	41 / 102	nonserious_only;arms_combined	registry:adverse_events
NCT00943917	A3	EXEN_SC	12	arm, events	19 / 53	nonserious_only	registry:adverse_events
SUSTAIN 8	A1	SEMA_SC	57	arm, events	89 / 394	nonserious_only	registry:adverse_events
SUSTAIN 8	A2	CANAGLIFLOZIN	57	arm, events	26 / 394	nonserious_only	registry:adverse_events
SUSTAIN™ 5	A1+A2	SEMA_SC	35	arm, events	37 / 264	arms_combined	R0012671:Table 2
SUSTAIN™ 5	A3	PLACEBO	35	arm, events	6 / 133		R0012671:Table 2
NCT02229227	A1	ALBI_SC	26	arm, events	37 / 402	nonserious_only	registry:adverse_events
NCT02229227	A2	INS_LISPRO	26	arm, events	7 / 412	nonserious_only	registry:adverse_events
NCT00382239	A1	PLACEBO	12	arm, events	0 / 40		R0027621:Table 3
NCT00382239	A2+A3+A4	EXEN_SC	12	arm, events	20 / 113	arms_combined	R0027621:Table 3
SUSTAIN™ 6	A1+A2	SEMA_SC	109	arm, events	322 / 1,648	nonserious_only;arms_combined	registry:adverse_events
SUSTAIN™ 6	A3+A4	PLACEBO	109	arm, events	128 / 1,649	nonserious_only;arms_combined	registry:adverse_events
SURPASS-SWITCH	A1	TIRZ_SC	44	arm, events	35 / 139	count_from_percent	R0008264:Results
SURPASS-SWITCH	A2	DULA_SC	44	arm, events	27 / 143	count_from_percent	R0008264:Results
PIONEER 9	A1+A2+A3	SEMA_PO	57	arm, events	11 / 146	nonserious_only;arms_combined	registry:adverse_events
PIONEER 9	A4	LIRA_SC	57	arm, events	0 / 48	nonserious_only	registry:adverse_events
PIONEER 9	A5	PLACEBO	57	arm, events	1 / 49	nonserious_only	registry:adverse_events
AGAC2	A1	PLACEBO	0.43	arm, events	0 / 21		R0020827:Supplement Table 2
AGAC2	A2	EXEN_SC	0.43	arm, events	4 / 30		R0020827:Supplement Table 2
ACHIEVE-1	A1	PLACEBO	42	arm, events	3 / 138	nonserious_only	registry:adverse_events
ACHIEVE-1	A2+A3+A4	ORFO_PO	42	arm, events	68 / 421	nonserious_only;arms_combined	registry:adverse_events
NCT01632163	A1	LIXI_SC	24	arm, events	51 / 224		R0014725:Table 3
NCT01632163	A2	PLACEBO	24	arm, events	12 / 224		R0014725:Table 3
DUAL™ I Japan	A1	IDEGLIRA_SC	53	arm, events	9 / 275		R0014857:Table 2
DUAL™ I Japan	A2	INS_DEGLUDEC	53	arm, events	5 / 271		R0014857:Table 2
DUAL™ I Japan	A3	LIRA_SC	53	arm, events	23 / 273		R0014857:Table 2
NCT05086445	A1	PLACEBO	14	arm, events	2 / 11		R0003844:Table 2
NCT05086445	A2+A3+A4	ORFO_PO	14	arm, events	19 / 49	arms_combined	R0003844:Table 2
NCT00423501	A1	PLACEBO	12	arm, events	3 / 49	printed_denominator	R0022337:Table 2
NCT00423501	A2+A3+A4+A5+A6	TASP_SC	12	arm, events	85 / 248	printed_denominator;arms_combined	R0022337:Table 2
LIXILAN JP-O1	A1	IGLARLIXI_SC	52.43	arm, events	24 / 161		R0015751:Table 3
LIXILAN JP-O1	A2	LIXI_SC	52.43	arm, events	45 / 160		R0015751:Table 3
GETGOAL-L	A1	PLACEBO	125	arm, events	16 / 167	nonserious_only	registry:adverse_events
GETGOAL-L	A2	LIXI_SC	125	arm, events	96 / 329	nonserious_only	registry:adverse_events
PIONEER 5	A1	SEMA_PO	31	arm, events	31 / 163	nonserious_only	registry:adverse_events
PIONEER 5	A2	PLACEBO	31	arm, events	12 / 161	nonserious_only	registry:adverse_events
DUAL™ II Japan	A1	IDEGLIRA_SC	27	arm, events	10 / 105		R0015589:Table 2
DUAL™ II Japan	A2	INS_DEGLUDEC	27	arm, events	4 / 105		R0015589:Table 2
NCT03550378	A1	COTA_SC	8.43	arm, events	9 / 21		R0019218:Table 2
NCT03550378	A2	PLACEBO	8.43	arm, events	4 / 20		R0019218:Table 2
AMPLITUDE-M	A1+A2+A3	EFPE_SC	56	arm, events	43 / 304	arms_combined	R0007136:Table 2
AMPLITUDE-M	A4	PLACEBO	56	arm, events	2 / 102		R0007136:Table 2
SUSTAIN™	A1+A2	SEMA_SC	35	arm, events	24 / 205	arms_combined	R0014736:Supplement Table S4
SUSTAIN™	A3	SITAGLIPTIN	35	arm, events	0 / 103		R0014736:Supplement Table S4
NCT02288273	A1	EXENER_SC	14	arm, events	4 / 61		R0025397:Table 2
NCT02288273	A2	PLACEBO	14	arm, events	0 / 56		R0025397:Table 2
LEAD-5	A1	LIRA_SC	27	arm, events	32 / 232		R0027336:Supplement Table 2
LEAD-5	A2	PLACEBO	27	arm, events	4 / 115		R0027336:Supplement Table 2
LEAD-5	A3	INS_GLARGINE	27	arm, events	3 / 234		R0027336:Supplement Table 2
Lixilan-L-CN	A1	IGLARLIXI_SC	30.43	arm, events	15 / 212		R0014540:Table 3
Lixilan-L-CN	A2	INS_GLARGINE	30.43	arm, events	3 / 214		R0014540:Table 3
NCT04998032	A1	EFSUBA_SC	24	arm, events	13 / 171		R0006975:Table 3
NCT04998032	A2	PLACEBO	24	arm, events	7 / 173		R0006975:Table 3
AWARD-1	A1+A2	DULA_SC	56	arm, events	129 / 559	nonserious_only;arms_combined	registry:adverse_events
AWARD-1	A3	EXEN_SC	56	arm, events	77 / 278	nonserious_only	registry:adverse_events
GETGOAL-M	A1+A2	LIXI_SC	76.43	arm, events	127 / 510	nonserious_only;arms_combined	registry:adverse_events
GETGOAL-M	A3	PLACEBO	76.43	arm, events	16 / 170	nonserious_only;printed_denominator	registry:adverse_events
NCT03311724	A1	PLACEBO	16	arm, events	2 / 26		R0010282:Table 2
NCT03311724	A2+A3+A4	TIRZ_SC	16	arm, events	28 / 85	arms_combined	R0010282:Table 2
NCT05048719	A1	PLACEBO	28	arm, events	3 / 55	nonserious_only	registry:adverse_events
NCT05048719	A2+A3+A4+A5+A6+A7+A8	ORFO_PO	28	arm, events	85 / 278	nonserious_only;arms_combined	registry:adverse_events
NCT05048719	A9	DULA_SC	28	arm, events	9 / 50	nonserious_only	registry:adverse_events
PIONEER 3	A1+A2+A3	SEMA_PO	83	arm, events	166 / 1,397	nonserious_only;arms_combined	registry:adverse_events
PIONEER 3	A4	SITAGLIPTIN	83	arm, events	31 / 467	nonserious_only	registry:adverse_events
DUAL™ II	A1	IDEGLIRA_SC	27	arm, events	13 / 207	nonserious_only	registry:adverse_events
DUAL™ II	A2	INS_DEGLUDEC	27	arm, events	7 / 206	nonserious_only	registry:adverse_events
NCT04466904	A1+A2+A3	MAZD_SC	20	arm, events	4 / 24	arms_combined	R0009340:Table 2
NCT04466904	A4	DULA_SC	20	arm, events	1 / 6	printed_denominator	R0009340:Table 2
NCT04466904	A5	PLACEBO	20	arm, events	1 / 12	printed_denominator	R0009340:Table 2
GETGOAL-MONO	A1	PLACEBO	12.43	arm, events	5 / 122	printed_denominator	R0022843:Table 2
GETGOAL-MONO	A2+A3	LIXI_SC	12.43	arm, events	53 / 239	arms_combined	R0022843:Table 2
NCT02113332	A1	LIRA_SC	24	arm, events	21 / 64		R0026157:Results
NCT02113332	A2	PLACEBO	24	arm, events	1 / 60		R0026157:Results
NCT00700817	A1+A2	LIRA_SC	52	arm, events	108 / 446	arms_combined	R0024199:Table 2
NCT00700817	A3	SITAGLIPTIN	52	arm, events	12 / 219		R0024199:Table 2
PIONEER 8	A1+A2+A3	SEMA_PO	57	arm, events	92 / 547	nonserious_only;arms_combined	registry:adverse_events
PIONEER 8	A4	PLACEBO	57	arm, events	13 / 184	nonserious_only	registry:adverse_events
NCT06256523	A1	BOFANG_SC	29	arm, events	3 / 27	printed_denominator	R0002476:Table 2
NCT06256523	A2	PLACEBO	29	arm, events	1 / 9	printed_denominator	R0002476:Table 2
S002858	A1	LIXI_SC	24	arm, events	6 / 51		R0001573:Supplement Table S1
S002858	A2	PLACEBO	24	arm, events	5 / 50		R0001573:Supplement Table S1
S002904	A1	LIRAGL_SC	12	arm, events	0 / 60		R0003210:Table 3
S002904	A2	LIRA_SC	12	arm, events	9 / 60		R0003210:Table 3
S002928	A1	PLACEBO	24	arm, events	1 / 41		R0007034:Table 4
S002928	A2+A3	PEGLOX_SC	24	arm, events	10 / 82	arms_combined	R0007034:Table 4
S002946	A1	SEMA_SC	26	arm, events	4 / 16		R0006360:Supplement Table S2
S002946	A2	DULA_SC	26	arm, events	0 / 16		R0006360:Supplement Table S2
S002947	A1+A2+A3	ECNO_SC	25	arm, events	13 / 109	arms_combined	R0006482:Table 3
S002947	A4	PLACEBO	25	arm, events	1 / 36		R0006482:Table 3
S002951	A1	PEGLOX_SC	16	arm, events	13 / 104		R0007588:Table 3
S002951	A2	METFORMIN	16	arm, events	4 / 52		R0007588:Table 3
S002969	A1	LIRA_SC	52.14	arm, events	6 / 13		R0010852:Table 3
S002969	A2	PLACEBO	52.14	arm, events	0 / 14		R0010852:Table 3
NCT05654831	A1+A2+A3+A4	ECC500_PO	4.86	arm, events	14 / 39	arms_combined	R0007796:Table 2
NCT05654831	A5	PLACEBO	4.86	arm, events	1 / 13		R0007796:Table 2
S002991	A1	SEMA_SC	13.04	arm, events	0 / 110		R0009861:Results
S002991	A2	INS_ASPART	13.04	arm, events	1 / 110		R0009861:Results
S002992	A1	IGLARLIXI_SC	26	arm, events	34 / 443	count_from_percent	R0010673:Results
S002992	A2	INS_PREMIX	26	arm, events	0 / 444	count_from_percent	R0010673:Results
S003009	A1	PEGLOX_SC	24	arm, events	4 / 44		R0011381:Table 4
S003009	A2	DAPAGLIFLOZIN	24	arm, events	0 / 44		R0011381:Table 4
S003023	A1	LIRA_SC	0.43	arm, events	8 / 32	printed_denominator	R0017408:Results
S003023	A2	STANDARD_CARE	0.43	arm, events	0 / 28	printed_denominator	R0017408:Table 5
S003041	A1	LINAGLIPTIN	2	arm, events	0 / 18		R0020035:Results
S003041	A2	LIRA_SC	2	arm, events	1 / 17		R0020035:Results
S003047	A1+A2	LIXI_SC	6.57	arm, events	24 / 80	printed_denominator;arms_combined	R0016337:Table 3
S003047	A3	PLACEBO	6.57	arm, events	1 / 40	printed_denominator	R0016337:Table 3
S003058	A1	LIXI_SC	12	arm, events	1 / 23		R0024376:Results
S003058	A2	VILDAGLIPTIN	12	arm, events	0 / 25		R0024376:Results
S003072	A1	VILDAGLIPTIN	14	arm, events	0 / 62		R0023470:Table 4
S003072	A2	LIRA_SC	14	arm, events	1 / 60		R0023470:Table 4
S003079	A1	EXEN_SC	5	arm, events	0 / 18		R0025923:Results
S003079	A2	STANDARD_CARE	5	arm, events	0 / 18		R0025923:Results

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab